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1Abstract
The objective of this thesis was to develop new methodologies to
assess upper gastro-intestinal function in health and disease.
Several different technologies were studied in a range of upper
gastro-intestinal diseases and adapted to try and provide more
meaningful insights. The thesis has three main sections.
In the first section, High Resolution Oesophageal Manometry
(HRM) was used to assess unexplained upper gastro-intestinal
symptoms in a group of patients referred to a tertiary centre. 46
patients were diagnosed with rumination syndrome following HRM.
A retrospective review was completed of these patients case notes
and HRM data. The predominant aim of this section was to identify
if common mechanisms exist within rumination and its variations
and to establish if the variety of presenting symptoms is due to
different underlying problems or a common behavioural response
to a variety of stimuli, with symptoms being dependent on the
circumstance the behaviour exists in. This would support a generic
biofeedback technique being useful regardless of presenting
complaint.
Comparing the variety of symptoms, exhibited behaviour and
manometric findings, a new classification system for rumination
was then developed;
1. Primary or classical rumination
2a. Increase in abdominal strain with corresponding rise in
intra-gastric pressure and return of gastric contents to
the mouth
2. Secondary or reflux-related rumination
a. Reflux event causes the patient to respond with
increase in intra-abdominal muscle strain and
subsequent rumination
3. Supra-gastric belching independent of meals.
a. Rise in intra-gastric pressure whilst a closed gastro-
oesophageal junction, therefore producing rapid
belching of air from the oesophagus without any return
of gastric contents
Generic biofeedback therapy was used (regardless of presenting
symptoms) to control the abnormal behavioural response to
symptoms. 20/46 patients reported full resolution of their
symptoms and a further 13 / 46 reported improvement in their
symptoms with this, while underlying mechanisms were targeted
e.g. reflux with proton pump inhibitors, pain in functional
dyspepsia.
In the second main section of this thesis, gastro-oesophageal
reflux disease (GORD) is considered. GORD is currently diagnosed
by 24 hour pH studies. These are often difficult for patients to
tolerate and require time off medication. A more attractive method
3would be for diagnosis to occur at the same time as gastroscopy. A
novel instrument is the EndoFLIP® device. This measures cross-
sectional area (CSA) and distensibility at the gastro-oesophageal
junction (GOJ) via a long catheter with a balloon at the end that
straddles the GOJ. It has been hypothesised that these
measurements will be increased in those with GORD, as the GOJ is
more distensible, allowing more retrograde movement of gastric
contents. The aim of this section of the thesis was to establish if
GOJ CSA and distensibility differentiate between healthy volunteers
(HV) and GORD patients based on i) symptoms and ii) prolonged
oesophageal acid exposure.
21 HV and 18 patients with GORD (based on symptoms) had
EndoFLIP® measurements and wireless pH studies to assess this.
14% of HV and 50% GORD patients had pathological acid
exposure. CSA and distensibility were both significantly higher in
the HVs compared to GORD patients. However, there was an
inverse correlation between CSA and body mass index (BMI) which
was significantly higher in the patient population. This may explain
differences seen due to corresponding higher intra-abdominal
pressure in those individuals with a high BMI, sub-sequentially
affecting the CSA and distensibility. The complex structure of the
GOJ and multiple factors involved in the pathogenesis of GORD
present difficulties in using EndoFLIP® to diagnose GORD. It may
4find applications in other areas, such as serial measurements in
single patients.
In the final section of this thesis, gastric emptying is the focus and
its pathogenesis in functional dyspepsia (FD). Current gastric
emptying studies only find abnormalities in approximately 40% of
patients with FD. Gamma scintigraphy is used in routine clinical
practice for gastric emptying studies. Magnetic resonance imaging
(MRI) is emerging as a modality in gastric emptying assessment
and potentially provides additional information.
This thesis hypothesised that standard gastric emptying studies
may not be measuring the parameters reflective of underlying
pathophysiology in FD. Also, most have a relatively small meal size
that may be too small to trigger dysfunction. MRI may provide
additional insights as can assess gastric contents and surrounding
structure (unlike GS). To investigate these a 400ml test meal was
utilised and gastric emptying parameters i) gastric contents volume
at time 0 (GCV0, representative of early emptying), ii) gastric
emptying rate at the time taken for half the meal volume to empty
(GE rate @T50, representative of later emptying) and the more
traditional measurement iii) time taken for half the gastric contents
to empty (T50) in bopth GS and MRI studies. The hypothesis of
this study is that early emptying is more rapid in FD due to
impaired accommodation (therefore a lower GCV0) leading to a
5slower later emptying (therefore a lower GE rate @ T50). Following
validation studies in a large healthy population (n=53), GS and
magnetic resonance imaging (MRI) studies with a test meal of
400ml were used in 8 FD patients and 24 matched HV (from the
pool of HV) . FD had a significantly lower BMI. Early emptying
(represented by gastric contents volume after ingestion of meal
(GCV0)) was significantly lower in GS for FD patients but higher in
MRI. Time for half the meal to empty (T50) and gastric emptying
rate at T50 (GE rate @T50) were similar. The difference between
the two modalities was thought to be due to increased secretion
production in the patients, which is measureable in MRI but not in
GS. A further study with a solid component of 12 non-nutrient agar
beads in addition to the liquid component was completed. 24 HVs,
17 FD patients and 11 gastro-oesophageal reflux disease (GORD)
patients were studied. FD patients and GORD patients had rapid
early gastric emptying in comparison to HV in gamma scintigraphy
(represented by GCV0) but higher GCV0 in MRI (significantly so
between HV and GORD), suggesting increased secretion production
is present in both conditions. These findings do support impaired
fundal accommodation within the FD population but that other
factors, such as secretion production and the rate of this in
comparison to gastric emptying are important in the later stages of
emptying. Further work is ongoing within the MRI department to
quantify and measure the emptying of these secretions.
6This thesis explores how existing and new technologies can be
applied to clinical conditions to identify possible pathophysiology
and potential targets for treatment. Only by these ongoing efforts
can we endeavour to improve the care we deliver to our patients.
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Chapter One  Overview of gastro-oesophageal
function in health and disease and methods for
assessment
1.1 Introduction
Gastro-oesophageal disorders are one of the major groups of
disorders presenting to gastroenterologists, with dyspepsia
accounting for 25% of presentations to out-patient services(1).
Currently, the majority of tests within the gastro-intestinal tract
(GI) use starved, static examinations, such as gastroscopy, for
investigation of symptoms. This will assess for any structural or
mucosal disorder but does little to look for any abnormality of
function. Current standard methods of investigation, such as
barostat measurements and 24 ambulatory pH studies are invasive
and are not necessarily representative of normal physiology as
either interfere with this or restrict individuals normal behaviour.
Therefore, the development of non or minimally invasive tests for
the assessment of GI dysfunction is attractive. This report reviews
the current methods of investigation of GI function, with a focus on
functional dyspepsia (FD) and gastro-oesophageal reflux disease
(GORD). Although these conditions are separate entities,
increasingly it is recognised that there is a great degree of overlap
between GORD and dyspeptic symptoms (2). A significant number
of patients with heartburn (the classic symptom in GORD) will have
negative 24 hour pH studies for reflux (3). Conversely many
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patients with epigastric pain have pathologic oesophageal acid
exposure (4). This suggests the possibility of similar underlying
pathophysiologies within the two conditions and a target for
investigation.
1.2 Gastro-oesophageal reflux disease and functional dyspepsia
Gastro-oesophageal reflux disease (GORD) is a common condition
in the community, with reported prevalence in the Western World
between 10-20%(5). GORD is defined as the reflux of gastric
contents into the oesophagus and causes symptoms (e.g. retro-
sternal burning and regurgitation) and/or complications (e.g.
Barrett Oesophagus) (6). Many individuals will experience these
symptoms within their life but frequency of symptoms to 2 or more
times a week is regarded as having an impact on quality of life by
patients (6, 7). As well as these symptoms of GORD many patients
complain of other upper abdominal symptoms including nausea,
post-prandial fullness and bloating. These are classified as
dyspeptic symptoms and patients with these and with no
concurrent diagnosis, such as GORD, are diagnosed as having
functional dyspepsia (FD). Currently 24 hour ambulatory
oesophageal pH monitoring is used as gold standard for the testing
of GORD, (by establishing whether patients symptoms are
attributable to prolonged oesophageal acid exposure time and a
relationship between symptom episodes and reflux events) (8)
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whilst functional dyspepsia (FD), as with many function gastro-
intestinal (GI) disorders as predominantly a diagnosis of exclusion
i.e. tests for organic disease are negative and symptoms are
attributed to FD.
1.3 Functional dyspepsia
1.3.1 Background and definition
Functional dyspepsia is defined as bothersome postprandial
fullness, epigastric pain, early satiation and epigastric burning in
the absence of structural disease, by the ROME III criteria (9). This
is further sub-divided into post-prandial distress syndrome and
epigastric pain syndrome, depending on which of the listed
symptoms are most prominent.
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Table 1. ROME III criteria for Functional Dyspepsia
B1. Diagnostic Criteria* for Functional Dyspepsia
Must include
1. One or more of:
a. Bothersome postprandial fullness
b. Early satiation
c. Epigastric pain
d. Epigastric burning
AND
2. No evidence of structural disease (including at upper endoscopy) that
is likely to explain the symptoms
*Criteria fulfilled for the last 3 months with symptom onset at least 6
months before diagnosis
B1a. Diagnostic Criteria* for Postprandial Distress Syndrome
Must include one or both of the following:
1. Bothersome postprandial fullness, occurring
after ordinary sized meals, at least several
times per week
2. Early satiation that prevents finishing a regular meal, at least several
times per week
*Criteria fulfilled for the last 3 months with symptom onset at least 6
months before diagnosis
Supportive criteria
1. Upper abdominal bloating or postprandial nausea
or excessive belching can be present
2. EPS may coexist
B1b. Diagnostic Criteria* for Epigastric Pain Syndrome
Must include all of the following:
1. Pain or burning localized to the epigastrium of at least moderate
severity at least once per week
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2. The pain is intermittent
3. Not generalized or localized to other abdominal or chest regions
4. Not relieved by defecation or passage of flatus
5. Not fulfilling criteria for gallbladder and sphincter of Oddi disorders
*Criteria fulfilled for the last 3 months with symptom onset at least 6
months before diagnosis
Supportive criteria
1. The pain may be of a burning quality but without a retrosternal
component
2. The pain is commonly induced or relieved by ingestion of a meal but
may occur while fasting
3. Postprandial distress syndrome may coexist
Although symptoms have been well described, the underlying
causation has not been clearly identified. Associations have been
made with various pathophysiological mechanisms but this partly
limited by the heterogeneous nature of functional dyspeptic
patients. Attempts at therapeutic interventions have only been
partially successful due to this and the lack of identifiable
therapeutic targets. Although there is rarely any mortality
associated with FD, patients with the condition describe a negative
effect on their health related quality of life, as reported in
population studies (10). It also causes patients to attend both
primary and secondary care physicians, resulting in a socio-
economic burden (1). Therefore methods to assess the cause of
symptoms and potential identify new areas of development for
drug therapies are attractive to improve quality of life but also
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attempt to reduce economic costs. Many mechanisms have been
studied as the potential cause of symptoms in functional dyspepsia
and these are outlined below.
1.3.2 Normal gastric physiology
In normal physiology the proximal stomach (fundus and upper part
of body) acts as a reservoir for food and accommodates it here
initially after ingestion, via relaxation of the stomach wall. This is
mediated by receptive relaxation (fall in gastric tone), initiated by
swallowing and promoted by gastric stretch by vagally mediated
release of nitric oxide (11, 12). These changes allow the stomach
to accommodate the food without a large, corresponding rise in
intra-gastric pressure. The reservoir action also allows pepsin (a
proteolytic enzyme) and hydrochloric acid to mix with the food to
begin the digestive process. Additionally, gastric tone is
modulated by nutrient feedback and other factors that are
important to regulate digestion (adaptive relaxation) which is
partly dependent on nutrient qualities of the meal ingested. The
mechanisms by which these responses are managed represent a
highly sensitive response to the calorie load and composition of the
meal. Neuro-hormonal mediators including cholecystokinin (CCK)
and other peptide hormones (13)act directly and via the vagal
nerve (14) to regulate the delivery of nutrients to the small bowel.
30
This adaptive mechanism also acts by modulating gastric tone and
the opening of the pyloric sphincter: the so-called ileal brake (15).
The distal part of the stomach (antrum and distal section of body)
acts rather differently to the proximal part. It exhibits regular slow
wave depolarisation activity at approximately 3 cycles per minute.
This is steady, sequential depolarisation of cells initiated by the
interstitial cells of Cajal, a type of smooth-muscle cell located in
the greater curve of the stomach (16) that act as the pacemaker of
the stomach (17). As food is moved distally by a tonic contraction
from the fundus, the distal part of the stomach responds with
rhythmic contractions. These allow mixing of the food and grinding
into small particles (trituration) to permit passage into the
duodenum through the pylorus(18). Food particles need to be
approximately 2-3 mm in diameter before they are small enough to
pass through the pylorus in the post-prandial fed state (19). Once
the stomach has emptied, in the fasted state, a regular set of
contractions, known as the migrating motor complex occurs. This is
split into four phases. Phase I is a quiescent phase, with very little
activity. Phase II is short, irregular contractions that rarely result
in bolus transport. Phase III are regular, high amplitude
contractions that move any remaining contents through the
stomach, although over a relatively short period of time. Phase III
contractions continue down the length of the small intestine and
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sweep remaining contents through the intestine. Phase IV
contractions are less regular and of lower amplitude than phase III
and represent the motility returning to phase I. The whole cycles
lasts on average 120 minutes but can be highly variable (12). This
set of contractions are often termed housekeeping activity within
the gut (20) and are present in the fasted state.
Gastric emptying is different for liquids and solids. Liquids enter
the stomach and move quickly from the proximal to distal stomach
and pass through the pylorus into the duodenum (21). Here,
feedback from the duodenum will affect subsequent gastric
emptying. Food with a nutrient value, when compared to non-
nutrient saline, causes a subsequent delay of overall gastric
emptying proportional to the calorie load (21). Solid emptying is
slower than liquid because of an initial lag phase(22). This delay in
gastric emptying is present because solids are initially retained in
the proximal stomach and must be triturated prior to passage
through the pylorus.
Once nutrients have moved into the duodenum, increasing
duodenal distention reduces distal stomach motility to reduce
content moving through the pylorus (23, 24). This negative
feedback mechanism is under neuro-humoral control. Glucose
within the duodenum of rats has been shown reduce proximal
gastric motility via 5-HT3 receptors on afferent vagal nerve fibres
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and it is thought that enterochromaffin cells lying within the
duodenal mucosa release 5-hydroxytrytamine (5-HT) to instigate
this (25). Distal stomach motility is also reduced by the presence
of duodenal lipids. These causes the release of CCK (26, 27) and
its effects on afferent vagal nerve fibres(28). This is sometimes
referred to as the duodenal break with similar mechanistic
properties as the ileal brake described above.
The duodenum also experiences regular depolarisation of cells. This
is at an increased rate in comparison to the distal stomach, with a
rate of 11-12 cycles per minute(29).
Once food is in the duodenum (as gastric chyme), activity of
pancreaticobiliary secretions allow the chyme to be broken down
into particles that can be absorbed via the epithelia barrier(30).
1.3.3 Pathophysiology in functional dyspepsia
Many different mechanisms have been suggested as potential
abnormalities in functional dyspepsia. The principle hypotheses are
represented in the schematic below.
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Figure 1. Normal gastric function  reproduced from Pathophysiology and
Treatment of Functional dyspepsia, Tack et al. Gastroenterology, Vol
127:4:1239-1255.2004
1.3.3.1 Delayed gastric emptying in FD
Delayed gastric emptying has long been documented in functional
dyspepsia (31). However, correlating severity of symptoms and
gastric emptying rates has not been straight forward. Most studies
report rates of delayed gastric emptying between 20-50% (32,
33). Therefore it is not uniformly present throughout the FD
population, although some studies found that those with delayed
gastric emptying are more likely to complain of post-prandial
fullness and vomiting (31) this is generally limited to those with
very severe delay (x3-4 normal) and has not been consistently
shown throughout the literature. A large, multi-centre trial of 551
FD patients in 2001 showed that the presence of post-prandial
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distress symptoms and their severity were not predictive of
delayed gastric emptying, although female sex was (34). 24% of
FD patients in this trial had delayed gastric emptying. Thus,
although delayed gastric emptying does appear to play a role in FD
it clearly is involved in a complex manner and as part of other
processes. Another study in 2009 compared 11 FD patients to 23
healthy volunteers. Gastric emptying was measured with 13C
breath test at t50 but also over time %dose per hour curves. This
showed that 3/11 FD patients had increased gastric emptying in
the early post-prandial phase and 4/11 had increased gastric
emptying in the mid-post-prandial phase, when compared to
healthy volunteers. However, t50 measurements were no different
between the two groups (35). This supports the previously
described findings that simple overall gastric emptying rate does
not explain the cause of symptoms in FD and suggests that
impaired accommodation plays an important role.
1.3.3.2 Impaired accommodation in FD
Normal physiology has been detailed above. Previous studies have
shown that impaired proximal accommodation is present in FD
(36), with reports of up to 40% of FD patients affected (37) and is
associated with symptoms of early satiety and weight loss (38).
However, other studies have shown no real difference in the intra-
gastric meal distribution between FD patients and healthy controls
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(39). These results demonstrate the heterogenicity of FD patients
and the complex nature of cause of pathology. A small study has
shown that increased early post-prandial fundal contractility
(<30mininutes) is increased in a small subset of 15% FD patients
and was also associated with bloating. However, differences,
although significant, are small and bloating was reported into 82%
of patient cohort, making cause and effect unclear (40). Some of
the variations in findings may be due to methods used for
interpretation, as both non-invasive and barostat methods are
used for assessment. Mundt et al found that the present of a
barostat bag (commonly used for assessment of gastric
accommodation and hypersensitivity) results in larger antral areas
and increased distal meal distribution(41).
1.3.3.3 Hypersensitivity
It has been suggested that FD patients are more sensitive to the
normal physiological stimuli and changes within the stomach. A
barostat is frequently used to monitor symptom response to gastric
distension, and shown to be reproducible (42). A balloon located in
the proximal or distal stomach (or both in double balloon
barostats) can be inflated to set volumes and/or pressures and
response monitored. Using this technique a variety of parameters
can be measured. A study in 2001 found that pressure
measurements of absolute over minimal distending pressure (equal
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to baseline intra-gastric pressure) were most likely to differentiate
between FD patients and healthy volunteers, with 37% of FD
patients displaying gastric hypersensitivity and that these patients
were more likely to complain of post-prandial pain, belching and
weight loss (37). These findings were consolidated by a further
study by the same group (43).
1.3.3.4 Helicobacter pylori
Helicobacter pylori is associated with the development of duodenal
and gastric ulcers. Many groups have looked for a link between FD
and this bacteria, with varying results (44). A systematic review
performed in 2000 found no reliable association(45).
1.3.3.5 Central Nervous System dysfunction/psychological factors
It has long been known that FD impacts on quality of life. A recent
Swedish study group have compared FD patients and controls with
health related quality of life questionnaire, using the validated
short-form 36 questionnaire(46). They found that quality of life
was reduced in their FD population (10). Questions arise about
whether the symptoms, such as anxiety and depression are
because of the FD or if they are part of the FD spectrum and
heterogenicity. A meta-analysis from 2003 found that functional
dyspepsia was associated with anxiety and depression (47). A long
term follow up study of FD patients in a tertiary referral centre
(mean follow up period 68 months) found that depressive and
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anxiety symptoms were more likely to be associated with
persistent dyspeptic symptoms than abnormal gastric sensorimotor
testing at initial visit (48). Also, up to 44% of women with
functional GI disorders report physical and/or sexual abuse (49)
and this has also been reported in the functional dyspeptic
population (50). Mechanisms have been debated about the
possible central processes that could be responsible for these
findings. The majority of work has been completed in functional GI
disorders as a whole, often with a focus on irritable bowel
syndrome (IBS). Autonomic nervous system dysfunction has been
suggested. It has been found that IBS patients displayed increased
peripheral sympathetic function by laser Doppler flowmetry, in
comparison to healthy controls (51). The stress response has also
been implicated. Hypothalamic-pituitary-adrenal axis hyper- and
hypofunction has been reported but such conflicting results make
interpretation of this difficult at present (52, 53).
Studies have been completed looking at gastric response to stress.
A study of healthy volunteers assessed sensorimotor function
response in the stomach with experimentally induced anxiety (54).
14 healthy volunteers underwent gastric barostat studies and 18
healthy volunteers underwent a nutrient drink test (NDT), whilst
experiencing emotionally fearful or emotionally neutral facial
recognition or recollection of events. Reduced gastric compliance
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was found in the anxious state in the barostat group, reflecting
impaired gastric accommodation. Also, higher symptom scores for
satiety, fullness and bloating were documented in the anxious state
in the nutrient drink test. However, although gastric response to
stress is implicated in the functional dyspepsia, it is difficult to
assess whether the dyspeptic symptoms have caused the anxiety
or vice versa.
1.3.3.6 Altered duodenal response to lipids/acid and dysmotility
Duodenal abnormalities have been thought to be involved in FD.
Duodenal distension normally reduces antral motility via negative
feedback mechanisms(55). FD patients have been found to have a
reduced motor response to a direct duodenal acid infusion. 59% of
patients reported nausea with the acid infusion, in comparison with
none of the control group(55). An initial study showed no
significant differences in symptoms between the patient and
control group were found with the infusion of lipid into the
duodenum. However, it is worth noting only a low volume of lipid
was used (5ml). Another group infused a much higher volume of
lipid into the duodenum and scored symptoms whilst increasing
gastric distension in healthy controls and FD patients (56).
Symptoms occurred sooner in the FD patients with lipid infusion
than in the fasted state. These findings suggest that abnormalities
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within chemoreceptors in the duodenum of FD patients may
account for some of their symptoms.
FD pathophysiology is heterogeneous and although abnormal
findings can be identified, they are not consistent through the
whole population. This represents significant challenges in identify
underlying mechanisms but also directing treatment strategies.
The development of further techniques and technologies to elicit
the causes of symptoms in subsets of functional dyspeptic patients
is required.
1.3.4 Other factors that can affect gastric motility and symptoms of
functional dyspepsia and upper gastro-intestinal disease
1.3.4.1 Exercise
Exercise has been associated with upper gastro-intestinal
symptoms. One study showed that up to 90% athletes have
reported fullness, regurgitation, belching and chest pain (57). We
know that gastro-oesophageal reflux disease is associated with
transient lower oesophageal sphincter relaxation (58). A study of
ten healthy volunteers found that episodes of reflux during
exercise were associated with transient lower oesophageal
sphincter relaxation (59). However, a review of 100 patients with
confirmed reflux disease found that differing levels of everyday
physical activity were not associated with increased reflux
symptoms (60).
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Gastric emptying has been found to be mildly accelerated or not
affected by light exercise (61, 62). However, strenuous physical
exertion, when VO2 maximum is around 70% ( i.e. 70% of the
maximum volume of oxygen that can be utilized in one minute
during maximal or exhaustive exercise) has been associated with
slower gastric emptying (63, 64) for both liquids and solids (65).
Overall, mild to moderate physical activity does not has significant
effects on gastric emptying, but more strenuous exertion can (66).
For the majority of patients with functional dyspepsia, they are
unlikely to reach the exertional level of exercise required to have
significant effects on gastric motility.
1.3.4.2 Alcohol
Alcohol is frequently consumed with a meal. Varying reports have
been described with its effects on gastric emptying and upper
gastro-intestinal symptoms. Several studies have found that
alcohol slows gastric emptying (67-69) while a study comparing
low and normal alcoholic concentration wine, had no differing effect
on gastric emptying which could imply that it is the calorie content
of the alcohol and not the alcohol itself that causes the delay in
gastric emptying (70). However, a recent study comparing the
effects of drinking black tea or Schnapps when eating cheese
fondue found that increasing alcohol concentrations were
associated with a very rapid delay in gastric emptying more
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consistent with direct than indirect effects (71). Patients do
sometimes report symptoms worsening with alcohol, but study
results have been inconclusive (72).
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1.4 Gastro-oesophageal Reflux Disease  pathophysiology and
current methods of diagnosis
1.4.1 Definition
GORD is a condition characterized by the occurrence of symptoms
or mucosal damage related to the retrograde movement of gastric
contents from the stomach into the oesophagus. Reflux occurs in
normal, healthy individuals but excessive reflux or excessive
sensitivity to reflux can cause symptoms of heartburn, indigestion
and regurgitation. The repeated exposure of the oesophageal
mucosa to acid stomach contents can lead to the development of
oesophagitis or Barretts oesophagus  the development of
columnar metaplastic epithelium within the oesophagus, replacing
the normal squamous lining(73). This increases the risk of
oesophageal adenocarcinoma therefore is of significant impact
(74). Extra-oesophageal symptoms of GORD, such as cough and
hoarse voice can also occur.
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1.4.2 Normal gastro-oesophageal structure and physiology
Figure 2. The normal structure of the lower oesophageal sphincter 
reproduced from GI motility online (May 2006) doi:10.1038/gimo21
The lower oesophageal sphincter (along with the crural diaphragm)
acts as an anti-reflux barrier via the mechanism of a high pressure
zone, to prevent retrograde movement of gastric contents from the
stomach. Reflux occurs when lower oesophageal sphincter pressure
is lower than that of gastric pressure. Rather than being a discrete
symmetrical ring of muscle, it is made up of a semicircular clasp
(transverse) and gastric sling (oblique) fibres. The clasp fibres sit
transversely across the area in between the oesophagus and
stomach and open anteriorly and posteriorly. The sling fibres reach
from the angle of His and greater curvature, in the direction of the
antrum, parallel to the lesser curvature of the stomach. On closure
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of the lower oesophageal sphincter the sling fibres pull the greater
curve down and towards the midline and the clasp fibres pull the
lesser curve transversely across (75). The clasp fibres have a high
degree of intrinsic tone which is relaxed by the release of nitric
oxide. The sling fibres respond to cholingeric excitation and relax
when this is absent.
Recent work has looked at the angle of insertion of the oesophagus
into the stomach, using MRI and HRM in GORD patients and
HV(76). This study found that the angle if insertion was greater in
the GORD patient population, suggesting this is a factor in reflux
disease.
Contractions of the crural diaphragm also add to the so called high-
pressure zone at the lower oesophageal sphincter, to facilitate
closure and prevent reflux especially during cough and physical
exertion that increases abdominal pressure.
1.4.3 Mechanisms of GORD
1.4.3.1 Transient lower oesophageal sphincter relaxation
Transient lower oesophageal sphincter relaxations (TLOSR) are the
relaxation of the lower oesophageal sphincter without a preceding
swallow(77). These normally occur to allow air to escape from the
stomach and are mediated by a vaso-vagal reflex due to gastric
distension. These occur most frequently after a meal (78, 79) and
along with air, often allow stomach contents to reflux into the
45
oesophagus. When first discovered it was thought that these
events were increased in GORD patients and the cause of reflux
but subsequent work has shown that numbers are similar in
healthy controls and GORD patients (80). This suggests increased
frequency is not the pathology of reflux disease but the increased
incidence of reflux within the TLOSR in GORD patients.
At other times not associated with a TLOSR, reflux can occur when
intra-gastric pressure is greater than that of the lower oesophageal
sphincter.
1.4.3.2 Gastric acid
Gastric acid causes oesophagitis after repeated/prolonged contact
with oesophageal mucosa. It had previously been suggested that
patients with GORD may produce larger amounts of gastric acid.
This has not been found to be the case (81). Mechanisms which
allow prolonged contact of the gastric acid with the oesophageal
mucosa may play a role, and are described below.
1.4.3.3 Oesophageal dysmotility
GORD is associated with oesophageal dysmotility. A recent high
resolution oesophageal manometry study has shown that
hypotensive oesophageal swallows in reflux patients were
associated with longer oesophageal acid exposure time.
Interestingly, water swallows did not consistently demonstrate this
dysmotility in comparison to solid swallows. The authors proposed
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that very little motility is required for water transport through the
oesophagus due to the effects of gravity but that solid swallows
provide a more significant challenge and are therefore more likely
to elicit abnormalities in the physiology. Hypotensive oesophageal
motility was not however associated with increased reflux events,
indicating that dysmotility is a cause of poor oesophageal
clearance, prolonging the reflux events rather than allowing an
increased number (82).
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1.4.3.4 Structural abnormalities - Hiatus hernia
Figure 3. Anatomy of a hiatus hernia. Reproduced from
http://www.kmcpa.com/gastroenterology/education/hiatal_hernia.ph
The presence of a hiatus hernia affects reflux. Van Herwaarden et
al compared GORD patients with and without hiatus hernia, with
oesophageal manometry and 24 hour pH studies. They found those
with a hiatus hernia had prolonged acid exposure and increased
reflux events. TLOSR were similar in both groups but hiatus hernia
patients were more likely to reflux when LOS pressure was low and
with normal relaxation of the LOS following a swallow (83).
Possible mechanisms underlying this have been identified by
Pandolfino et al who identified that the gastro-oesophageal
junction (GOJ) of GORD patients with hiatus hernia opened wider
than GORD patients without hiatus hernia and normal controls
(84). They also found that distension pressures greater than
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atmospheric pressure (but less than gastric) provoked GOJ opening
in the hiatus hernia group only. Patients with hiatus hernia also
have poorer clearance, with acid/reflux material accumulating in
the hiatal sac and subsequently refluxing into the oesophagus(85).
1.4.3.5 Acid pocket
The acid pocket is a concept recently revisited in current research.
Intra-gastric pH rises after meal (due to meal related buffering)
but the pH of the proximal stomach remains remarkably low. This
is referred to as the acid pocket (86). It is thought to be
particularly important in the post-prandial reflux and be a potential
specific target for the relief of reflux-related symptoms.
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1.5 How do we measure Gastro-intestinal function?
1.5.1 Current assessment of methods of upper GI function?
There are many possible options when investigating the GI tract.
Methods that can assess function as well as structure are detailed
below.
1.5.1.1 Gastroscopy
Any patient presenting with symptoms such as weight loss,
recurrent vomiting or dyspepsia will undergo gastroscopy to
exclude structural disease. The majority of functional dyspepsia
patients and those with reflux symptoms that do not respond to
acid suppression medications will undergo this early in the disease
process.
1.5.1.2 Pepsin testing
Pepsin is a proteolytic enzyme produced by the chief cells in the
stomach mucosa. It is produced as a precursor, pepsinogen, and
is converted to pepsin in the presence of an acidic pH. It is
damaging to laryngeal cells and disrupts intercellular junctions and
thought to be one of the major causes of symptoms of extra-
oesophageal reflux symptoms, classically cough and hoarse voice,
via aerosoled reflux. Tests for the presence of pepsin have been
developed as a potential marker of reflux disease, as its presence
in salvia can only be explained by reflux from the stomach(87). It
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is yet to be seen if this will become standard practice for the
investigation of GORD.
1.5.1.3 24 hour pH studies
If heartburn is a predominant feature or significant oesophagitis
seen on gastroscopy then ambulatory 24 hour pH studies are
recommended. A pH catheter is inserted trans-nasally, through the
oesophagus and the GOJ, into the stomach. This records pH in an
oesophageal sensor 5cm above GOJ and gastric pH sensor, 2cm
below the GOJ. The patient then records any symptoms on
electronic device and these can then be correlated to the pH
recording and any drops in oesophageal pH below 4, indicating
reflux into the oesophagus. The addition of impedance can add
additional information. Impedance measures the electrical
resistance of a substance. Multiple impedance sensors can be
added to a pH probe and record retrograde and anterograde flow of
substances (88). Substances with higher impedance (with a lower
number of ions) such as air will produce a different impedance
trace to low impedance substance, such as gastric acid.
51
Figure 4. Impedance trace showing swallow on the left and reflux of
liquid on the right (due to drop in impedance). Reproduced from Intra-
oesophageal Impedance Monitoring for the Bolus Transit and GORD.
Conchillo and Smout. APT. 2009;29(1):3-14.
Therefore, impedance can document reflux events that are non-
acid and weakly acid, gas and liquid, providing further evidence of
whether refluxing material (acid or not) is the cause of symptoms.
Although this is the current gold standard for GORD testing, the
invasive nature of the test and variability of symptoms on a day-
to-day period provides many problems. Patients often adapt their
behaviour and diet with the presence of the pH catheter with
subsequent results not being representative of their normal
symptoms.
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1.5.1.4 Wireless pH studies
A group of patients do not tolerate nasal intubation for catheter
based studies or tolerate it badly such that their eating and activity
is reduced to a degree that impacts on the frequency and severity
of reflux. An alternative is a wireless capsule which is attached 6
cm above the Z line and transmits pH data to a radio receiver worn
by the patient. The advantage of these is prolonged measurement
time of up to 96 hours, reducing the potential for variability
encountered in 24 hour studies (89). Patients are also more likely
to perform normal tasks and data therefore more representative of
real life is obtained. A study looking at patients with a negative
24 hour pH recording and persistent symptoms consistent with
GORD showed that in 14/38 patients wireless pH recording
demonstrated abnormal oesophageal acid exposure time, when
considering average exposure time over the 96 hour period (90).
This can have significant impact on clinical management as 12 of
these patients went on to have anti-reflux surgery on the basis of
these findings and subsequent improvement in symptoms.
Wireless pH studies are not without disadvantages. The cost is
significantly higher than a 24 hour catheter study, endoscopy is
often used to confirm position, the capsule can detach early and no
impedance values can be measured with this technique. In
addition, there is debate over the best measurement to use. Worst
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day of symptoms, average over recording period are both
discussed in the above paper with cases made for both. Further
studies with comparison in negative and positive catheter studies
with wireless technology is needed provide answers to these issues
(study cited only used patients whod had negative catheter based
studies). Currently, within the United Kingdom it is used when
catheter studies have failed in a small number of hospitals.
1.5.1.5 High resolution oesophageal manometry with impedance
Oesophageal manometry records pressure measurements within
the oesophagus. A catheter is inserted as in a pH study. Multiple
sensors are spaced along the length of the catheter and pressure
measurements recorded. Conventional manometry used a low
number of sensors (approximately 3-5 cm apart) and produces line
plots of pressure. A relatively new technology, high resolution
manometry (HRM) uses 36 sensors, less than 1 cm apart to record
pressure. The HRM then produces spatio-temporal plots which
provide far more information about the structure and function of
the oesophagus (91). Impedance sensors can also be added to the
catheter to provide information about bolus transport. The
pharynx, oesophagus and lower oesophageal sphincter can all be
studied in detail.
Gastro-oesophageal reflux can be identified with HRM. A transient
lower oesophageal relaxation is seen, followed by the retrograde
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movement of gastric contents in to the oesophagus(with
impedance). A clearance swallow will then follow.
An advantage of HRM is that symptoms can be elicited during the
study e.g. during a test meal. The observer can than directly
identify the mechanism of symptoms by concurrent measurement
of oesophageal activity. This can be especially useful in treatment
resistant/unexplained symptoms, such as proton pump inhibitor
(PPI) resistant reflux or unexplained vomiting/regurgitation.
Figure 5. Representation of normal swallow  as represented by HRM
spatio-temporal plot and conventional manometry line plot. Reproduced
from Fox and Bredenoord. Gut 2008;57 :405-423
Manometry is not that useful within the stomach. To record
pressure measurements the organ needs to come into contact with
the catheter. As the stomach is a large cavity and the average HRM
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catheter approximately 4mm in diameter, there is rarely the
contact needed to provide pressure measurements.
1.5.1.6 EndoFLIP®
Another way of approaching the diagnosis of GORD is to assess
whether any other physiological investigation could establish the
diagnosis, without the need for pH testing. A novel probe has been
suggested for this using impedance planimetry. The Endoluminal
Functional Lumen Imaging Probe (EndoFLIP®, Cropson, Galway,
Ireland) is a probe with a balloon at the end, with 16 paired
electrodes situated inside, at constant distances. The balloon is
filled with a conductive medium with a known conductivity at a
constant temperature. An AC current is then passed through the
medium. Using the principles of Ohms law, the diameter of the site
the balloon is inflated in can be calculated.
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Figure 6. EndoFLIP® technology. Reproduced from
http://www.cropson.com/
Impedance (Z) = voltage (V)/current(I)
= GLVWDQFHEHWZHHQHOHFWURGHV/&6$ɇ
&6$ FURVVVHFWLRQDODUHDɇ FRQGXFWLYLW\FRHIILFLHQW
Therefore;
9, /&6$ɇ
&6$ U '
Therefore;
9, /'ɇ
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Voltage is measured across the electrodes, current and distance
between electrodes is fixed and conductivity is known at a certain
temperature. Therefore the diameter of the area of the balloon is
inflated in can be estimated from the voltage. With a cylinder and
paired electrodes throughout, diameter can be estimated
throughout the length of the balloon, and subsequently cross
sectional area (92). The distensibility of the area can then be
studied as this is equal to cross-sectional area divided by the intra-
bag pressure.
This probe is passed through the mouth and straddled across the
GOJ. The balloon is inflated sequential volumes and diameter,
cross-sectional area and distensibility recorded. Lower oesophageal
sphincter incompetence is implicated in GORD, especially in the
context of hiatus hernia(93). It has therefore been suggested that
this could be important (without hiatus hernia) in the
pathophysiology of reflux disease. If distensibility could be
measured at the time of endoscopy, it could potentially identify
GORD patients without the need for pH monitoring, making it an
attractive option. A study based on symptoms has shown that
increased GOJ distensibility and cross-sectional area are associated
with symptoms of GORD, in 20 healthy volunteers and 20 patients
with symptoms consistent with GORD (94). However, only 2/20
patients had confirmed prolonged oesophageal acid exposure
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meaning the diagnosis of GORD was based on symptoms alone in
the vast majority. For endoFLIP® to be useful in the diagnosis of
reflux disease, the GOJ distensibility and CSA need to be compared
to symptomatic patients and those with confirmed GORD on pH
studies. Only then can its value as a diagnostic aid be confirmed.
An alternative use for the EndoFLIP® probe could potentially be in
known GORD patients being assessed for anti-reflux surgery. If a
patients GOJ was very distensible with EndoFLIP® this could
predict who would be most likely to benefit from anti-reflux
surgery. However, no prospective trial has been completed using
the EndoFLIP® in this way to date.
1.5.1.7 Barostat studies
The barostat has been used to measure gastric accommodation
and sensitivity to gastric distension in many studies of functional
dyspepsia (38, 95) and shown to be reproducible(42). Studies are
normally done fasted and a double lumen tube with balloon on the
end (normal possible volume 1000-1200ml) is inflated in the
proximal stomach to either set pressure (isobaric) or set volume
(isovolume). When isobasric measurements are performed the
barostat is first calibrated for intra-gastric pressure. This has been
defined as the pressure required to unfold the balloon, normally to
about 30ml, and termed the minimal distending pressure (96). The
barostat balloon is then inflated to set pressures with subsequent
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measurements of intra-balloon volume recorded. This reflects
gastric tonic relaxation and allows measurements of gastric
compliance and, if sensation scores are assessed, sensitivity.
Isovolumetric measurements involve pre-selected volumes inserted
into balloon and subsequent intra-balloon pressures recorded
during interventions (e.g. a meal), reflecting accommodation.
Differences in patient and volunteer groups have been described
earlier in pathophysiology section.
Although barostat is currently regarded as the gold standard, it is
invasive, unpleasant for the patient and the presence of the
balloon itself can interfere with normal physiology(41).
1.5.1.8 Gamma scintigraphy
Gamma scintigraphy is currently used in clinical practice to assess
gastric emptying. Liquids and/or solids are radiolabeled with
radionuclide. These are then ingested and a gamma camera
monitors emitted gamma rays as the radionuclide decays. As the
radiolabeled substrate moves through the stomach, a 2D image is
produced from the gamma camera. Within the stomach this can
inform on meal distribution within the proximal and distal stomach,
gastric emptying rate and small bowel transit time. It is a non-
invasive test and performed in the physiological, upright position
(unlike some other non-invasive methods). It does require a
relatively low dose of radiation exposure.
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It has been used in FD to demonstrate abnormal gastric emptying
and impaired gastric accommodation in terms of the differences in
meal distribution within the FD population and their relevance to
symptoms(14). However these effects have never been repeated in
an unselected population or validated in comparison to other tests.
Also currently, gastric emptying study results have little correlation
to symptoms or have any effect on guiding treatment. Reasons for
this may be many. Is the correct test meal being utilised or the
correct gastric emptying parameters being measured?
1.5.1.9 Single Photon Emission Computed Tomography (SPECT)
SPECT studies involve the intra-venous administration of a gamma
emitting radioisotope which is taken up by parietal and mucin-
producing cells of the gastric mucosa (97) with a gamma camera.
3D images of the stomach are produced (via analytical software)
and information about gastric volume and volume response to a
meal can be obtained. A recent review by Breen et al of 433
previous study participants undergoing SPECT (volunteers and
patients) demonstrated comparable inter-individual coefficients of
variation of fasting and post-prandial gastric volumes and
comparable intra-individual coefficients in those who had had
repeat studies when compared to other modalities such as gamma
scintigraphy for gastric emptying. (98)
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The advantages of SPECT are that it is non-invasive and can
provide detailed 3D images in both the fasting and fed state. It
does however require the participant to be supine, expose the
individual to a relatively high radiation dose, is expensive and
requires specialist centre and equipment.
1.5.1.10 Magnetic Resonance Imaging (MRI)
MRI is commonly used in clinical practice for diagnostic imaging.
The object to be studied is placed in a magnetic field. Hydrogen
nuclei will align with this magnetic field (due to protons) and create
a directional magnetic field. A radiofrequency pulse is then applied
to the directional magnetic field, causing this to move away, via
exciting the protons within the nucleus. The radiofrequency pulse is
removed and the nuclei realign themselves with the original
magnetic field. As they return to this position, they emit their own
electromagnetic field, which is recorded by a coil (signal detection)
and used to reconstruct a 3D image of the object being studied
(99).
Functional upper GI MRI can gather many different parameters.
Gastric emptying, accommodation, secretions and intra-gastric
distribution can all be measured. A recent study compared inter-
observer reproducibility with gastric MRI and found it satisfactory
with greatest agreement at larger gastric volumes (100).
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MRI is an attractive source of imaging as it is non-ionising, non-
invasive and provides detailed images of the internal organs.
However, it is expensive, not readily available in all centres (used
as a research tool at present), requires the patients to be supine
and is not available to patients who have contraindication to going
into a magnetic field e.g. cardiac pacemaker.
1.5.1.11 Breath tests for gastric emptying
Breath test appeal for measurement of gastric emptying as they
are quick, cheap, easy to use and can be repeated in one subject
many times. An isotope is added to a meal which is them
converted within the duodenum to a measurable substance.
The 13C-octanoic breath test is commonly used. The isotope is
added to a solid meal, this remains stable until the duodenum
where it is then absorbed and oxidised by the liver (transported via
portal venous system) to 13CO2 (101). 13C-acetic acid breath test
has also been used, with the similar principles. This labelled carbon
dioxide can then be measured in the breath by mass spectrometry.
The arrival of 13C in the duodenum and subsequent detectable
levels in the breath, is rapid, indicating any variation in time is
primarily because of gastric emptying into the duodenum, rather
than other steps such as transport to the liver and oxidisation
(102). However this is contradicted by the fact that only about
20% of the 13C dose is recovered over the course of the study. Also
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there is no agreement about the most appropriate method for
analysis with important differences documented for different
analytical techniques. Further the test provides information only
about gastric emptying without detail as to the dynamics of this
process or information about meal distribution.
1.5.1.12 Gastric Ultrasound
Gastric ultrasound predominantly provides information in gastric
volume, either total or partial. Both 2D and more recently 3D,
ultrasound have been used for this purpose. It is desirable as is
non-invasive and non-ionising. It is however, still highly specialist
and operator dependent.
3D ultrasound scanning (USS) was compared to the current gold
standard of barostat for gastric volume. 3D USS performed best
with proximal stomach volume, in comparison to barostat, with an
r value of 0.55 (103). Correlation was less for total gastric volume
and non-significant for distal gastric volume. Comments from the
authors were that air pockets were the greatest problem in gastric
USS, making assessment with this technique more problematic.
Gastric USS exists currently as a research tool with variability in
recorded values and is limits by technological factors.
Doppler ultrasonography has also been used to study trans-pyloric
flow to estimate gastric emptying (104).
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1.5.1.13 Nutrient drink tests
The techniques described already provide information about
anatomy and physiology. However, most are expensive, invasive or
require exposure to radiation. As one of the predominant
symptoms in FD is that of post-prandial distress, drink tests (water
and nutrient) have been suggested as an easy and accessible way
of assessing symptoms. Early satiety has been associated with
abnormal fundal accommodation and therefore an indirect way of
measuring accommodation (38). A drink test involves the patient
drinking water or nutrient at a set rate, whilst scoring dyspeptic
symptoms until a maximum tolerated volume is reached (when
symptoms prevent further ingestion). However, there are many
different options for nutrient drink tests. Drinking rate, nutrient or
non-nutrient substrate, best outcome measure are examples. A
Dutch group compared nutrient drinking and water drinking tests
in FD patients, those with mild dyspeptic symptoms and healthy
volunteers with the results of barostat studies(105). Although the
FD group drank less water and nutrient than the two control
groups, it was not associated with one particular symptom and did
not predict an abnormal barostat study. It was noted that the rate
of drinking was 100ml/min, a relatively high rate of ingestion. A
different study by Tack et al showed that a slow drinking test
(15ml/min) with calorific nutrient showed a weak but significant
correlation in functional dyspeptic patients with maximum tolerated
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volume and impaired accommodation in concurrent barostat
studies(106). A possible explanation suggested for this was that
rapid drink tests don't allow for gastric accommodation, which can
take up to fifteen minutes to have full effect (38) and that non-
nutrient drink tests dont evoke the inhibition of gastric emptying
from via negative feedback from lipid within the duodenum.
These results suggest a slow rate, calorific drink test is the most
appropriate to use as within a functional dyspepsia population.
However the drink test alone provides no direct information about
the mechanism of symptoms which could be related to impaired
accommodation or heightened sensitivity or some other
abnormality of gastrointestinal function.
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2 Chapter Two: Rumination Variations: aetiology and
classification of abnormal behavioural responses to
digestive symptoms based on high-resolution
manometry studies
2.1 Introduction
2.1.1Definition
Rumination, as classified by the ROME III criteria (107) is the
voluntary, albeit unconscious, contraction of the abdominal
muscles forcing return of food to the mouth, followed by re-
chewing, swallowing or spitting.(108) Although these events are
often described as vomiting, no violent retching is involved and
stomach contents are usually returned to the mouth as a series of
small volume events rather than one large volume expulsion. They
are not necessarily preceded by nausea, as is normal in vomiting.
Associated symptoms, including repetitive belching is also a
consequence of abnormal behaviour, either due to excessive
swallowing of air (i.e. aerophagia), or suction of air into the
oesophagus during forced inspiration (i.e. supra-gastric belching)
(109-111). This is distinguished from gastric or normal belching
in that there is no associated relaxation of the lower oesophageal
sphincter or release of air from the stomach. Rumination and
supra-gastric belching are similar due to both being behavioural in
origin.
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2.1.2Epidemiology
Rumination was previously diagnosed predominantly in the
paediatric and learning disabled populations, but it is increasingly
recognised in an adult patients with normal intelligence (112-114).
Although rumination itself is rarely associated with significant
mortality, it can be associated with major morbidity, such as social
embarrassment and weight loss (115, 116)
2.1.3Approaches for diagnosis
The diagnosis of rumination and belching disorders can be made
from clinical history (Table 2); however there is often a delay due to
lack of awareness of these conditions by physicians (112). As a
result, those affected may see many doctors and undergo multiple,
invasive investigations before a definitive diagnosis of rumination is
made (112)
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Table 2. Definition or rumination syndrome and aerophagia- symptoms
must have been present for at least 6 months with 3 months prior
affected
Rumination Syndrome in Adults
Diagnostic criteria. Must include both of the following:
1. Persistent or recurrent regurgitation of recently ingested food into the mouth
with subsequent spitting or remastication and swallowing
2. Regurgitation is not preceded by retching
Supportive criteria
1. Regurgitation events are usually not preceded by nausea
2. Cessation of the process when the regurgitated material becomes acidic
3. Regurgitant contains recognizable food with a pleasant taste
Aerophagia
1. Troublesome repetitive belching at least several times a week
2. Air swallowing that is objectively observed or measured
Gastric belching
1. Venting of air from the stomach, with increase in intra-luminal impedance
from distal to proximal oesophagus
Supra-gastric belching
1. Anterograde movement of gas followed by followed by rapid expulsion
(Rapid increase in impedance from proximal to distal, with rapid retrograde
return to baseline)
Objective diagnosis can be based on the close temporal association
of typical symptoms with evidence of abnormal behaviour on
physiologic studies. Recent advances, such as High Resolution
Manometry (HRM), facilitate the detection and diagnosis of
dysmotility and dysfunction during and after meals.(82, 91, 110,
117-119) Combination with impedance provides independent
confirmation that these pressure events are associated with
retrograde movement of food, fluid or gas through the oesophagus
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(118). This work has raised awareness of these conditions;
however the aetiology and classification of abnormal behavioural
responses to digestive symptoms events have not been well
defined. Specifically, the symptoms that provoke abnormal
behaviour and the clinical utility of advanced physiologic
measurement in describing this response remain uncertain, as
diagnosis has predominantly been based on manometric findings
alone.
2.1.4New classifications of rumination
This study proposed that rumination and many cases of repeated
belching are not distinct conditions but are caused by a common
behavioural response to abdominal pain or other, unpleasant
digestive symptoms (.
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TRIGGER SYMPTOM
COMMON
BEHAVIOURAL
RESPONSE
PRESENTING
SYMPTOM
Air Food FoodAir
Dyspepsia Reflux Dysphagia
Abdominal / Gastric strain generating
reverse pressure gradient
Air/food in
oesophagus
OGJ intact
Air/food in
stomach
OGJ open
Supra-gastric
belch
Supra-gastric
rumination
Forced Gastric
Belch
Classic
Rumination
Figure 7. Flowchart of trigger symptom, behavioural response and resulting presenting symptom in rumination
and its variations
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This view is supported by several observations. Both rumination
and repeated belching have been associated with chronic
abdominal pain and the presence of psychiatric disorders (113,
120). Cases of regurgitation and belching have been associated
with abdomino-gastric strain (3) and both conditions have been
shown to respond to cognitive behavioural interventions (121).
This hypothesis was tested. If a common behavioural response is
the cause of both conditions then (i) the presenting complaint (i.e.
return of food to the mouth or belching) should be produced by
similar behavioural responses to a variety of digestive symptoms
(e.g. epigastric pain, bloating, reflux), (ii) a generic behavioural
intervention should provide effective management whether the
presenting complaint is vomiting / regurgitation or belching and
(iii) effective treatment can be directed either at the symptoms
that trigger the behaviour or at the abnormal behaviour itself. A
retrospective review of consecutive cases with a diagnosis of
rumination and repetitive belching made on HRM based on
published diagnostic criteria (82, 91, 110, 117-119) to assess
whether these predictions were supported by clinical observation.
Based on the results a new classification system for these
behavioural disorders is proposed based not on the presence of
repetitive regurgitation or belching or manometry (e.g. R wave)
alone, but rather on the underlying mechanism of disease.
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In summary, the main aims of this study are:
x To assess if the variety of symptoms exhibited by patients
with rumination are produced by a similar mechanism,
identified through HRM
x To assess if a simple and generic biofeedback mechanism will
help all patients despite a variety of different symptoms
2.2 Methods
2.2.1Patients
A retrospective case note review and evaluation of HRM data of
consecutive patients with a diagnosis of rumination or other
belching / regurgitation disorders based on HRM studies performed
at Nottingham University Hospital NHS Trust, Queens Medical
Centre (QMC) site between August 2009 and October 2011.
Patients were identified from the specialist upper gastro-intestinal
clinic at QMC referred for HRM or who were referred directly for
HRM from other hospital trusts. As retrospective work with no
intervention and data presented anonymously, no ethical
submission was necessary.
2.2.2High Resolution Manometry
HRM with (impedance when available) were performed in the
upright, seated position by a 36 channel solid-state catheter
(Manoscan 360, Given Imaging, Yoqeam, Israel). Following a
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standardized protocol (122), baseline measurements of upper and
oesophago-gastric junction (OGJ) pressure were followed by 10
swallows of 5ml water and 200ml water taken by rapid, repeated
swallows. A solid test meal of cheese and onion pasty (Ginsters of
Cornwall, Tavistock Road, Callington, Cornwall, per pasty; 521
kcal, 33.1g of fat, 38.9 g carbohydrate, 13.3g protein) was then
ingested followed by a further 200ml drink and 10 minute
postprandial observation period. The cheese and onion pasty was
chosen as symptoms are commonly reported after fatty food in
upper GI discomfort (especially functional dyspepsia and reflux
disease (72, 123) and was a meal that was easily reproducible.
Patients were instructed to report any swallowing problems,
dyspeptic or reflux symptoms and these were documented in the
electronic record, as were any events such as the return of food to
the mouth or belching. Only those symptoms / observations
documented within 10 seconds of the manometric event were
considered to be causally related.
Proprietary software (ManoView v1.2, Given Imaging, Yoqeam,
Israel) analysed water swallows and the Chicago classification
system defined oesophageal dysmotility,(124) modified for use in
the upright position and with solids.(122) Rumination was defined
as a rise in intra-gastric pressure (abdomino-gastric strain) of at
least 20mmHg above baseline associated with a retrograde
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pressure gradient and return of gastric contents without retching to
the mouth up to 10 seconds after the strain event.(110) This is
commonly referred to as they R wave. Reflux regurgitation and
gastric belching were defined as the passage of liquid or air from
the stomach respectively with most such events occurring during a
transient OGJ relaxation without evidence of abdominal strain on
HRM (119). Supra-gastric belching was defined as a patient report
or direct observation of belching in the presence of an intact
OGJ.(109) These events were subdivided into supra-gastric
belching after (i) air swallowing with subsequent expulsion related
to abdominal strain as above, and (ii) intake of air through the
open upper oesophageal sphincter by negative intra-thoracic
pressure with rapid expulsion.(109, 111) Impedance confirmed
retrograde flow of gastric or oesophageal contents (liquid, gas)
during these events.(110) Cough was distinguished by the
presence of rapid pressurisation through the stomach and
oesophagus with contraction of the lower and upper oesophageal
sphincters. Retching was distinguished from voluntary behaviour
by the presence of a massive increase in abdominal and thoracic
pressure with coordinated and prolonged relaxation of the
oesophageal sphincters to facilitate rapid expulsion of luminal
contents.
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Ambulatory reflux studies were performed off acid suppression;
however this was not performed in most patients with rumination
on HRM since abnormal behaviour confounds the results. This is
due to multiple repeated events of gastric contents return with
rumination, which are often seen as weakly acidic events on pH
studies. When performed a 2 pH sensor, 6 paired impedance
sensor system (Sandhill Scientific Instruments) was used according
to standard techniques (125). A pH-impedance probe is inserted
through one nostril after anaesthetising with local anaesthetic
spray. The proximal pH sensor is placed 5 cm above the upper
border of the lower oesophageal sphincter after identification of the
LOS by HRM. A band of high pressure is seen at the level of the
distal oesophagus representing the LOS on HRM (126). The distal
pH sensor lies 2 cm below GOJ. The pH-impedance probe has the 6
impedance sensors at 3, 5, 7, 9, 15, and 17 cm above the LOS.
The catheter was secured and the patient was instructed to eat
normally and maintain normal activity for the next 24hr while
documenting symptoms on the electronic log, and providing a food
diary. Analysis was completed by automatic software (Sandhill)
with pH measurements related to retrograde bolus movement, with
a 50% drop in impedance from baseline, and exclusion of meal
periods. Patients recorded symptoms (up to 3) and these were
recorded as associated with either acidic, weakly acidic, weakly
alkali events. Traces were then checked by manually by the study
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team. Symptom index and symptom association probability were
also recorded as percentage values. Routinely, all tests were done
off all anti-acid medication and analysis as published protocols (8).
2.2.3Therapy and Follow-up
All patients received a 20 minute behavioural intervention by a
clinician (Dr Emily Tucker or Dr Mark Fox) immediately after HRM
investigation. This included a description of the rumination events,
cause of symptoms and explanation of the rationale for behavioural
therapy.
The patient assumed a semi-recumbent position on the
examination couch within the HRM laboratory. Following a
demonstration of the different breathing techniques of chest wall /
thoracic and diaphragmatic / abdominal breathing by the
clinician, the patient and the investigator each placed a hand on
their own abdomen. Behavioural instruction was focused on deep
muscle relaxation and diaphragmatic breathing (generic techniques
applied in many conditions (127)). In this case, diaphragmatic
breathing with relaxation of the abdominal wall prevents the
patient from contracting the abdominal wall muscles to force
gastric contents back in response to any symptoms. True
biofeedback with the HRM catheter in place was not performed in
most cases since the presence of the catheter is very
uncomfortable and impairs patient compliance. Once the patient
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was able to adopt diaphragmatic breathing on command, the
behavioural control was challenged with a drink of water or a bread
roll to induce postprandial symptoms. This challenge made it
obvious that regurgitation / belching did not occur as long as
diaphragmatic breathing was maintained.
Following the diagnosis patients referred to the consultant
gastroenterologist (Dr Mark Fox) received further treatment in
clinic as required. If these brief interventions were not effective,
then further physiotherapy by a trained practitioner was requested.
Leaflets describing the condition and the rationale of therapy were
provided to the patient, primary care physician and physiotherapist
to promote understanding of the condition and the rationale of
therapy.
Additional treatments directed at reducing the dyspeptic or reflux
symptoms that trigger abnormal behavioural response were
recommended, depending on the individual patients symptom set.
Follow-up of success of behavioural intervention was performed by
review of the notes and electronic patient record at a minimum 3
months after initial diagnosis and therapy, with initial diagnosis
being the date of HRM study as this was an objective time point,
even if rumination had been suspected at initial clinical review.
Summary of study process:
78
HRM performed with biofeedback as normal clinical protocol on
clinical basis ї HRM database reviewed for those with diagnosis of
rumination ї case notes then reviewed for symptoms ї patients
grouped depending on symptoms ї HRM data then reviewed to
identify patterns within patient groups ї response to
biofeedback/treatment assessed ї common categories identified
2.3 Results
2.3.1Patients
46 patient notes and HRM data were reviewed.
Of the 46 patients (34 (74%) female; age range 18-68 years), 1
patient had mild learning difficulties but all others were of normal
intelligence.
A variety of presenting complaints and associated
symptoms were reported (
Table 3). 25 referrals were from Nottingham University Hospitals
and 21 from other hospital trusts. The majority were referred for
chronic unexplained repetitive vomiting, 11 with a working
diagnosis of treatment resistant reflux and 4 with presumed
motility disorder. Only 8 (17%) had clinically suspected
rumination.
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Table 3. Presenting complaint and associated symptoms
Primary Complaint N=46
Volume Reflux / Regurgitation / Vomiting 32 (70%)
Belch with meals 8 (17%)
Belch independent of meals 6 (13%)
Associated symptoms (may overlap)
Treatment resistant reflux (heartburn, chest
pain, acid regurgitation)
11 (24%)
Post-prandial dyspepsia (early satiety,
nausea, bloating, epigastric pain on eating)
13 (29%))
Dysphagia 5 (11%)
Belching 12 (26%)
Symptoms had been present for median 23 (inter-quartile range
12-39) months prior to diagnosis. Of 38/46 (83%) patients with
adequate records, 5 (11%) had symptoms for >60 months prior to
diagnosis and only 2 (4%) had a diagnosis within 6 months.
Further 5 (11%) patients required enteral nutrition (2 naso-jejunal
tubes, 2 surgical jejunostomy and 1 percutaneous gastrostomy).
No case received parenteral nutrition.
A number of patients described an acute event that precipitated
the onset of symptoms, or worsened pre-existing symptoms. 11/46
(24%) described an acute medical illness prior to the development
of symptoms. 5 had an acute episode of gastroenteritis with
vomiting +/- diarrhoea, one had an episode of biliary colic, one
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pancreatitis, one following surgery for a perforated duodenal ulcer,
one following surgery for a choledocal cyst and two patients
following respiratory infections.
Two cited acute psychosocial stress as a precursor with one patient
having occasional symptoms only but with dramatic worsening
following a burglary at his home. Another individual was in UK as
an asylum seeker with unclear immigration status. As well as
rumination, he displayed multiple symptoms consistent with
somatisation disorder.
2.3.2Previous investigations and procedures
All patients had undergone diagnostic studies prior to referral. Of
37/46 (80%) patients with adequate records, 34 had undergone
upper gastrointestinal endoscopy (many had multiple procedures),
12 barium swallow (some with follow through), 6 abdominal
ultrasound, 3 computed tomography of the chest and abdomen, 8
gastric emptying studies and 3 oesophageal transit studies. None
of these tests had demonstrated findings that explained patient
symptoms. Additionally, 13/46 (28%) had undergone conventional
manometry with water swallows only. These excluded major
dysmotility in all cases; but rumination or other behavioural
abnormality was not reported. Ambulatory pH or pH-impedance
studies showed pathologic acid reflux and/or a significant symptom
association diagnostic of GORD in 8/13 (62%).
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2.3.3Previous therapy
All patients had been prescribed medications; however these rarely
improved symptoms. Proton pump inhibitors (PPI) had no effect on
rumination or belching in 27/46 (59%) patients. A partial response
was present in 16 (35%). Only 2 had never received PPI. A variety
of anti-emetics were prescribed to 31/46 (67%) patients
(metoclopramide, domperidone and prochloperazine). Although
this improved nausea in some and occasionally reduced the
frequency of vomiting, these medications never suppressed the
problem completely. Other medications included tricyclic anti-
depressants, anti-spasmodics and opiates. Additionally, 1 patient
had received cognitive behavioural therapy to help cope with
functional digestive symptoms.
Endoscopic therapy had been performed in 2 patients, 1 received
botulinum toxin injection to the distal oesophagus and lower
oesophageal sphincter for presumed spasm and 1 had botulinum
toxin injection to the pylorus for presumed gastroparesis. A gastric
neuromodulator was implanted in one patient. No patient reported
any benefit from these procedures.
Anti-reflux surgery had been performed in 5 patients. In 2 cases
symptoms appeared de novo several years after fundoplication. In
3 cases symptoms were either similar or identical to those present
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before fundoplication but were not identified as abnormal
behavioural responses until after the procedure.
2.3.4Previous psychological diagnoses
2 patients had a previous diagnosis of obsessive compulsive
disorder, with one also having co-existent non-epileptic attack
disorder and depression.
2.3.5HRM findings
Standard HRM procedures with 5ml water swallows revealed
normal oesophageal motility in 34/46 (74%) patients, hypotensive
dysmotility in 10/46 (22%) and hypertensive dysmotility in 2/46
(4%). During the 200ml water swallow oesophageal motility was
suppressed fully and there was no evidence of impaired OGJ
function. With solid swallows 7/10 patients with hypotensive
motility improved to normal limits (122).
Rapid, repetitive belching was observed independent of oral intake
in 6/46 (13%) patients. Digestive symptoms were reported during
the study prior to the onset of abnormal behaviour by 33/46 (72%)
patients (33/40 (83%) of those with postprandial symptoms).
25/46 (54%) individuals reported postprandial distress compatible
with functional dyspepsia, 7 (15%) typical reflux symptoms, and 1
dysphagia. No digestive symptoms were reported during the study
by 7 (15%) patients.
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An abnormal behavioural response diagnostic of rumination or
supra-gastric belching was considered positive if (i) observed
events were typical of the symptoms that led to referral and (ii)
associated with rumination behaviour (abdomino-gastric strain / R
waves) on several occasions (at least twice, but usually many
occasions). These events occurred during or immediately after the
water swallows in 22/46 (48%), 7 (15%) after the first 200ml
water swallow and the remaining 17 (37%) after the test meal.
Table 4 relates patient symptoms to objective HRM findings during
the test meal. The majority of patients (35/46 (76%)) showed
manometric findings of classical rumination with a sharp increase
in abdomino-gastric pressure (R-wave) before return of gastric
contents to the mouth (Figure 8. Rumination demonstrated by
combined HRM with impedance.).
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Table 4. Comparison of patients symptoms and objective behaviour
during HRM test meal study.
Objective Mechanism / Abnormal
Behaviour during HRM study
Predominant
Observation of Patient
Rumination
gastric
content
Rumination
oesophageal
contents
SG belching
rapid,
repeated
Regurgitation of food
after meal
32*
Regurgitation of food and
air during / after meals
4 4
Belching independent of
food
6
*includes all 5 reflux ruminators who may return gastric air as well as food
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Figure 8. Rumination demonstrated by combined HRM with
impedance.
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Figure 8 shows how gastric strain overcomes the OGJ barrier and
the retrograde pressure gradient drives retrograde flow of gastric
contents through the oesophagus and upper oesophageal
sphincter. The patient reports vomiting and swallows producing
effective clearance by primary peristalsis.
In the classical rumination manometry cases (n=35) 31 patients
the increase in abdominal pressure exceeded the resting OGJ
pressure. In other cases (4/35) the abdominal contraction
appeared to trigger a transient OGJ relaxation on each occasion.
In the latter, the abdomino-gastric strain prior to OGJ relaxation
differentiated these events from normal reflux events. Both
variants were observed in certain individuals. In the remaining 11
(24%) patients, who didnt display classical rumination manometric
patterns, and on occasion in those with classical findings, a
number of other rumination variations were observed. These are
summarised in Table 5. Rumination variations from the classical
mechanism / behavioural abnormality and illustrated in Figure 9,
Figure 10 and Figure 11. More than one behavioural abnormality
was occasionally in some cases. Figure 12 demonstrates how
retching and cough differ from the behavioural abnormalities that
characterize rumination and belching disorders.
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Table 5. Rumination variations from the classical
mechanism / behavioural abnormality
Rumination
Variation
Patient details Mechanism
Cough
1/46 (2%)
Previous anti-reflux
surgery as a child
Cough used with gastric strain to
create pressure required to cause
retrograde gastric contents
movement across previous
fundoplication
Gas trapping
1/46 (2%)
Unable to co-ordinate relaxing
UES with gastric strain, resulting
in gas trapping in oesophagus
and forced retching by inserting
fingers to back of throat to
relieve trapped air
Reflux
rumination
5/46 (11%)
Figure 11
Gastric strain occurs immediately
following a transient lower
oesophageal sphincter relaxation
with common cavity pressure
Supra-gastric
rumination
4/46 (9%)
Figure 9
Air swallowed and subsequent
gastric strain then used to return
contents from oesophagus, prior
to passing into stomach. At meal
time, food returned in similar
manner
Supra-gastric
belching
6/46 (13%)
Figure 10
Includes 2 post-
fundoplication
patients
Air suctioned into the
oesophagus through the open
UOS by negative intra-thoracic
pressure (forced inspiration) and
then immediately released
88
Figure 9. Rumination variations in the same patient.
Figure 9 shows the first gastric strain (left) is associated with OGJ
relaxation and results in forceful expulsion of gastric contents
(typical rumination). The next gastric strain occurs with closed OGJ
and results in the expulsion of only oesophageal contents (supra-
gastric rumination).
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Figure 10. Supra-gastric belching in a representative patient
during combined HRM and impedance
In Figure 10 the OGJ is closed while the UOS opens repeatedly as
air is sucked in and expelled rapidly (see impedance trace
superimposed on left hand side of image)
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Figure 11. Reflux rumination
In Figure 11 transient Lower Oesophageal Sphincter Relaxation
(TLOSR) with gastro-oesophageal common cavity (i.e. reflux) is
rapidly followed by gastric strain with UOS relaxation (i.e.
rumination) resulting in more forceful expulsion of gastric contents.
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Figure 12. Retching (left) - Coughing (right)
Figure 12 demonstrates two variations on rumination.
Retching. Note prolonged OGJ and UOS relaxation coordinated with
a massive increase in gastric pressure. This produces a large
retrograde pressure gradient and allows rapid expulsion of large
volumes of gastric contents.
Coughing. Note rapid increase in gastric and oesophageal pressure
coordinated with UOS contraction to protect the airway. There is no
retrograde pressure gradient
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2.3.6Treatment outcome
All patients received a brief behavioural intervention including
abdominal breathing exercises at the time of diagnosis. 23 patients
received further instruction at follow-up. Outcome assessment was
based on patient reported improvement in symptoms as no scoring
system has been developed to evaluate treatment response in
these conditions. After median 5 (3-11) months follow up,
complete improvement in rumination and / or belching was
reported in 20/46 (43%) patients, including 3/6 with supra-gastric
belching. Partial improvement was reported by 13 (28%) patients.
2 patients reported no improvement and 11 patients had no follow
up within NUH Hospitals. No patient was given an alternative
diagnosis. However, in 3 cases, further investigation led to specific
therapy directed at the underlying cause of the symptoms that
provoked abnormal behaviour.
x 46 year old women. Presented with intermittent dysphagia,
vomiting with abdominal pain with background of
pancreatitis. HRM showed rumination. Endoscopic Ultrasound
(EUS) showed pancreatic pseudocyst with herniation through
diaphragmatic hiatus. A coeliac plexus block via EUS was
performed for abdominal pain. Resolution of dysphagia and
rumination occurred on drainage of pseudocyst
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x 59 year old women with abdominal pain, weight loss and
vomiting with previous abdominal surgery. HRM showed
rumination. A laparoscopy planned for insertion of surgical
jejunostomy to support nutrition. Adhesions removed at the
time of laparoscopy / jejunostomy insertion. Rumination and
pain resolved after removal of adhesions
x 18 years old female. Presented with heartburn and large
volume regurgitation. HRM showed hypotensive dysmotility
and rumination following typical reflux events. pH-studies
confirmed correlation of symptoms with acid reflux events,
(not only at meal times). Fundoplication was performed
following successful biofeedback. Resolution of reflux and
rumination (trigger for rumination removed) and behaviour
addressed
2.4 Discussion
This study provides evidence that rumination and many cases of
repetitive belching are not distinct conditions but represent
common behavioural responses to a variety of digestive symptoms.
Only rapid, supra-gastric belching independent of oral intake
represents a distinct abnormal behaviour. The findings also
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demonstrate the clinical utility of advanced physiologic
measurement during a test meal to describe mechanism of disease
and establish diagnosis in patients with chronic, unexplained
symptoms. In addition, encouraging data is presented that even
one, brief behavioural intervention can produce lasting clinical
benefit in many cases.
2.4.1Results summary
The clinical presentation, investigation, treatment and outcome of
46 adult patients in with rumination and other belching /
regurgitation disorders identified by HRM were reviewed. This
patient group was typical of those in previous studies.(110, 112,
116, 118). The majority were female with a long history of
functional gastrointestinal symptoms. As reported in children
(116), a proportion of patients reported onset of symptoms
following acute infection (interestingly not always gastrointestinal),
surgery or psychosocial stress; however the presenting symptoms
of these individuals was otherwise no different than the group as a
whole. In almost all cases extensive investigation, sometimes
including conventional manometry, had failed to establish a
diagnosis and a variety of empirical treatments had failed to
improve symptoms. Referral letters noted a variety of symptoms
but rarely included rumination syndrome in the differential
diagnosis and never mentioned supra-gastric belching.
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Since the study investigators also provide therapy for these
conditions in our region, this finding is almost certainly due to low
awareness and not because other physicians are making the
diagnosis based on clinical presentation alone.
2.4.2Manometric criteria in ruminations
Physiologic measurement with concurrent documentation of
symptoms and clinical events during a test meal provided objective
evidence of behavioural disorders. HRM with impedance is
considered to be an accurate test;(82, 91, 110, 117-119) however
we suspect false negative results in a small number of patients
with typical symptoms that had a normal stationary manometry
but findings on ambulatory pH-impedance that may represent
rumination (e.g. repeated, symptomatic non-acid reflux after
meals) or supra-gastric belching (e.g. aerophagia followed by
expulsion). These individuals were excluded as our analysis
focused on the mechanism of disease and required a definitive
description of the physiologic events. False positive results are also
possible; however further investigation did not change the
diagnosis for any individual during median 5 month follow-up.
During HRM studies, the majority of patients (33/46 (72%))
spontaneously reported dyspeptic symptoms before diagnostic
pressure events and the return of gastric or oesophageal contents
to the mouth. The handful that reported no postprandial symptoms
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prior to the onset of rumination tended to have a long history
(often since childhood). In these cases, the abnormal behaviour
may be so well established that even the normal sensation of
fullness after a meal could trigger this response. About half the
patients had diagnostic results after 10 water swallows; however
the yield was doubled by the inclusion of free drinking (200ml
water) and a test meal. The close temporal association of
abdominal symptoms before the appearance of rumination or
belching confirms the behavioural aetiology of these conditions.
Moreover it provides patients with a clear explanation of the cause
of symptoms that many found extremely helpful in coming to
terms with the diagnosis and engaging with behavioural treatment.
2.4.3Symptoms and behavioural response
Consistent with the study hypothesis, the symptoms that preceded
the onset of rumination and supra-gastric belching were varied;
however the range of behavioural responses was very limited.
Almost all the rumination and belching events were preceded by
voluntary, albeit unconscious, contraction of the abdominal wall. In
the majority with dyspeptic symptoms after the meal this
behaviour resulted in typical rumination of gastric contents;
however, the same response could force out oesophageal contents
if it occurred during eating. In other patients abdomino-gastric
strain occurred exclusively in response to typical reflux events and,
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since lower oesophageal sphincter relaxation reduced the
resistance to retrograde flow, such individuals tended to eject large
volumes of gastric contents. These observations with combined
HRM impedance technology build on those of Rommel et al (110)
and show that the timing of abdominal strain in relation to drinking
and eating can determine the clinical presentation. Specifically,
what was present in the lumen at the time the abdominal muscles
contracted determined whether air, liquid or food returns to the
mouth. Thus, the same mechanism can result in gastric
rumination, reflux rumination, supra-gastric rumination (i.e.
return of oesophageal contents) and, in cases of aerophagia,
supra-gastric belching (
Table 4).
2.4.4Supra-gastric belching
The exception was rapid, repetitive belching that occurs
independent of meals as described by Bredenoord et al (111). This
cannot be produced by aerophagia and / or straining. Rather, it is
achieved by suction of air into the oesophagus through an open
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UOS during forced inspiration with immediate release on
expiration. In our experience this behaviour can produce such a
rapid succession of belches that it caused breathlessness and
distress reminiscent of panic attacks.
2.4.5Treatment options in rumination
Once the diagnosis is established behavioural treatment is the
mainstay of treatment.(128, 129) It was shown that even a single,
brief intervention can suppress rumination and belching. However,
if the study hypothesis is correct and abnormal behaviour is a
response to digestive symptoms, then it should be possible to
direct therapy either at those symptoms or at the response itself.
The majority of patients with rumination and supra-gastric belching
had functional dyspepsia. In addition to behavioural management
these patients were prescribed low-dose antidepressants that
reduce gastric hypersensitivity (130) and visceral pain in this
condition.(131, 132) Control of rumination and / or belching could
be achieved quickly with behavioural management; however,
initially, some individuals struggled to maintain control because of
on-going dyspeptic symptoms. This became easier as the
abdominal pain settled on the medication (typically over 4-8
weeks). These observations are consistent with the study
hypothesis; however, in a small number of cases, investigations
revealed specific, treatable causes of symptoms.
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In one patient, abdominal pain was the result of a pancreatic
pseudocyst and drainage resulted in immediate relief. In another,
adhesiolysis around the proximal jejunum during insertion of a
feeding tube released occult obstruction with immediate
improvement in both dyspepsia and rumination such that the
jejunostomy never had to be used. In another patient rumination
occurred exclusively in response to typical reflux events and
fundoplication provided excellent control of her symptoms. The
immediate effect of specific treatment in these instructive cases
supports the view that relief of unpleasant digestive symptoms can
be sufficient to suppress also abnormal behaviours related to these
symptoms.
2.4.6Associations with rumination syndrome
Rumination is most often associated with dyspepsia; however
abnormal behavioural responses associated with reflux disease
may also be quite common.(133, 134) Direct observations by HRM
with impedance can document whether abdomino-gastric strain is
forcing gastric acid into the oesophagus or whether spontaneous
reflux events trigger the abnormal behavioural response. If
rumination is the cause of, rather than a response to, acid reflux
then pH-studies will often produce false positive results (see
above). In these cases fundoplication may physically prevent
rumination, but dyspeptic symptoms are likely to increase and
100
patient behaviour will adapt to the new circumstances. Conversely,
if reflux is the trigger for rumination then reflux suppression with
the Gamma-Aminobutyric acidB (GABAB ) receptor agonist
baclofen (135) or anti-reflux surgery (136) may be effective
options.
2.4.7New treatments in rumination syndrome
A recent study has utilised baclofen in 16 patients with rumination
+/- belching (135). A HRM with impedance was completed at the
start and at the end of a week long period of open label baclofen,
(10mg three times a day). Patients recorded symptoms of
regurgitation or belching throughout each recording period. This
did significantly reduce rumination events. Interestingly, increased
lower oesophageal sphincter tone was associated with a reduction
in flow events, but the reduction in TLOSR was not. This may
suggest that some of the effects of baclofen are central, sedating
effects causing changes in the patients behaviour, rather a
mechanistic change.
2.4.8Anti-reflux surgery in rumination syndrome
If anti-reflux surgery is considered then patient selection is critical.
In our case series, 5 patients had rumination syndrome diagnosed
after anti-reflux surgery. In two cases this behaviour commenced
de novo years after surgery following an acute physical or
psychological stress. However, in the three other cases, although
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fundoplication suppressed rumination, dyspeptic symptoms
persisted and abnormal behaviour either overcome the wrap or
resulted in supra-gastric rumination and belching.
2.4.9New proposed classification in rumination syndrome
On the basis of these observations a classification of rumination
and other regurgitation / belching disorders can be proposed:
(i) primary or classic rumination with or without belching
during / after a meal
(ii) secondary or reflux-associated rumination
(iii) supra-gastric belching independent of meals
Previous attempts at classification have been descriptive, based on
the presence and timing of abdominal strain and association with
retrograde flow of liquid and gas (110). In contrast, this system
identifies three groups with distinct mechanisms of disease that
may respond to specific management. Classic rumination is most
often triggered by dyspeptic symptoms. In this condition,
abdomino-gastric strain results in the return of food or belching
(depending on what is in the lumen), from the stomach or
oesophagus (depending on the timing of contraction). Reflux
rumination has a similar mechanism but is triggered by reflux
events. Both may respond to behavioural therapy directed at
abdominal wall relaxation; however the events that trigger this
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behaviour are different and may respond to specific therapy. In
contrast rapid, repetitive supra-gastric belching is produced by a
distinct behavioural abnormality and may require specific therapy
focused on the upper oesophageal sphincter.(137)
2.4.10 Study limitations
This study has the limitations of most case reviews, discussed
below.
2.4.11 Follow up data
Clinical data and follow-up was not always complete, especially in
out of area referrals, and medical treatment was not provided in a
systematic manner. In particular, although all patients received at
least one session of behavioural instruction, only a minority
received physiotherapy in the community. This is due to healthcare
providers and staff being unfamiliar with the diagnosis. The
behavioural instruction requires no specialist knowledge, simply
the principles of diaphragmatic breathing applied at the time of
symptom onset. As a result of this this study almost certainly
underestimates the potential benefits of this approach. However,
even in cases where behavioural therapy was not effective and
individuals continued to have recurrent rumination or belching a
definitive diagnosis was helpful as it helped to avoid further
investigation and inappropriate treatment.
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2.4.12 Psychological factors
2 patients within our cohort had stressful life events associated
with the development of rumination syndrome. 1 had significant
worsening of symptoms following a burglary and another was an
immigrant with unclear residency status. In the largest previously
published case series of 147 children and adolescents with
rumination, an acute onset of symptoms following a stressful life
event was described in 15 (10.2%) (116). It would seem sensible
for any therapy to address the rumination should focus on
biofeedback techniques but should also include methods to deal
with the original stressor.
2.4.13 Patient response to diagnosis
Patient response to the diagnosis was not recorded in the HRM
data or patient notes. However, anecdotally as one of the clinical
staff delivering the diagnosis and behavioural therapy, the majority
of patients and their family members present were accepting of the
diagnosis. They felt that a behavioural element could be a
causative factor. The important fact to deliver was that although
the behavioural component was voluntary it is sub-conscious.
2.5 Conclusion
These findings support the hypothesis that rumination and many of
its variations represent common behavioural responses to digestive
symptoms after meals and that a simple, generic behavioural
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intervention can provide effective management whether the
presenting complaint is vomiting / regurgitation or belching.
Further, this study demonstrates the clinical utility of HRM studies
during a test meal in a group of patients with medically
unexplained, treatment resistant symptoms. Advanced physiologic
measurement identifies three groups with distinct mechanisms of
disease that are likely to respond to specific management.
Moreover the vivid, visual demonstration of oesophageal function
provided by HRM can help patients (and their doctors) understand
the cause of their symptoms; enhance patient acceptance of the
diagnosis and the effectiveness of behavioural therapy.
105
3 Chapter 3  Assessment of oesophago-gastric junction
and novel assessments for gastro-oesophageal reflux
disease
3.1 Introduction
3.1.1GORD  definition and treatment
Gastro-Oesophageal Reflux Disease (GORD) is a common condition
that typically presents with heartburn and acid regurgitation (5).
Extra-oesophageal features such as chest pain and cough can also
be associated (138). Proton pump inhibitors are recommended as
first line empirical management after lifestyle adaption(139). When
symptoms do not respond to acid suppression, and especially if
volume regurgitation is prominent, further investigation is required
to confirm the diagnosis and guide further management including
anti-reflux surgery.(140)
3.1.2GORD - diagnosis
Upper gastrointestinal endoscopy is often performed in patients
with persistent reflux symptoms to identify mucosal disease related
to chronic acid exposure (e.g. oesophagitis, Barretts oesophagus),
peptic ulcer disease and malignancy. Those on long term acid
suppression often exhibit no mucosal disease and ambulatory pH
monitoring is required to provide objective evidence of pathologic
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oesophageal acid exposure and/or symptom-reflux association (8,
140). However ambulatory studies require time off medication
prior to the investigation and during it (normally a total of 7-8
days), involve invasive procedures, require compliance with
instructions and additional hospital visits. Most patients also find
catheter based pH studies uncomfortable and tolerate them poorly
(141).
3.1.3Novel methods for diagnosis of GORD
New approaches which can provide a reliable diagnosis of reflux
disease at the index endoscopy and/or without the need for
catheter based pH studies would be attractive to patients and
physicians and potentially reduce costs to the health care system.
3.1.3.1 Oesophageal histology
Histology has been proposed as a surrogate marker for disease
severity. In the absence of macroscopic oesophagitis, various
microscopic changes have been reported in the mucosa of GORD
patients (142). However, similar to macroscopic oesophagitis,
these microscopic changes often resolve on PPI therapy and the
clinical utility of using histology to diagnose GORD in patients on
acid suppression has not been confirmed (143).
This has been addressed by certain groups, with efforts being
made for histology to be utilised in the diagnosis of GORD. Zentilin
et al have developed a reflux score to try and use histology as a
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diagnostic marker for reflux disease. 6 criteria were used, each
with an associated score and compared between controls and
reflux patients with some success  listed in Table 6
Table 6. Histological parameters
Histological
parameter
Scoring system
Basal cell thickness 0 = none 1 = mild 2 = marked
Papillary length 0 = none 1 = mild 2 = marked
Dilation of
intercellular spaces
0 = none 1 = mild 2 = marked
on basis of
size
Intra-epithelial
eosinophils
0=absent 1=1 eosinophil 2=>1
eosinophil
Intra-epithelial
neutrophils
0=absent 2=present
Necrosis/erosion 0=absent 2=present
3 biopsies were taken (Z line, 2 cm above and 4cm above), but
results found to be comparable with just two biopsy results (Z line
and 2cm above). A score of more than 2 in one single parameter
distinguished healthy controls from reflux patients (established on
the basis of pH studies, symptoms and endoscopy findings) with a
reflux score above 2 in 100/ (84%) reflux patients and 3/20 (15%)
healthy controls, with significant difference. The negative predictive
value and positive predictive value were 46% and 97%
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respectively (142). The specificity was highest for intra-epithelial
neutrophils and erosions at 100%.
This work has further been elaborated on by colleagues in St
Thomass Hospital. Sweis et al (144) compared histology with
prolonged pH monitoring in reflux patients. 57 patients were
separated into reflux (n=37) with prolonged oesophageal acid
exposure and/or positive symptom index (>50%) or functional
heartburn (n=20) with both parameters negative. All histological
parameters were similar in both groups except for intra-epithelial
neutrophils (IEN) This group found a combined Zentilin reflux score
RIDQGLQFUHDVHG,(1VWLOOKDGUHODWLYHO\ORZVHQVLWLYLW\EXW
improved specificity; for IEN at Z line sensitivity 30%, specificity
92.6% then 2cm above Z line sensitivity 20% and specificity
$=HQWLOLQUHIOX[VFRUHKDGVHQVLWLYLW\DQG
specificity 95% at Z line and sensitivity 18.9% and specificity
100% proximally. Histology may be used to diagnose GORD and
potentially replace pH studies in certain cases.
3.1.3.2 EndoFLIP®
An alternative and novel approach is to interrogate the anatomy
and function of the Oesophago-Gastric Junction (OGJ) as pathology
within this region is the most important cause of GORD (140). The
Endoluminal Functional Lumen Imaging Probe (EndoFLIP®,
Crospon, Galway, Ireland) is a novel technology that applies
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impedance planimetry to measure cross-sectional area (CSA) and
pressure at the OGJ, therefore allowing distensibility of the reflux
barrier to be measured.
The EndoFLIP® assembly is 240 cm long with a 3-mm outer
diameter. The distal end of the probe is 14cm long comprised of a
catheter with 16 paired impedance electrodes and pressure sensor
enclosed within an infinitely compliant bag able to fill a volume of
40ml. The catheter is passed through the mouth until the
impedance electrodes straddle the OGJ at its mid-point. The bag is
filled with a conductive medium to set volumes (20ml and 30ml).
An AC current is passed through the medium and impedance is
recorded. This allows the diameter and cross-sectional area (CSA)
of the bag to be measured, along with intra-bag pressure.
Figure 13. EndoFLIP® images at GOJ and catheter  reproduced from
Cropson, Galway, Ireland.
Catheter with inflatable bag
EndoFLIP® images of GOJ
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Both increased cross-sectional area and decreased OGJ opening
pressure have been documented by barostat studies in GORD
patients, being most marked in those with hiatus hernia (84).
Consistent with these findings, initial trials with EndoFLIP® in
reflux patients reported increased OGJ distensibility in 20 reflux
patients with evidence of oesophagitis (LA grade A-C) on
endoscopy compared to 20 asymptomatic healthy controls (94).
However there was a wide variability in the results with important
crossover of values between health and disease. Moreover, only
4/20 of the patient group had pH studies and only 2 of these had a
GORD diagnosis based on prolonged oesophageal acid exposure.
3.1.3.3 Wireless pH monitoring
The wireless Bravo® capsule uses is a capsule suctioned to the
oesophagus to monitor oesophageal pH for up to 96 hours. This
has the advantage of allowing prolonged measurements, allowing a
more normal day in the patient in comparison to a nasal catheter
and also has better patient tolerability(145). It also potentially
reduces the problem of day-to-day variability of symptoms (146)
as a longer measurement. In one study it was used to identify
patients with prolonged oesophageal acid exposure who had had
previously had a negative catheter based study(90). The
disadvantages of Bravo® compared to conventional pH-studies
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include increased costs and the need for endoscopy to guide
placement of the capsule in the oesophagus and unavailability of
any impedance measurements.
3.1.4Aim of the study
The aim of this study was to assess the feasibility OGJ CSA and
distensibility measured by the EndoFLIP® device for the diagnosis
of GORD. Can EndoFLIP® could differentiate between participant
groups based on clinical (patient vs. healthy volunteer) and/or
physiologic (normal vs. pathological acid exposure ambulatory pH-
studies) parameters. For EndoFLIP® to be useful in this manner,
patients with high OGJ distensibility will have pathological levels of
oesophageal acid exposure on prolonged, wireless pH testing. If
proven, this would remove the need for ambulatory pH-studies to
confirm the diagnosis. As well as the opportunity to establish the
diagnosis of GORD at the time of endoscopy, measurement of OGJ
distensibility with EndoFLIP® may identify a subgroup of patients
with a highly distensible OGJ that report volume regurgitation
more often than patients with normal OGJ distensibility. This is
clinically relevant because regurgitation associated with persistent
weakly acid reflux is the predominant cause of persistent
symptoms in patients on double-dose proton pump inhibitors
(147), and regurgitation is less likely to respond to acid
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suppression than heartburn or chest pain (148, 149). In these
GORD patients, surgery may be the most effective treatment
option. Prolonged, wireless pH monitoring would be used alongside
distensibility measurements.
In summary, the aims of this study are:
x Is measurement of OGJ CSA and distensibilty feasible in
GORD patients and HV with the EndoFLIP® device?
x Will the differences in OGJ CSA and distensibility differentiate
between GORD patients and HV based on symptoms?
x Will the differences in OGJ CSA and distensibility differentiate
between GORD patients and HV based on prolonged
oesophageal acid exposure?
x Will increased OGJ distensibility be associated with volume
regurgitation within the GORD patient group?
3.2 Methods
Healthy volunteers were recruited and studied were completed at
the National Institute of Health Research Biomedical Research Unit,
University of Nottingham and were recruited by poster around QMC
hospital. Patients were recruited from referrals for pH
measurements and studies were completed at Guys and St
Thomass NHS Foundation Trust. Identical procedures were
adhered to in both centres. Approval was through National
Research Ethics Committee (Ref: 09/H0802/104) for patient
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studies and the University of Nottingham Ethics committee for the
healthy volunteer studies. Patient recruitment and EndoFLIP®
measurement were completed by Dr Rami Sweis at Guys and St
Thomass but all analysis of data from both patients and healthy
volunteers was completed by Dr Emily Tucker.
3.2.1Screening visit
At the screening visit upper gastrointestinal symptoms were
documented. Demographic information including height and weight
were recorded together with any past medical history of disease
and current use of medication. Healthy volunteers had to have no
symptoms of reflux disease and be on no regular medications and
have no history of gastro-intestinal disease or surgery.
Patients had typical symptoms of reflux disease (heartburn,
regurgitation) with at least partial response to acid suppression
therapy, no previous upper gastro-intestinal surgery and no
evidence of oesophageal dysmotility on oesophageal manometry
(these were performed on a clinical basis and had to be completed
before recruitment into this study). Dysphagia could be co-existent
(often reported by GORD patients (150)) but could not be the
predominant symptom. Participants with co-morbidity requiring
medical management were excluded. Pregnancy was excluded by
XULQHǃKXPDQFKRULRQLFJRQDGRWURSLQǃ+&*WHVWLQJSULRUWRDOO
invasive procedures. All anti-acid and pro-kinetic medications were
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stopped for 7 days prior to study day and for the duration of the
study.
All participants completed written consent.
Healthy volunteers with endoscopic evidence of GORD were
excluded from the categorical analysis (i.e. large hiatus hernia,
Barrett oesophagus LA grade B-D oesophagitis).
3.2.2Gastroscopy
On the study day participants were starved from midnight. The
participant was placed in the left lateral position. Sedation and
analgesia were provided to all participants using midazolam (2-
10mg) and pethidine (25-50mg). Pharyngeal anaesthesia was not
used due to the risk of aspiration with the Bravo capsule should it
not adhere correctly to the oesophagus. A protective mouth guard
was inserted to protect teeth. An endoscope (Olympus, KeyMed
House, Stock Road, Southend-on-Sea, SS2 5QH) was then inserted
through the mouth. Complete visualisation from the oesophagus to
the second part of the duodenum was obtained before any study
procedures. Z line distance was recorded and any oesophagitis or
hiatus hernia documented. Oesophageal biopsies were then taken
from the Z line at the 3 oclock and 9 oclock position and in the
same pattern from 2cm above Z line.
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3.2.3Endoluminal Functional Lumen Imaging Probe -
EndoFLIP®
This was completed following biopsies as the oesophageal mucosa
could potentially be damaged by the inflation of the EndoFLIP®
bag, preventing accurate analysis of the biopsies.
Data analysis was performed as described by Kwiatek et al (94).
The median of each of 16 CSA and intra-bag pressure
measurements along the length of the EndoFLIP® device was
taken over a 30 second recording at each of the distension
volumes. It was assumed that the OGJ position represented the
segment with the smallest CSA (94). The minimum CSA with intra-
bag pressure was used to calculate OGJ distensibility (CSA/intra-
bag pressure).
3.2.4Prolonged, wireless pH measurements
Following the oesophageal biopsies and EndoFLIP® measurements,
the pH capsule was attached. The Bravo capsule (Bravo®, Given
Imaging, Yoquem, Israel) was first calibrated in pH 7.01 buffer for
ten minutes. After this time the Bravo receiver was activated and
wireless connection between receiver and capsule ensured. The
receiver calibrates to pH 7.01. Once complete the capsule was
rinsed in sterile water and placed in pH buffer 1.07. The same
calibration process was completed except that only 30 seconds
soaking is required. Once this is complete the capsule was rinsed
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again in sterile water and placed back into the pH 7.01 buffer. The
receiver was then checked to ensure the correct pH is recorded
(7.01).
The capsule was inserted trans-orally on an introducer. A wireless
pH capsule was placed 6cm proximal to the Z-line after 1 minute
suction according to manufacturer instructions and as previously
described (90, 146). A small section of oesophageal mucosa was
sucked into the capsule and a locking pin then released that fired
through the mucosa to hold the capsule in place. The capsule was
then released from the introducer and the introducer removed from
the mouth. The wireless receiver was activated to start recording
pH at the end of the procedure. Participants documented reflux
symptoms, position (upright, supine) and all oral intake on the
Bravo data logger and these were noted also in a paper diary. Data
from the wireless recorder was downloaded after 48 hours, the
position and function of the Bravo capsule was checked by
measuring pH and ensuring data recording. The batteries were
replaced for a further 48 hours monitoring with the intention of
completing up to 96 hours of monitoring (or as long as capsule
stayed attached).
3.2.5Data analysis of pH monitoring
Data analysis documented the number of reflux events, total
oesophageal acid exposure time (% time oesophageal pH dropped
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below 4); an average 5.3% acid exposure over the study was
defined as the upper limit of normal (146). Meal periods were
excluded from analysis. Symptom association was measured using
a 2 minute window. Symptom index (SI) is the percentage of
symptoms associated with reflux episodes (diagnostic cut off
>50%). Symptom Associated Probability (SAP) is a statistical
function which calculates the probability that the observed
association between reflux and symptoms is not by chance
(diagnostic cut off >95%)(151).
3.2.6Histology
Oesophageal biopsies were orientated and embedded in paraffin
and were assessed by single pathologist, who was aware these
were all healthy volunteers but blinded to the gastroscopy and pH
study results.
3.2.7Statistical analysis
With parametric and nonparametric data, unpaired t test and the
Mann Whitney test were used for comparison respectively.
Association between demographic and physiologic variables with
CSA and distensibility was calculated using univariate and
multivariate linear regression.
In summary, the process of data collection
x Patients awaiting pH studies recruited
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x Healthy volunteers recruited
x Gastroscopy performed
x Oesophageal biopsies (HV only)
x EndoFLIP® measurements taken
x Bravo capsule attached
x Wireless pH measurements taken
x Results compared between HV and patients
3.3 Results
3.3.1Participant groups and demographics
21 healthy volunteers (16 females, 5 male, Age 22  46 years)
with mean body mass index (BMI) mean 24 kg/m2 (range 19-32
kg/m2) and 22 patients were recruited. 2 patients were excluded
due to Schatzki ring on endoscopy, 1 due to early drop off of Bravo
capsule and 1 due to negative bag pressure on EndoFLIP®. The
consort diagram below shows recruitment for trial.
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Excluded: n=9
bravo capsule failed attached n=1
bravo receiver broken n=1
early bravo drop off n=2
grade 2 oesophagitis n=1
no endoflip catheters n=3
negative balloon endoflip pressure n=1
21 volunteers
30 volunteers
33 volunteers screened
Withdrew n=3
22 patients screened
Excluded n=4
Schiatzi ring n=2
Early bravo drop off n=1
negative balloon endoflip pressure n=1
18 patients
Figure 14. Consort diagram for EndoFLIP® trial
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Thus 21 healthy volunteers and 18 patients (13 female, 5 male,
age range 27  78 years) with mean BMI 33.9 kg/m2 (range 21-57
kg/m2) were included in final analysis. Patients were older than
healthy volunteers (p<0.0001). Mean BMI was also higher than
that of healthy volunteers (p=0.001).
3.3.2Endoscopy findings
No healthy volunteer was taking acid suppressant medications. 7
healthy volunteers had grade A oesophagitis and 1 volunteer grade
B oesophagitis on white light endoscopy.
All patients had been taking proton pump inhibitors until 7 days
before the procedure. 7 patients had persistent grade A
oesophagitis (5 of whom also had a hiatus hernia) and 3 further
patients had hiatus hernia but with no oesophagitis.
3.3.3Bravo© oesophageal acid exposure
Occasional mid-chest discomfort was reported by 2 healthy
volunteers on eating due to the presence of the wireless pH
capsule, but this did not prevent them from eating or interfere with
daily function. In total, 21 healthy volunteers and 18 patients had
at least 48-hours of wireless pH recording and EndoFLIP®
measurements.
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Average oesophageal acid exposure time was greater in the patient
group, although this did not reach significance compared to HVs
(5.2 (IQR 2.3-7.7) % vs. 2.0 (1.2-5.1) %; p=0.088, Figure 15).
Figure 15. Comparison of Healthy Volunteer and patient group for
percentage of time oesophageal acid exposure >pH 4
Categorical analysis found 3/21 (14%) healthy volunteers and 9/18
(50%) patients had oesophageal acid exposure above 5.3%. No
healthy volunteers had reflux symptoms during the study. The only
symptom recorded by any healthy volunteers was mid-chest
discomfort as discussed earlier. 7 patients had positive symptom
index above 50% and 10 patients had a SAP >95% for at least one
symptom. 9 patients complained of volume regurgitation and 5 had
a positive SI and SAP for this symptom. 6/9 patients with
regurgitation also had pathological acid exposure.
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3.3.4EndoFLIP® OGJ Cross-sectional area and distensibility
OGJ cross-sectional area was greater in HV than patients at 20ml
(p=0.018) and trended towards being greater at 30ml (p=0.0580)
as displayed in Figure 16.
Figure 16. Cross-sectional area of OGJ in healthy volunteer and
patient groups at 20ml and 30ml endoFLIP® balloon volume
3.3.5OGJ Distensibility
Figure 17 shows the distensibility was lower in the GORD patient
group than healthy controls, at both 20ml and 30ml bag inflation
volume (p=0.001 and p=0.020 respectively).
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Figure 17. Distensibility of OGJ in healthy volunteer and patient
groups at 20ml and 30ml endoFLIP® balloon volume
3.3.6Oesophageal acid exposure and EndoFLIP®
When participants were separated into those with and without
pathological oesophageal acid exposure (>5.3%), there was no
significant difference between the two groups in terms of OGJ
cross-sectional area, shown in Figure 18 or distensibility, as
demonstrated in Figure 19.
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Figure 18. Comparison of participants with oesophageal acid
exposure time over 5.3% with cross-sectional area of OGJ
Figure 19. Comparison of distensibility of OGJ with varying
oesophageal acid exposure time
6 patients had pathological oesophageal acid exposure and
regurgitation as one of their prominent symptoms. Also in this
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predefined sub-group OGJ CSA and distensibility were not
significantly different to healthy volunteers or participants with
pathological acid exposure.
Figure 20. Comparison of distensibility in participants with and
without regurgitation
3.3.7Association of EndoFLIP® results with demographic
variables
Due to the unexpected findings of the primary analysis, a post-hoc
analysis was performed to assess whether demographic factors
explained the lack of association between EndoFLIP® results and
acid exposure / patient group. On univariate linear regression there
was no correlation of OGJ CSA or distensibility with sex. Similarly
there was no consistent correlation between age and OGJ CSA or
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distensibility, only a weak correlation between age and CSA at
30ml bag volume (R2=0.1218, p=0.030,Figure 21).
Figure 21. Cross-sectional area of GOJ against age
In contrast, a significant link between EndoFLIP® results and
obesity was present. Univariate regression showed an inverse
correlation between BMI and OGJ CSA decreasing with increasing
BMI (R2=0.2758, p=0.001). This is shown in Figure 22.
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Figure 22. Correlation of BMI with cross-sectional area at 30ml
endoFLIP® balloon volume
An inverse correlation was present also between BMI and
distensibility (R2=0.2005, p=0.005).
3.3.8Histology
No oesophageal biopsies were taken from the patient group. This
was due to the constraints on time on during the endoscopy, with
the EndoFLIP® measurements adding significant length to the
overall procedure time. The healthy volunteer biopsies were still
examined as there were some positive pH results within the
healthy volunteer population.
21 volunteers were included in final analysis (see previous consort
diagram, Figure 14). 3 were excluded from histological analysis as
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there was no squamous epithelium in the GOJ samples and their
corresponding proximal biopsies were also excluded.
Table 7. Prevalence of individual histological lesions with score of
1 or 2 in controls
GOJ biopsy
N=18
2cm above GOJ biopsy
N=18
Basal cell thickness 14/18
78%
11/18
61%
Papillary length 9/18
50%
6/18
33%
Dilated intercellular
space
13/18
72%
15/18
83%
Intra-epithelia
eosinophils
7/18
39%
8/18
44%
Intra-epithelial
neutrophils
1/18
6%
0/18
0%
Necrosis/erosions 0/18
0%
0/18
0%
11/18 had a score less than 7, the score used in the comparison of
histology and wireless pH monitoring.
The healthy volunteers were then separated into 4 groups,
depending on endoscopy and pH study results. Positive pH was
based on oesophageal acid exposure time >5.3% and positive
endoscopy on any oesophagitis (LA grade A-D) present.
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x Group 1: positive endoscopy, positive pH study
x Group2: negative endoscopy, positive pH study
x Group 3: negative endoscopy, negative pH study
x Group 4: positive endoscopy, negative pH study
Table 8. Comparison of endoscopy, pH and histology results
Group 1 2 3 4
No of cases
(total n=18)
2 1 12 3
Basal cell
thickness
1 0 10 3
DIS 1 8 3
Papillary
length
6 3
Intra-
epithelia
eosinophil
5
Intra-
epithelial
neutrophils
1
Necrosis
Both the Zentilin (142) paper and Sweis (144) had increased
histological findings at the GOJ, seen within this healthy volunteer
cohort. However, neither noted any intra-epithelial neutrophils
within pH negative groups while we have one control with
neutrophils present despite no symptoms, gastroscopic changes
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and negative pH study. This suggests that these can still occur
within a healthy population, although rarely.
3.4 Discussion
The primary aim of this diagnostic feasibility study was to assess
whether measurements of OGJ cross-sectional area (CSA) and
distensibility by the EndoFLIP® device had the potential to identify
GORD patients with pathological oesophageal acid exposure on pH
monitoring. The results demonstrate that this technology cannot be
used to diagnose GORD in isolation. Further analysis indicates that
this failure may be due to an important interaction between BMI
and the biophysical properties of the OGJ.
3.4.1EndoFLIP® results
The result that both OGJ CSA and distensibility were greater in the
healthy volunteers than patients referred for investigation of
typical reflux symptoms was unexpected. Even when participants
were re-assigned into groups based on the presence or absence of
pathological oesophageal acid exposure time there were no
differences between CSA and OGJ distensibility in health and
disease. EndoFLIP® measurements were not increased in those
with severe reflux symptoms, (including volume regurgitation).
3.4.2Results compared to previous literature
These results are not consistent with those of Kwiatek et al. which
reported significantly higher OGJ distensibility in GORD patients
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compared to healthy controls (94). That study used reflux
symptoms and endoscopic findings to identify GORD patients
rather than definitive evidence from ambulatory pH studies. It is
impossible to know whether the severity of disease was
comparable; however, endoscopic findings were similar in both
studies and it is unlikely that the GORD patients recruited in the
previous study had much more severe disease. It is more likely
that these inconsistent findings are due to wide variability within
the study populations. In both studies, EndoFLIP® measurements
of OGJ distensibility ranged between 1 and >30mm2/mmHg with
median values in single figures at both 20 and 30ml distension
volumes. This variability impacts on the power of any study to
show a significant difference between groups; however, together,
these findings indicate that, even if OGJ distensibility is higher in
GORD patients, establishing a set of normal values for
EndoFLIP® measurements would be difficult.
3.4.3Technical factors with EndoFLIP® measurement
It is well-established that the OGJ reflux barrier in GORD patients
is weak and distensible compared to healthy controls (84).
However, there are several reasons why EndoFLIP® measurement
of OGJ distensibility may not reflect this and does not predict the
presence or absence of reflux symptoms or the severity of acid
reflux.
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x Patient and control groups were selected on the basis of
symptoms and not objective diagnosis based on endoscopy
or pH-studies; it is inevitable that some HVs will have GORD
on testing and some patients will not. Supporting this, a
study of 1000 randomly selected responders to a postal
questionnaire who then underwent gastroscopy found
oesophagitis in those without symptoms. 155 individuals had
erosive oesophagitis of whom 57 (36.8%) reported no reflux
symptoms at all (152). Conversely of 1307 consecutive
patients referred for investigation of typical reflux
symptoms, only 50% had pathological acid exposure (153).
The possibility of confounding due to misclassification of
participants based on a symptom based diagnosis within our
study was addressed by a secondary analysis in which
patients and controls were reallocated as GORD positive and
GORD negative on the basis of the pH studies rather than
symptoms.
x Technical factors such as body position and the use of
sedation and analgesia during the endoscopic procedure may
also impact on the biophysical properties of the OGJ and
EndoFLIP® results.
x It may be that measurements of OGJ distensibility do not
capture relevant pathophysiology. GORD is a multifactorial
disease and the OGJ is a complex structure with the lower
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oesophageal sphincter, crural diaphragm and clasp and sling
fibers at the angle of His all contributing to the reflux
barrier.(154) Endo-luminal measurement of CSA and
distensibility may not reflect the action or interaction of all of
these parameters.
3.4.4Demographic factors on EndoFLIP® results
Age and BMI were higher in the patient population compared to the
healthy controls. Both of these demographic parameters are
associated with increased acid exposure (153, 155). Univariate
regression showed a positive correlation of age and OGJ CSA that
was significant only at the 30ml distension level; however the
effect was very weak. In contrast, the correlation between obesity
and EndoFLIP® findings was consistent and relatively strong. High
body mass index (BMI) was associated with reduced CSA and
decreased distensibility. As a result the comparatively obese
patient group had lower CSA and distensibility than the healthy
controls and this effect appears to dominate any effect abnormal
OGJ properties in GORD may have had on these measurements.
The mechanism of this effect could be due to mechanical factors, in
particular the effects of increased intra-abdominal pressure (156),
that may not be fully corrected by baseline correction. An in vivo
experimental model that may provide some insight into this effect
is EndoFLIP® measurement during the introduction of
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pneumoperitoneum. Nathanson et al. reported findings from 50
patients undergoing a variety of laparoscopic operations that had
EndoFLIP® measurements after induction of anaesthesia, post-
pneumoperitoneum and just prior to extubation (157). Note that
insufflation pressure in this surgical study was 13mmHg of CO2,
which is similar to the intra-abdominal pressure seen in morbid
obesity. The findings showed that intra-bag pressure (IBP) and
CSA decreased following pneumoperitoneum, but distensibility
increased (157). This result is not that expected from simple
mechanical compression of the EndoFLIP® bag which
would increase intra-bag pressure due to pneumoperitoneum and,
therefore, decrease CSA and distensibility. For distensibility
(=CSA/IBP) to increase during insufflation, intra-bag pressure
must decrease disproportionally more than CSA due to changes in
OGJ anatomy or, just as likely, OGJ relaxation triggered by
stimulation. These findings highlight the complex relationship
between obesity, intra-abdominal pressure, OGJ physiology and
reflux that is reflected also in a recent clinical series of nearly 600
GORD patients. Anggiansah et al showed that, although obesity is
associated with impaired OGJ function and prolonged oesophageal
acid exposure on univariate regression, this association could not
be explained by simple mechanical effects of obesity on the OGJ on
multivariate analysis (155).
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3.4.5Histological analysis
The histological analysis was limited to the healthy volunteer
cohort of this study and descriptive analysis. The changes reported
by Zentilin et al (142) were reported more frequently in our
healthy population and 7/18 had a reflux score greater than 7,
reported to have greater specificity. However, these biopsies were
reported by a single pathologist (although was blinded to
endoscopy and pH results) limiting the value. However, in routine
clinical practice oesophageal biopsies would only be reported by a
single pathologist, suggesting there are limitations to using
histology alone for diagnosis of reflux disease without pH studies.
3.4.6Limitations of study
In retrospect, a limitation of this study was that the healthy
controls and GORD patients were not matched for demographic
factors including age and obesity. It is well known that obesity is
associated with an increased risk of GORD (158) and so any
patient population is likely to have a greater BMI than a control
cohort. However controlling for obesity is not possible in clinical
practice and this further emphasizes that establishing usable
normal values of OGJ CSA and distensibility for diagnosis of
GORD in clinical practice would be very difficult as multiple
parameters affect these measurements.
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Histology was only measured in HV and ideally should have been
completed in the patient cohort as well.
There were some cases of positive pH studies within the HV
population. Expanding the number of healthy controls to have a
greater number of normal results may have been useful.
The study was completed at two centres, one for HV and one for
patients. This was to increase recruitment and reduce overall study
time. Although both teams attended training at the same time for
equipment use, differences inevitably occur. This is exemplified by
no histological data being collected in the patient cohort. Ideally,
both sets of participants would have been studied at the same site
to minimise differences between the patient and volunteer
populations, but it was not possible with time constraints within
this study. Is also means there may have been differences in how
the tests were carried out in each centre.
The EndoFLIP® device was placed through the mouth and to the
level of the OGJ, after the endoscopy had taken place (therefore
length to the OGJ known) but not with the endoscope present. This
was under advice from the manufacturing team. The EndoFLIP®
images then take on a classic hourglass shape which also
confirmed position. A more robust method would have been to put
the EndoFLIP® probe through a channel of the scope and directly
view the OGJ to ensure exact placement. The EndoFLIP® probe is
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designed to be used without the need for concurrent endoscopy,
however, within a trial context it would have been a more vigorous
process to use down a scope channel and minimised possible
variability.
3.5 Conclusion
EndoFLIP® is a technically viable means of measuring OGJ CSA
and distensibility at endoscopy; however, results from this
feasibility study demonstrate that these measurements do not
predict the presence or severity of reflux disease. This is due to
wide variability of these parameters within the study groups and
the presence of an important interaction between obesity and
these measurements. Thus the EndoFLIP® technique is not
suitable for GORD diagnosis. However, this technology may well be
of use in other settings where patients have serial measurements
(i.e. act as their own controls) and in which the complex
interaction of structure and function is less problematic. For
example increasing use of EndoFLIP® has been made as a smart
bougie to guide anti-reflux and bariatric surgery (157, 159-161)
and to monitor response to dilatation pre and post treatment in
achalasia or eosinophilic oesophagitis(162).
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4 Chapter 4 - Non-invasive methods for the
measurement of gastric emptying in health and
disease
4.1 Introduction
The principles of investigation and current status of gastric
emptying studies has been described in the main introduction of
this thesis. A more thorough explanation of the techniques used in
the work in this MD and their relevance to clinical practice will be
detailed, along with a comprehensive description of the functional
dyspeptic population.
4.1.1 Gastric emptying andmethods of assessing
Delayed gastric emptying, impaired accommodation and
hypersensitivity have all been recognised as pathophysiologic
mechanisms in functional dyspepsia (32). Current methodology for
measuring these includes barostat studies, gamma scintigraphy
gastric emptying studies, SPECT and MRI. A simpler method that is
thought to provide a representative assessment for some of the
parameters measured by more complex technologies is the
nutrient drink test.
Gamma scintigraphy and the Nutrient Drink Test can be used in
routine clinical practice but other technologies are confined to
research unit settings either requiring specialist, expensive
equipment (such as MRI) or invasive procedures poorly tolerated
by patients (e.g. barostat studies). Invasive procedures also risk
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interfering with normal physiology and in a population where
visceral hypersensitivity is important, this is especially undesirable.
Therefore, the development of non-invasive methods of assessing
gastric function are required. This study was designed to develop
such techniques.
4.1.2 Symptom scoring
Recording and documenting symptoms in functional dyspepsia has
created challenges, to try and objectify them as much as possible
and allow comparison between different individuals. A method used
and validated by several different studies is the visual analogue
score (VAS). In this, a 100mm line, with 0 at the bottom and 100
at the top is listed above each dyspeptic symptom. 0 indicates
none of the symptom and 100 indicates maximum. Text
descriptors indicating none, mild, moderate, severe, maximum
serve to reduce individual variation. The patient then scores a line
through the point on the line they feel represents the severity of
their symptoms. This VAS has been used in nutrient drink tests and
gastric barostat studies, for gastric hypersensitivity (54, 163) in
both functional dyspepsia patients and healthy volunteers.
Dyspeptic symptoms used included epigastric pain, heartburn,
nausea, fullness, satiety and bloating.
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4.1.3 Psychological state assessment  questionnaires
As discussed in the introduction, psychological state is implicated in
functional dyspepsia. Methods of assessing this have always been
difficult. Full psychological testing is time consuming and requires
access to a dedicated psychiatrist/psychologist. Most commonly in
studies on functional dyspepsia, questionnaires are used.
4.1.3.1 PHQ-15
The Patient Health Questionnaire 15 is 15 questions to assess
somatization, the description of multiple symptoms that cannot be
accounted for by medical or organic disease(164). The PHQ-15
uses criteria from the Diagnostic and Statistical Manuel of Mental
disorders, version IV, produced by the American Psychiatric
Association. Each symptom is scored from 0-not bothered at all to
2- bothered a lot. In a study of 6000 individuals in America PHQ-
15 scores have been compared to functional status, sick days,
clinic visits and difficulties related to symptoms (165). A score of 5
was associated with low somatic symptom severity, 10 with
medium and 15 and above with high.
4.1.3.2 EuroQuol Health Questionnaire
The EuroQuol heath questionnaire asks participants to grade a total
of 5 aspects of general health, such as mobility and self-care from
three options, from no difficulties, some problems or unable to
complete. It also includes a visual analogue scale for state of
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heath on the day of completion, from 0-100. It is also known as
EQ-5D. It has been validated in a dyspeptic cohort of 113 patients,
of which 70% were functional dyspeptics (166). Its advantages
over other questionnaires is that it is relatively short so easy for
participants to complete and is generic health questions, so can be
used easily in comparison to healthy volunteers and other disease
cohorts.
4.1.3.3 The Hospital and Anxiety Depression scale (HADS)
The HADS scale has been used for over 30 years to assess
depression and anxiety in a variety of diseases (167). It has
fourteen questions asking regarding the frequency of symptoms
relating to anxiety and depression, seven questions relating to
each. A maximum score of 21 can be given for both depression and
anxiety. 8-10 is associated with low level anxiety/depression, 11
and above shows significant depression/anxiety. It has been used
and validated in the dyspeptic population (168).
4.1.4 Nutrient drink test
As one of the predominant symptoms in FD is that of post-prandial
distress, drink tests (water and nutrient) have been suggested as
an easy and accessible way of assessing symptoms. Early satiety
has been associated with abnormal fundal accommodation and
visceral hypersensitivity on barostat and, therefore, an indirect way
of measuring these aspects of gastric function (38). A drink test
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involves the patient drinking water or nutrient at a set rate, whilst
scoring dyspeptic symptoms until a maximum tolerated volume is
reached (when symptoms prevent further ingestion). However,
there are many different options for nutrient drink tests. Drinking
rate, nutrient or non-nutrient substrate and best outcome measure
are examples. A Dutch group compared nutrient drinking and
water drinking tests in FD patients, those with mild dyspeptic
symptoms and healthy volunteers with the results of barostat
studies(105). Although the FD group drank less water and nutrient
than the two control groups, it was not associated with one
particular symptom and did not predict an abnormal barostat
study. It was noted that the rate of drinking was 100ml/min, a
relatively high rate of ingestion. A different study by Tack et al
showed that a slow drinking test (15ml/min) with calorific nutrient
showed a correlation in functional dyspeptic patients with
maximum tolerated volume and impaired accommodation in
concurrent barostat studies(106). A possible explanation suggested
for this was that rapid drink tests don't allow for adaptive gastric
accommodation, which can take up to fifteen minutes to have full
effect (38). Further non-nutrient drink tests dont evoke the
inhibition of gastric emptying from via negative feedback from lipid
within the duodenum. Tacks group have also shown that drink test
results (in terms of maximum volume tolerated) are reproducible
in both healthy volunteers and functional dyspeptics (169).
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Although the nutrient drink test has reasonable sensitivity for
functional dyspepsia, specificity is lower with overlap between
health and disease. Tacks study from 2003 found in a multivariate
analysis, gastric accommodation to a meal was the only
independent factor related to maximum tolerated volume in the
drink test, whereas gastric emptying rate and sensitivity not (106).
However, other researchers using drink tests of a fixed volume
found that visceral sensitivity was a key determinant of patient
symptoms after a test meal. Further, the maximum tolerated
volume measured by drinking test cannot differentiate between a
small stomach with a small overall capacity and a normal stomach
with decreased accommodation, from, due to simple biomechanics
(170), although these are associations. Assessing the development
of normal and dyspeptic symptoms as gastric volume increases
could potentially help to discriminate these two possibilities. It
should be noted also that in the study by Tack et al gastric
emptying was assessed by a 13C octanoic acid breath test. The
authors acknowledge that the breath test will only give information
about overall gastric emptying, rather than early and late phases,
which may be important in functional dyspepsia.
Together these results suggest a slow rate, calorific drink test of a
fixed volume is the most appropriate and practical to use as within
a functional dyspepsia population, with symptom monitoring
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alongside. Studies have shown that 100% of healthy subjects can
ingest >400ml of liquid nutrient with female and male healthy
volunteers averaging ~850ml and 1200ml respectively (169). The
same study shows that at least 80% of FD patients can ingest
>400ml of liquid nutrient, averaging ~500ml (169). These findings
were repeated in pilot studies in our own institution (see results)
4.1.5 Gamma scintigraphy
Gamma scintigraphy gastric emptying studies have long been used
in the investigation of functional dyspepsia and post-prandial
symptoms (31, 171-173). These currently use small, solid meals
labelled with a radioactive component (normally technetium-99m)
which is then measured with a gamma camera, for approximately
3-5 hours. For each time point measured a 2D image of the radio-
labelled stomach contents is produced. The principles of the
technique are described below.
Gamma scintigraphy has been used many years now on the study
of drug absorption and gastro-intestinal transit times. A substrate
(commonly foodstuff or drug) is labelled with a gamma ray
emitting radioisotope, commonly technetium -99 due to its half-
life of 6 hours and pure gamma emitting nature(174)). These then
pass through a gamma or Anger scintillation camera. Within the
gamma camera these rays pass through a collimator, which only
rays from a set direction are allowed to pass through, so images
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can be created of organ studied, such as stomach, which would
otherwise be indistinct. Collimators can be converging, diverging,
pin hole or parallel hole. The gamma photons then hit a scintillation
crystal, which releases a burst of light. This is detected by
photomultiplier tubes. The resulting signal can be digitalised to
produce quantative images. As peak photon energies vary
depending on isotopes used, multiple isotopes to be used in the
same study to label separate foodstuffs/drugs (175).
To calculate gastric emptying a region of interest (ROI) is drawn
round the stomach area as counts are produced. These are
corrected for radioactive decay, to ensure images from the start of
the study can be compared to later images. As the stomach lies at
an angle with the gastric antrum more anterior, counts from this
area travel through less tissue for detection by the gamma camera,
giving a larger number of counts from the antrum in comparison to
the fundus unless corrected. To compensate for this anterior and
posterior images are taken. Once both these images are taken the
counts can be used to calculate the geometric mean for a given
time point for a gastric ROI. This is the square root of the product
of the counts in the stomach ROI on the anterior and on the
posterior views [geometric mean = (anterior * posterior) 1/2 ]. This
compensates for the variation in counts due to attenuation through
tissues.
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An international standard has been established for meal usage and
time periods, with a 2 pancake meal commonly being used or
batter based meal substrate(176) with imaging at 0, 1,2 and 4
hours (177). This recommendation has been endorsed by the
American and European Neurogastroenterology and Motility
societies. Gastric emptying is considered delayed if 60% of meal is
retained at the 2 hour time point or more than 10% at the 4 hour
time point or of the time taken for half the meal to empty (t50) is
prolonged. However, in practice, the test meal applied and other
aspects of the performance and analysis of gastric scintigraphy can
vary between centres dramatically and this has proved a lack of
uniformity between different centres and tests.
Every different test meal if significantly different in calorie load,
physical structure and / or frequency of imaging, needs its own
normal values establishing. Subject characteristics are also
important. It has been reported also that age and sex affects
gastric emptying. Tougas et al studied 123 healthy volunteers with
gamma scintigraphy gastric emptying. They found that gastric
emptying was increased with age and was initially faster in men,
although was comparable between the sexes at 4 hours (176).
Interestingly, body mass index had no effect in this study.
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4.1.6 Magnetic Resonance Imaging
Another methodology increasingly being applied in gastric
emptying studies is magnetic resonance imaging. Currently, it uses
are limited to a research setting due to the requirements of
dedicated MRI scanners and the expensive involved. Its main
advantages are 3D images are gained and that no ionizing
radiation is used, meaning repeated scans, multiple
measurements and long study times can be performed in a wide
population.
The principles of MRI involve the object to be studied is placed in a
magnetic field. Hydrogen nuclei will align with this magnetic field
(due to protons) and create a directional magnetic field. A
radiofrequency pulse is then applied to the directional magnetic
field, causing this to move away, via exciting the protons within
the nucleus. The radiofrequency pulse is removed and the nuclei
realign themselves with the original magnetic field. As they return
to this position, they emit their own electromagnetic field, which is
recorded by a coil (signal detection) and used to reconstruct a 3D
image of the object being studied (99).
Initial studies with MRI have shown that it provides additional
information such as two distinct early and late phases of gastric
emptying (178). This has not been described with gamma
scintigraphy because, by current convention, gastric volume is
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normalized to 100% after ingestion of the meal. This automatically
reduces sensitivity of the test to receptive accommodation which
occurs during ingestion in response to the volume but not the
calorie load of the meal. The measurement of gastric emptying by
MRI has been validated by a study in healthy volunteers assessing
the inter-observer error, at 12% for 200ml volumes and decreasing
to 6% at larger volumes (600, 800ml). T50 measurements varied
by less than 5% (100). Another advantage of MRI is that it can
visualise gastric secretions. A 400ml chocolate meal was mixed
with the contrast agent gadolinium. Meal volume was then
assessed separately to total gastric contents volume (meal plus
secretion) and secretion separately, in 14 healthy volunteers on
rapid MRI scanning (179). The group found that meal volume
decreased from the stomach over time, whilst gastric section
increased, and this amount of gastric secretion was affected by the
rate of meal volume emptying. There was significant variability
between individuals however. A complex relationship obviously
exists between the two parameters, which need further
understanding. MRI has also been used to assess antral contraction
waves and its potential to assess gastric motility remains promising
(180)
MRI has been validated against scintigraphy, the conventional
standard in assessment of gastric emptying. 8 healthy volunteers
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underwent liquid and liquid and solid meals, with gastric emptying
assessed by scintigraphy and MRI. Intra-class correlation was
0.988 for liquids and 0.917 for solids(181).
4.1.7 Pathophysiology in functional dyspepsia
Previous studies have reported that approximately 40% of FD
patients have abnormalities on gastric emptying studies (32).
However, there is a poor correlation between symptom severity
and improvement in gastric emptying rates does not necessarily
result in improved symptoms. Thus the results of existing gastric
emptying studies do not necessarily establish diagnosis or guide
effective treatment (34). Therefore, there is little in the way of
tests to make a positive diagnosis of functional dyspepsia, with the
majority of cases diagnosed when all other tests are negative.
Another group where similar difficulties lie is the population with
symptoms suggestive of gastroparesis. Gastroparesis is
characterised by symptoms of nausea, fullness and post-prandial
vomiting with no structural abnormality to account for
symptoms(182). Type 1 diabetes is commonly associated with
these symptoms, but the condition can occur with autonomic
disturbance, Parkinsons disease, collagen disorders and idiopathic
associations have all been reported (183). As with functional
dyspepsia, the degree of delay in gastric emptying does not
necessarily correlate with severity of symptoms and objective
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improvements in gastric emptying does not necessarily correlate
with improvement in symptoms. A recent review in 2011 of the
Gastroparesis Registry in America has found that up to 25% of
those with gastroparetic symptoms have normal gastric emptying
(173).
Similarities in symptoms and variability in gastric emptying
between patients with functional dyspepsia and gastroparesis
suggests that functional dyspepsia with post-prandial distress may
be in fact part of the spectrum of gastric disorders. Conceptually
gastroparesis can be considered as severe gastric motor
dysfunction in which there is a loss of tone and contractility leading
to severe delays in overall gastric emptying as assessed by gastric
emptying half time, whereas functional dyspepsia is characterized
by less marked motor dysfunction that have little or no impact on
overall gastric emptying (although the dynamics of early and late
emptying may be altered)(184). In both cases the severity of
symptoms will be related to the severity of gastric motor
dysfunction but also visceral sensitivity. Indeed in 40% of patients
with functional dyspepsia heightened visceral sensitivity is the only
abnormality detected on current physiological investigations(32).
4.1.8 Treatment options in functional dyspepsia
Currently treatment strategies for FD and gastroparesis are not
very successful (185, 186). This is partly due to the heterogeneous
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nature of patients and lack of one single pathophysiology
mechanism to target with drug therapy. Current strategies for
treatment options are listed below.
4.1.8.1 Histamine-2 receptor anatognists and proton pump inhibitors
Histamine-2 receptor antagonists and proton pump inhibitors are
frequently used initially when patients are complaining of
dyspepsia. The benefits of this in functional dyspepsia are limited
with therapeutic gain of 7-10% (186). The majority of trials with
H2RA were completed those with non-ulcer dyspepsia and did not
use the ROME criteria for functional dyspepsia. Trials of PPIs have
been completed in those with functional dyspepsia. A meta-
analysis of randomised controlled trials of PPI in functional
dyspepsia found there was an improvement against placebo, but
required a number needed to treat of 14.6(187). They also found
those with symptoms suggestive of dysmotility rather than reflux-
like symptoms as a predominance, did not respond.
4.1.8.2 Prokinetic agents
Prokinetics can provide symptomatic relief in a small proportion of
patients and are often tried as one the first line therapies in
primary care. However, study results have shown variable
response. A meta-analysis of pro-kinetics agents including
metoclopramide, domperidone (both peripheral dopamine
antagonists) trimebutine (an agonist for opiate receptors and
152
possesses anti-serotonin activity) and , cisapride, itopride,
mosapride, - all 5-HT4 agonists, was completed in 2007 (188). All
trials included were randomised controlled trials and placebo
controlled. They found a 30% excess probability that FD patients
would respond to prokinetics. ). Thus, a large proportion of FD
patient do not respond and moreover, the most consistently
effective medication, cisapride, has been withdrawn due to
cardiovascular side effects.
4.1.8.3 Tri-cyclic antidepressants and other anti-depressants
Tri-cyclic antidepressants (TCA) have been used to reduce visceral
hypersensitivity but have been effective in irritable bowel
syndrome. Trials with FD patients have been relatively small.
Amitriptyline has been shown to have superior response to placebo
in 27 FD patients (70% vs 20).(189) Despite such small patient
numbers this is a commonly used medication in this patient group.
A study comparing venlafaxine and placebo found no benefit in FD
patients (190). Paroxetine has also been seen to improve gastric
emptying but studies in FD havent been completed yet(191).
There is currently a lack of large, prospective studies looking at
TCAs in FD.
4.1.8.4 Alternative therapies
The herbal remedy iberogast has been used in a number of
patients to provide symptom relief. It has been shown in healthy
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volunteers to increased proximal gastric volume and antral motility
(192), which is how it is thought to help in functional dyspepsia. .
It is commonly sold as a combination, as STW 5. A randomised,
double blind, controlled trial of 315 patient had a 8 week treatment
of either the STW 5 preparation or placebo (193). They found a
significant improvement in symptoms in the medication group
based on symptom scores completed by the investigator. However,
the absolute differences between the two groups in scores was
small and there was a high responder rate in both groups.
4.1.8.5 New drug agents in functional dyspepsia
One possible new agent that is being considered is sildenafil, a
phosphodiesterase inhibitor that increases availability of nitric
oxide. This medication facilitates nitric oxide related relaxation of
the proximal stomach and improved accommodation (impaired in
functional dyspepsia). A study of 10 healthy volunteers measured
fundal barostat measurements following placebo and sildenafil and
liquid and solid gastric emptying rates(194). Sildenafil increased
fasting intra-gastric volumes and delayed liquid gastric emptying.
It also increased volumes of first perception. No randomised trials
have been completed to date in the functional dyspeptic population
but it remains a promising future therapy.
The lack of successful pharmacological therapy in functional
dyspepsia means that identifying the underlying mechanisms of
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symptoms is important as a means of targeting appropriate
therapy in this difficult to manage population of patients. Such
investigations would be invaluable also in the investigation of novel
pharmacological products.
4.1.9 Strategies for investigating pathophysiology in functional
dyspepsia
The above section summarised what is currently known regarding
the mechanism of functional dyspepsia (and methods used to elicit
this) and attempted treatment strategies. Changes are seen within
the patient population but not consistently throughout. Why is
there no correlation between symptoms and conventional
measurements of gastric emptying in functional dyspepsia with
post-prandial distress, or delays not seen in a larger proportion of
the population? Two important possible reasons exist for this and
central questions as to why are raised below.
o Is the size of the current test meal (approximately
200ml) not large enough to trigger symptoms and
dysfunction on patient group
o Are parameters that are currently recorded ( emptying
time for half of meal, T50 or contents retention at set
time periods, such as 2 or 4 hours) reflective of
pathological processes?
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There are many factors which make the development of gamma
scintigraphy gastric emptying studies in FD desirable. As it is a
technology already in use and readily available to most clinicians,
adapting the current process would be rapidly turned out to the
everyday gastroenterologist. It is non-invasive and well tolerated
by patients. It requires only a small dose of radiation (much less
than that of a computed tomography (CT) or barium study).
Therefore if current protocols for gamma scintigraphy gastric
emptying studies could be adapted with the above points taken
into consideration, could reliable differences be established
between health and functional dyspepsia and a new method for
making a positive diagnosis of functional dyspepsia established?
In developing new gastric emptying studies by gamma scintigraphy
it would be attractive to compare results with MRI studies of
gastric function to validate that similar results were reached and
assess whether any additional, clinically relevant information could
be obtained by more detailed assessment of gastric structure and
function (e.g. tonic relaxation, contractility, acid secretion).
Both of the above tests require specialist referral and hospital
based investigation. The spectrum of individuals seen with
functional dyspepsia within this setting tend to be those with more
severe symptoms, often with alarm symptoms (e.g. weight loss)
that demand investigation. A large proportion of patients with less
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severe symptoms remain within the primary care setting. In
patients with no alarm symptoms that do not require investigation,
a technique to obtain a positive diagnosis within a primary care
setting is desirable. The simple, nutrient drink test is one such
technique. Individuals simply ingest a nutrient at a set rate until a
maximum tolerated volume is reached. Dyspeptic symptoms are
recorded throughout the test. This could be potentially used as a
screening test and for the diagnosis of functional dyspepsia. If
completed in the same individuals alongside more accurate
measurements of gamma scintigraphy and MRI potentially drink
tests could be used in primary care to confirm the diagnosis of FD
without secondary care referral and avoiding further more
expensive tests. It does have important limitations, most obviously
it does not provide insight into the pathophysiology behind
symptoms nor any detail regarding gastric emptying, which is why
this would be regarded as a simple initial test in the patient
population.
Evaluating the three different methodologies alongside one another
has the advantages of providing options for the investigation and
positive diagnosis of functional dyspepsia in multiple health care
settings. The drink test being able to be used in the community
setting, gamma scintigraphy being used in most secondary care
157
settings and MRI potentially provides additional, new markers of
gastric function in specialist centres.
4.1.10 Meal choice in gastric emptying studies
When developing any new methodology to study gastric emptying,
meal size, content and physical form are all important factors to be
considered.
4.1.10.1 Calorific content and size of meal
In a study by Kwiatek et al in 16 healthy volunteers, a variety of
meal volumes (200, 400, 600, 800ml) and calorific load (200, 300,
400kcal) were studied by MRI and intra-gastric pressure
measurements by a minimally invasive fiber-optic recording
system (FORS) (178). They found that (i) gastric emptying began
during delivery of the meal (ii) larger meal volumes produced
larger gastric volumes initially, regardless of calorific load, however
the relative magnitude of this effect decreased with increasing
meal volume due to more rapid early gastric emptying at high
filling volumes, (iii) total gastric contents volume could increase
after meal delivery due to the rate of gastric secretion being
greater than the rate of gastric emptying, (iv) late gastric
emptying was modulated by meal volume and calorie load .
A study using SPECT to assess liquid emptying (via 300ml labelled
Ensure nutrient drink) and gamma scintigraphy labelled eggs,
looked at FD patients (195). They assessed gastric emptying at 1,
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2 and 4 hours. In the FD population initial gastric emptying at 1
hour was increased but overall gastric emptying delayed (at
4hours).
These studies support the contention that a larger meal than the
conventional eggbeater meal may be required to reveal
pathophysiology and also that there the traditional measurements
of T50 gastric emptying are not sufficient to describe gastric
dysfunction and the cause of symptoms in FD.
4.1.10.2 Liquid versus solid meal in gamma scintigraphy
Currently, in gamma scintigraphy gastric emptying studies, solid
food is used in routine clinical practice to assess emptying. This is
because of previous findings from dual-isotope simultaneous
studies of liquid and solid emptying show significant differences in
gastric emptying time (as measured by T50 and constant
emptying times) in solids between patients and controls, but not
on liquid emptying (196, 197). However, there is conflict within
the literature with some studies suggesting delays in liquid only
meals area predictive of delays in liquid-solid meals, although
participant numbers are small (198). Liquid only studies have
traditionally been reserved for those unable to take solid foods.
There were also concerns about the effects of liquid and solid
emptying on one another. Previous work has shown that liquids are
more rapidly emptied than solids, liquids follow an exponential
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pattern of emptying and liquid emptying is slowed by the presence
of solids, but not vice versa (199). Ziessman et al published a
study in 2009 where a 30 min clear liquid only gastric emptying
study was performed just prior to the standard solid phase of the
study in 101 patients and 30 healthy controls (200). In the patient
studies, 16 had delayed solid emptying and 36 in liquid emptying
(at least 3 standard deviations from the mean). The authors also
completed imaging at minute intervals in the liquid phase of the
study. They suggest that the infrequent imaging of traditional solid
studies assesses only antral contractility and emptying and does
not assess fundal emptying. They propose this may explain the
lack of abnormalities seen in the patient population, if fundal
dysfunction is the primary cause of symptoms, then other methods
and modalities may be more suited to evaluate this. These are
complex data as this study has chosen to separate the phases;
however, although dual phase studies are more complex, they are
obviously more representative of real life as the majority of
symptomatic patients eat a combined liquid/solid diet.
One potential technical issue with dual isotope studies is the
downscatter from the first ingested isotope into the second
ingested isotope activity. In the Ziessman study discussed above
there was no significant downscatter when using 10:1 99mTc (
technetium 99m) (solid) to 111In (liquid) (Indium 111) (200). This
160
has also been confirmed in other studies, using doses of 99mTc 5 -6
times greater than that of 111In (201, 202)
4.1.11 Development strategy of Nottingham Test Meal
The current practice in gastric emptying studies has been
discussed and the difficulties in correlating this to pathophysiology
and symptoms have been described. The modular Nottingham Test
Meal was designed to address these challenges. It is applicable for
all three investigations (drink test, GS, MRI) and settings. Its
features include:
x A relatively large, liquid meal to trigger symptoms in the
majority of patients with functional dyspepsia. The presence
of symptoms is thought to reflect gastric motor or sensory
dysfunction. Thus, if a meal is large enough to cause
symptoms then it will also be more sensitive to gastric
dysfunction. However, the meal needs to be of a size that
will realistically be taken by patients with significant post-
prandial symptoms.
x Addition of a solid component to assess gastric trituration.
The rate of break down (MRI) and / or emptying (GS)
represents an objective assessment of the mechanical work
done by the stomach. Ideally this solid component would be
non-nutrient, therefore assessing mechanical work only.
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x Both liquid and solid components need homogenous and
stable labelling to ensure that scintigraphic measurements
are representative of the whole meal
x Volume and calorie load selected to allow assessment of
liquid gastric emptying within 2 hours in most individuals
x Gastric parameters measured should be reflective of changes
in underlying pathophysiology.
In developing a new technique such as this, normal ranges within
healthy volunteers with no history of gastro-intestinal disease must
be established. This provides normal ranges but also ensures the
test is feasible in real life and time points and procedures can be
completed as planned. (55)
Functional dyspepsia is a heterogeneous patient group. Whilst
developing this new method of gastric emptying assessment,
functional dyspepsia with post-prandial distress will be assessed,
as underlying fundal +/- antral dysfunction is more likely to be
present, that in the epigastric pain subgroup. Once this has been
assessed, a more heterogeneous group of functional dyspepsia can
be assessed, along with a disease control, such as gastro-
oesophageal reflux disease. This latter disease control is
important to establish if any abnormal pattern of gastric emptying
clearly distinguishes patients with functional dyspepsia from
patients with GORD; the most common differential diagnosis of
162
dyspepsia. Establishing this would allow treatment to be directed at
specific therapeutic targets (e.g. reflux suppression, prokinetics).
In summary, the main aims of this study were:
x Assess the maximum tolerated volume ingested at nutrient
drink test in health, FD and GORD.
x Assess whether a 400ml liquid test meal is a feasible test
meal in health and establish normal values in a HV cohort
with MRI and GS
x Assess whether differences can be established between FD
and HV using new gastric emptying parameters, Gastric
contents volume at time 0 (GCV0), gastric emptying rate at
the time taken for half the stomach to empty (GErate@T50)
and the established gastric emptying parameter, time taken
for 50% of emptying to occur, (T50).
x In a smaller subset, add in 12 non-nutrient agar beads to the
liquid test meal to assess differences between FD, GORD and
HV with the above mentioned gastric emptying parameters.
4.2 Method
The principles behind development and reasoning for methods
chosen have been described earlier. This section details methods
used in the studies.
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4.2.1 Liquid only study- Establishing normal values
4.2.1.1 Subjects  Healthy volunteers
Healthy volunteers with no functional dyspepsia as defined by the
Rome Questionnaire and no more than mild symptoms on a
maximum of 1 day a week on the GSRS, that met inclusion and
exclusion criteria were recruited. Eligible subjects were block
randomized by sex and age. Men and women in each age group
(<40, 41-60, >60) were recruited. The aim was to recruit 10 in
each group.
Healthy volunteers repeated the study days with (i) the same liquid
test meal (ii) the liquid and mixed liquid / solid test meal, to assess
whether results were reproducible and affected by the solid
component of the Nottingham Test Meal (small, non-nutrient agar
beads) respectively.
4.2.1.1.1 Inclusion Criteria
For inclusion into the study, subjects had to:
1. Be an adult patient above 18 years old
2. Meet the block randomization criteria for age and sex
3. Have a body mass index of >18 and <30kg.m2 and not
exceed a waist circumference of 99cm at 5cm above ileal
crest
4. Be able to give voluntary informed consent and from whom
written consent to participate has been obtained.
164
5. Be able to understand the study, willing to co-operate with
the study procedures and able to attend all study
assessments.
6. Be willing to abstain from alcohol for 24 hours before and
during the imaging appointment
7. Be willing to fast from midnight prior to the screening and
imaging appointment
8. Be able to ingest at least 400ml nutrient liquid (0.75kcal/ml
at 40ml/min) during a Nutrient Drinking Test without
experiencing more than moderate dyspeptic symptoms
9. Be willing to consent to their General Practitioner (GP) being
informed of their participation.
4.2.1.1.2 Exclusion Criteria
Subjects must not:
1. Have a history of gastrointestinal disease or surgery (other
than appendicitis or hysterectomy)
2. Have ongoing disease requiring active management
3. Have a documented history of alcohol or drug abuse
4. Fail to satisfy the investigators assessment of fitness to
participate based on a survey of inclusion and exclusion
criteria
5. Have consumed alcohol within 24 hours of start of study
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6. Have participated in a similar study involving the use of
radioisotopes in the previous 3 months such that
participating in the current study would exceed the
recommended yearly exposure limit (5mSv)
7. Take any medication which may affect oesophageal or gastric
motility for a minimum 7 days
8. Have had previous history of gastric surgery
9. Have active upper gastrointestinal diseases
10. Have an active Eating Disorder
11. Have an allergy to milk protein (milk based, lactose
free test meal)
12. Be a vegan
13. Be pregnant or breastfeeding
14. Have any contraindication to MRI scanning according to
local guidelines
4.2.2 Recruitment
Posters were placed on Nottingham University Hospital NHS Trust
site and the University of Nottingham sites. Volunteers then
contacted the investigators directly, if interested in participating in
the trial, via telephone or e-mail. An information sheet and copy of
the consent form was then sent to the participant. A screening visit
was then arranged to assess suitability for the trial, at least 24
hours after the information sheet had been sent.
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4.2.3 Study Schedule
During the study, each subject was required to attend the unit on
three occasions as follows:
Screening Visit with Nutrient Drink Test,
Scintigraphy and MRI Imaging Appointments
Each visit was separated by a minimum 2 days and maximum 28
days
For participants taking part in repeat studies to assess test-retest
reproducibility, each of these investigations were separated by
more than 2 days but less than 4 months
This study was sponsored by Nottingham University Hospitals NHS
Trust. The study was conducted at (i) the Research Unit,
Department of Medical Physics, Queens Medical Centre,
Nottingham, UK (scintigraphy study days). (ii) the Nottingham
Digestive Diseases Centre and Biomedical Research Unit, Queens
Medical Centre, Nottingham, UK (screening visit and nutrient drink
test) and (iii) the Sir Peter Mansfield Centre for Magnetic
Resonance Imaging (MRI study day).
4.2.4 Screening visit
Age, sex, height, weight and waist circumference 5cm above the
iliac crest was recorded for all prospective participants. For women
menstrual state was noted. The presence of functional GI
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symptoms was assessed by the Rome III Adult Questionnaire,
Psychologic state documented by the Hospital Anxiety and
Depression Score (HADS) and the Perceived Health Questionnaire
(PHQ15), and GI health related quality of life assessed by the
EuroQual.
Subjects attended the screening visit time between 08.00 and
11.00 (to ensure no diurnal variation in gastric function), having
abstained from strenuous exercise and alcohol for at least 24 hours
and fasted from midnight.
Each subject was evaluated according to the inclusion/exclusion
criteria, and a survey of demographics, medical history, ongoing
conditions, and concomitant medications. A brief physical
examination was performed including height, weight and waist
circumference 5 am above the iliac crest, heart rate, blood
pressure and abdominal examination. Before admission into the
study, each subject was given a verbal explanation of the study
and supplied with a copy of the Informed Consent Form. Written
informed consent was then obtained. He/She was then allocated a
study number.
The Nutrient Drinking Test was performed as part of the screening
visit to ensure that all participants that consented to participate in
the full study were able to complete the imaging studies that
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require ingestion of 400ml liquid nutrient (Fortisip Vanilla (Nutricia
Clinical) diluted 1:1 with water to 0.75kcal/ml, 4.5g fat/100ml).
Subjects drank from a series of beakers containing 40ml liquid
nutrient every minute. Compliance was confirmed by the
investigator. During the drinking test, subjects scored satiety,
fullness, bloating, heartburn, nausea and epigastric pain at 5-min
intervals using the 100mm visual analogue scale. Participants were
instructed to cease intake when they reported maximal satiety or
very severe dyspeptic symptoms (defined as VAS score of >90
mm). The total volume ingested was recorded. Symptoms were
then assessed again 15 and 30 min after cessation of intake.
If the participant satisfied inclusion criteria and completed the
nutrient drink test, imaging appointments were planned in a
randomized sequence and took place between 2 days and 4
months after the screening visit. Each imaging appointment was
also separated by 2 days and occurred within 4 months of the
initial screening visit.
4.2.5 Imaging appointments
The subject attended the Unit between 08.00 and 11.00, and again
abstained from strenuous exercise and alcohol for at least 24 hours
and fasted from midnight the previous evening. Each subject was
questioned to ensure no changes in his/her health had occurred
that may affect eligibility. In the case of pre-menopausal female, a
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the imaging appointment. Participants were randomly allocated to
either GS/MRI or vice versa using a randomising sequence.
4.2.5.1 Gamma scintigraphy
4.2.5.1.1 Radiolabelling of the investigational product
Dispensing was performed in the Radiopharmacy unit at Queens
Medical Centre Nottingham. 12MBq Technetium-99m-DTPA
(diethylene-triamine-pentaacetate) was added as a non-absorbable
marker incorporated into liquid nutrient drink Fortisip Vanilla
(Nutricia Clinical). The radiolabelling was performed by the study
staff under Good Manufacturing Practice (GMP) conditions.
4.2.5.1.2 Radiation Dosimetry
The total effective radiation dose to each subject who consumes
the entire liquid drink for one investigation will be 0.3 milliSievert
(mSv) and 0.6 mSv for those undergoing reproducibility studies.
4.2.5.1.3 Investigational Product Accountability
The radio-labelled test meal was produced in the radiopharmacy at
Queens Medical Centre Nottingham. All documentation recording
the production procedure is be stored according to GMP and is
available for the study monitor to audit as required.
4.2.5.1.4 Study day - GS
After eligibility was confirmed the subjects ingested the
radiolabelled liquid nutrient test meal according to a standardized
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protocol. Subjects drank one from a series of eight beakers
containing 50ml liquid nutrient every 30 seconds. Thus, the 400ml
test meal was ingested in 10 minutes. During the test liquid meal,
the subjects scored satiety, fullness, bloating, heartburn, nausea
and epigastric pain at baseline, 5 minutes (following first 200ml of
liquid meal) and 10 minutes (following full 400ml of liquid test
meal) using a visual analogue scale (VAS 0100 mm). These
measurements were repeated at following every image taken and
15 minutes and 30 minutes following the end of the imaging scans.
The time of dosing was recorded. Radioactive markers were affixed
to the subject at the right costal margin, both anteriorly and
posteriorly, for accurate image position. Subjects stood in front of
the gamma camera, and acquisition of anterior and posterior
images recorded using a Mediso Gamma Camera (Nucline X-Ring-
R, Budapest, Hungary). The time of the imaging was recorded.
Gastric imaging was performed at baseline, after 200ml ingestion
and 400ml ingestion. The imaging procedure was repeated at the
following times after the meal: 5, 10, 15, 30, 45, 60, 75, 90, 115
and 120and at 30 minute intervals until isotope had reached the
caecum. Symptoms were recorded with each imaging procedure on
the VAS chart.
Light refreshments were provided after the study and the subject
was be free to leave the Unit. The subject was not permitted to
171
eat, drink or smoke during the study period until all imaging had
been completed.
4.2.5.2 Magnetic resonance imaging
Subjects ingested the paramagnetic contrast (0.5 mmol/l Gd-DOTA
(gadolinium and 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid; Dotarem®, Laboratorie Guerbet, Aulnay-sous-
Bois, France)) labelled liquid nutrient test meal according to a
standardized protocol, as in the gamma scintigraphy imaging day
described above, with the same symptom recording.
Studies were performed using a 1.5T whole MRI system (Intera,
Philips, Best, The Netherlands). Six rectangular surface coils
(height = 20 cm, width = 10 cm), fixed around the abdomen and
connected to independent receive channels and were used for
signal detection.
The time of the imaging was recorded case report file. Baseline
fasting gastric scan was completed before meal ingestion. Gastric
imaging was then performed after 200ml ingestion and 400ml
ingestion. The imaging procedure was repeated at the following
times: -5, 0, 5, 10, 15, 30, 45, 60, 75, 90, 115 and 120 minutes.
Symptoms were recorded with each imaging procedure.
Gastric volumes were calculated in the same way for both the
liquid and mixed studies by semi-automatic outlining of the
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contents and air on each image slice using an intensity based
method to define both high signal intensity gastric content volume
(GCV) and low signal intensity air volumes using custom-written
software (IDL version 6.4,Research Systems Inc., Boulder, CO,
USA),. The total gastric volume (TGV) was calculated from the sum
of the air and content regions. The segmented area on each slice
was multiplied by the slice thickness and summed over all
contoured slices to measure the different stomach volumes (TGV
and GCV).
Gastric and duodenal motility scans were performed after each
volume scan. Motility scans were obtained from three oblique
coronal images slices covering luminal wall. Planning the optimal
imaging plane for the complex 3D (3-dimensional) duodenal
morphology was facilitated by three-point plan scan. Contraction
Waves were recorded using a dynamic bFFE (balanced fast field
echo) sequence accelerated with the parallel imaging technique
sensitivity encoding (TR/TE = 3.0/1.48msec; flip angle = 60°;
SENSE (SENSitivity Encoding) reduction factor 2.0). A total of 177
dynamics will be acquired over a period of 124 seconds. Sequence
parameters were as follows: slice thickness = 8 mm, FOV (field of
view) = 360 mm, and matrix size = 180* 142 (spatial resolution =
2.00 *2.03 * 8.0 mm3).
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Light refreshments were provided after the study. The subject was
not be permitted to eat, drink or smoke during the study period
until all imaging was completed.
4.2.6 Data analysis
Gastric motor function was assessed by objective endpoints
specific for each measurement technique. Gastric sensation during
filling is, however, similar during each procedure and is considered
separately and via symptoms.
4.2.6.1 Nutrient Drink Test and Assessment of Sensation during
Gastric Filling
In addition to the maximum volume ingested sensation will be
assessed for satiation / fullness, bloating, nausea, heartburn and
epigastric pain in terms of threshold (i.e. volume at which each
symptom is first recorded), sensation at 400ml (for direct
comparison with imaging studies) and sensation at maximal
volume ingested.
4.2.6.2 Gamma scintigraphy
Gastric scintigraphic images were acquired until contents reached
the small bowel. Measurements: time taken for 50% gastric
emptying (T50), gastric contents volume at time 0 (which is after
ingestion of 400ml meal) and gastric emptying rate @ T50 (GE rate
@T50).
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Liquid gastric empting begins during ingestion before completion of
the test meal. To measure this early gastric emptying two
regions of interest (ROI) were defined around the labelled meal on
the 0 min scan immediately after completion of the test meal (1)
around the stomach only representing the volume of the test meal
in the stomach after completion of the meal (2) around the
stomach and small bowel representing the total volume of the test
meal (i.e. 400 ml). The same process was repeated for all
subsequent scans from 5-120 min. This analysis allows volume of
the meal in the stomach to be expressed as a volume (ml) and also
as a proportion (%) of the total meal volume at every point in
time. All counts were corrected for background radiation and
isotope decay.
4.2.6.3 Magnetic Resonance Imaging
Gastric volume data for GS were fitted to a previously described
and validated three-parameter model of gastric emptying (eqn 1)
using Matlab® (The Mathworks Inc), to characterise gastric
emptying(178, 180).
Eqn 1
The model had a constraint that the kappa coefficient (N) could not
exceed 1;A value above 1 indicates an increase in gastric content
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volume after completion of the meal. Any such increase is related
to secretion and thus applicable only to MRI data. To improve the
reliability of parameters derived from the fitted data only time
points up to 80 mins were used in the fit, provided that by 80 mins
the volume had reduced to below 50 % of the ingested volume
(200 ml). If this was not the case, additional time points were
included until such a time where the volume fell below 200ml. .
For the MRI data, which has the additional complexity of secretions
included in the gastric contents measured, a more complex 5-
parameter model was used (Eqn 2). This model was adapted from
Eqn 1 with a linear term added to better describe the later phase of
emptying. All data acquired over the 120 mins (liquid), 115 mins(
mixed meal) were included for fitting. Both TGV and GCV data
were fitted to Eqn 2.
Eqn 2
Key parameters during emptying were derived from a least-square
fit of each volume-time curve to the models described above.
These included; T50, the time at which the meal volume had
dropped to 50 % of V0 (Eqn 1 and 2) in mins; GCV0, the modelled
initial volume at t=0 in ml (V0 from eqn 1 and 2); GErateT50, the
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rate of change of volume at the calculated T50 time point in
ml/min.
4.2.7 Primary and Secondary Outcome Parameters
4.2.8 Nutrient Drink Test
Primary outcome:
Maximum tolerated volume in nutrient drink test.
Secondary outcome:
Sensation threshold volume for fullness, bloating, nausea,
heartburn, epigastric pain and sensation at 200ml and 400ml
ingested.
4.2.9 Imaging Studies (MRI and GS)
Primary outcome:
Estimates of early gastric emptying  gastric contents volume at
time 0 (assessed following full 400ml meal ingestion), gastric
emptying rate after 50% meal emptying (ml/min) and time taken
for 50% gastric emptying (T50) derived from the model.
Secondary outcome:
Sensation threshold volume at 400ml ingested.
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4.2.10 Methods of analysis
4.2.10.1 Data summaries:
Demographic and baseline characteristics are summarised.
The gastric emptying curve, and the T50 summary parameter, was
calculated for each subject and for each imaging study. A statistical
analysis compared the primary outcome parameters between
diagnostic tests to assess agreement between techniques.
4.2.10.2 Determination of Sample Size
(This advice was provided by a statistician at Trent Research &
Development Support Unit).
It is assumed that the percentile reference ranges can be
calculated from an approximate Normal Distribution, possibly after
a suitable transformation such as a Box-Cox transformation.
A general criterion for sample size for reference ranges is given by
Harris and Boyd (1995), based on the 90% confidence interval for
the reference limit being small compared with the 95% reference
range for the population.
The width of the 95% reference range is 2x1.96*s = 3.92s where s
is the estimated standard deviation. The 97.5th percentile is
estimated as x V¥1DQGLWVVWDQGDUGHUURULVDSSUR[LPDWHO\
¥^V2/N){1+(1.962`` ¥V2/N), so the width of the 90%
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&,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V¥1
7KHWDUJHWUHODWLYHYDULDWLRQ5 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ZKLFKXVLQJD
medium-sized value for R of 0.2 as a criterion for small yields a
required sample size of 52 studied.
The Box-Cox family of transformations may be expressed as
follows:
¸¸¹
·
¨¨©
§  U
U
1x
y where U is a parameter to be estimated.
If 1 U then the data are essentially untransformed apart from a
location shift, but as U approaches zero, the transformation
approaches a logarithmic form. This approach addresses the
common problem of skewness, but not distributions in which the
tails are heavier or lighter than a Normal distribution. The value of
U that optimises the fit to a Normal distribution may be found
using maximum likelihood (as in the Stata boxcox routine).
It has been suggested that to allow for sampling variation in this
parameter the sample size should be increased by as much as
179
56%, but in practice this seems to be not needed in many real
applications.
If there is evidence that the data do not fit a Normal distribution
even after the Box-Cox transformation then efficient estimation of
reference limits may be performed using quantile regression (again
available in Stata)  this does not require transformation of data.
(203)
The initial liquid study has been conducted as a pilot to assess
feasibility in a patient group and 8 FD patients were planned to be
recruited.
The clinical and physiologic measurements from patients with
functional dyspepsia (N=8) represents pilot data; however
previous studies have shown that relevant differences in gastric
function can be detected between this size of patient and control
groups. At approximately the same rate of calorie delivery to be
provided in the NDT (nutrient drink test), previous studies have
shown good reproducibility and that maximal satiety was reached
at a lower volume in dyspeptic patients (489 +/- 276 and 503 +/-
248 mL for first and second test respectively) than controls (937
+/- 428 and 1048 +/- 421 mL, P < 0.0001).(169) There was good
separation between the two groups with >95% of patients but only
~40% of patients able to ingest >600ml liquid nutrient (>80% of
patients were able to drink 400ml, the volume at which initial
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imaging will be acquired (a secondary outcome measurement)).
Based on these figures, power calculations show that 12 patients
and controls provide a 90% chance of detecting a significant and
clinically relevant (200ml) difference on maximal drinking volume.
It was planned to complete MRI and GS studies in 12 FD and GORD
patients in the mixed meal study.
Concerning imaging, recent publications have shown that the
accuracy and reproducibility of MRI measurements of gastric
volumes and emptying is very good both in health and dyspeptic
patients.(184) Power calculations show that comparing 12 patients
and controls before and after intervention provides an 80% chance
of detecting a 20% difference in gastric emptying rate at p < 0.05.
4.2.11 Development of solid component
The inclusion of 12 solid agar beads of known breaking strength
will allow calculation of the time taken to break down solids and for
these to empty from the stomach.(204)
These beads were composed of food grade agar as non-nutrient so
represents mechanical component of gastric emptying only. Barium
was added to ensure the beads sank. They beads are 11.5 mm in
diameter so easily swallowed but unable to pass through the
pylorus whole. Therefore this allows assessment of mechanical
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work of antrum as the beads need to be broken down before being
able to leave stomach.
To ensure the agar beads maintained their own radiolabelling and
the radiolabelling of the liquid component of the meal did not leak
into the beads within the scintigraphy part of the study. To do this
12 non-labelled agar beads were placed in a solution of fortisip
with 0.5 Mbq In-111 Cl. The addition of 0.1M HCl, heating to 37oC
and mixing were completed to recreate the stomach environment.
The agar beads were removed after 4 h Instant Thin Layer
Chromatography (ITLC) documented that only 0.002% of In-111 Cl
had permeated the solid component. 12 agar beads labelled with
Tc-99 MAA (microaggregated albulim) were submerged in non-
labelled fortisip, again heated to 37oC and mixed. Samples were
taken from this solution over 4 hours and counts measured. These
showed that less than 10% of Tc-99 MAA leaked out into fortisip
solution. The beads also remained uniformly labeled.
The end composition of the 12 agar beads was food grade agar
(1% Agar-Agar; Cuisine-innovation, Dijon, France), 7.0 g barium
sulphate (E-Z-Paque: Buckinghamshire, UK Ph Eur 96% w/w) with
5 Mbq Technetium-99m-MAA (Technescan® LyoMAA (DRN4378),
Mallinckrodt Medical B.V.,The Netherlands). The breaking strength
was 0.8 N/mm2 as calculated by a tablet hardness tester (Erweka
THB100, Heussentamm, Germany).
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Within the MRI section, the beads required no separate labeling as
the fortisip was had the contrast agent gadolinium-DOTA (0.5
mmol/l Gadolinium-DOTA; Dotarem®, Guerbet, Aulnay-sous-Bois,
France). This means the fortisip appears bright within MRI images
while the barium within the beads causes them to appear dark,
therefore providing contrast between the liquid and solid
components of the meal within MRI images.
4.2.12 Mixed meal study  Healthy volunteers
After the development of the solid component for the test meal, 12
food grade solid agar beads of known breaking strength have been
added.
The participants will follow the same procedure as for the liquid
only test meal, with the following changes:
4.2.12.1 Screening visit and nutrient drink test
The screening visit had no changes. The nutrient drink test
proceeded as previously, but at the end the test, following all
symptom recording, one test agar bead was ingested whole by the
participant, to ensure there would be no difficulty in swallowing the
beads on imaging study days.
4.2.12.2 Imaging study days
The randomisation sequence was taken out of the protocol. This
was predominantly done to enable easier allocation of imaging
days in the patient population, to minimise the time spent off
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medication. There was no difference in the liquid only results
depending on the order of MRI or GS.
Subjects drank the full 400ml test meal and ingest the 12 agar
beads within 10 minutes. The first 200ml liquid test meal were
ingested within 2 min, 50ml every 30 seconds (100ml/min). The
subject was then imaged (GS/MRI depending on study day). The
second 200ml of the nutrient drink was then given, 50ml every 30
seconds, with 3 agar bead swallowed whole alongside every 50ml
of liquid meal (100ml/min, 12 agar beads in total). Imaging
sequences then proceeded as per liquid study.
4.2.12.3 Additions to liquid meal method for solid component;
4.2.12.3.1 Gamma scintigraphy
Technetium-99m was added as a non-absorbable marker
incorporated into the agar beads. The agar beads were weighted
with barium sulphate and were 11.5mm in diameter. The
participant swallowed 12 beads. The total amount of radiation in all
of the beads equalled 5MBq (mega Becquerel).
The liquid nutrient drink Fortisip Vanilla (Nutricia Clinical) will be
radiolabelled with 0.5 MBq of the non-absorbable marker Indium-
111.
184
The total effective radiation dose to each subject who consumes
the entire liquid drink and agar beads for one investigation will be
0.3 mSv.
Liquid and solid gastric emptying were measured in the same way
as the liquid only study. The same ROIs were used to calculate the
volumes and percentage of liquid and solid meal in the stomach.
The In-111 overlap onto the Tc99 channel was estimated from the
first 200 ml of fortisip administered to the subject. The numbers of
counts were then converted to a percentage of the total test meal
volume. Due to the low count produced by the 0.5 Mbq In-111
label in the mixed meal, the counts were corrected also for
background radiation (average of anterior and posterior images
taken separately assessed at 0 min). The number of beads present
in the stomach at 1 h and 2 h calculated as a percentage of counts.
4.2.12.3.2 Magnetic resonance imaging
Apart from the addition of the agar beads, as detailed in imaging
study days sections above, there were no additional procedures
during MRI study days from the liquid meal study.
The volume of the agar beads included in the GCV and TGV of the
mixed meal study was small (9.6 ml). The number of intact agar
beads left in the stomach at 1 h and 2 h was counted directly from
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volume and coronal scans. Counting was aided by use of custom
written software (IDL 6.4) which allowed semi-automatic tracking
of beads through the different slices.
4.2.12.4 Outcome measures and sample size calculation
The primary outcome measurement is gastric emptying time T50
and the number of participants to be recruited will provide an 80%
power to detect a 20% difference in this parameter between
healthy volunteers and patients with functional dyspepsia. T50 was
used to generate power calculations because this is the most
widely published summary assessment of gastric function. Previous
studies suggest that 40% of FD patients have delayed gastric
emptying using gastric scintigraphy (205). The normal range of
T1/2 was 129+/88 min (mean+/2SD (standard deviation)) among
the control group. The mean T1/2 of the patient group was
160+/96 min (P<0.01). Twelve of 22 male patients and 11 of 13
female patients had prolonged T1/2. Based on these results at least
13 participants are required to show a significant difference
between the healthy and FD patient groups.
4.2.12.5 Statistical analysis
Data analysis was completed using Graphpad Prism 6 (GraphPad
Software Inc., La Jolla, CA, USA). Students t-test and Mann-
Whitney test were used to compare quantitative parametric and
non-parametric variables respectively. Significance was set at p <
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0.05. Paired students t-test (Wilcoxon signed rant test in non-
parametric data). Inter individual variation in gastric emptying was
analysed using Bland-Altman plots. The bias and the standard
deviation of the bias are presented. Inter observer correlation
coefficients (ICC) were calculated with SPSS version 16.0 (SPSS,
Chicago, Illnois, USA).
4.2.13 Functional dyspepsia patient recruitment
4.2.13.1 Patient identification
Patients were identified through the specialist upper gastro-
intestinal functional clinic of Dr Mark Fox (consultant
Gastroenterologist and MD supervisor) at Queens Medical Centre,
Nottingham University Hospitals NHS Trust, Nottingham. They
were given an information sheet and copy of consent form and
allowed at least 24 hours before being contacted to arrange a
screening visit for the study. Patients were also recruited from
endoscopy lists where upper gastro-intestinal endoscopy was
normal and symptoms of functional dyspepsia present. In this
instance, permission was always sought first from the referring
consultant before any information sheet was given to the patient.
4.2.13.2 Inclusion and exclusion criteria in patients
Inclusion/exclusion criteria were as for healthy volunteers for the
liquid and mixed meal, with the additional points:
187
1. Symptoms consistent with functional dyspepsia with
postprandial distress syndrome as defined by the Rome IV
Questionnaire and at least moderate symptom severity on at
least 3 days a week
2. Have a normal upper gastro-intestinal endoscopy
3. Have a negative 24 hour ambulatory pH-impedance study, if
any symptoms suggestive of possible gastro-intestinal reflux
disease
4. Be able to stop all medications that affect upper gastro-
intestinal motility and sensory function for one week prior to
the screening visit and for the duration of the study. If these
were given for important medical conditions e.g. calcium
channel blockers for hypertension, the patient would be
excluded from entering the study. Prohibited medications
included:
a. Proton-pump inhibitors
b. Pro-kinetic agents
c. Calcium channel blockers
d. Tricyclic antidepressants
e. Nitrates
f. Opiates
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4.2.14 Ethical and other required approvals for the studies
Both the liquid and mixed studies were given ethical approval from
the National Research Ethics Service East Midlands  Derby
Committee.
The Research and Innovation Department approval from the
Nottingham University Hospitals NHS Trust was given for both
studies.
The Administration of Radioactive Substances Advisory Committee
(ARSAC) from the Health Protection Agency approved certificates
of administration for all radioactive medicinal products given in the
studies.
4.3 Study results
This study was split into two main sections, summarised in the
methods section.
1. Liquid Nottingham Test Meal in HV and FD patients.
2. Liquid Nottingham Test Meal with 12 solid agar non-nutrient
beads in HV, FD and GORD patients.
In each case GS and MRI measurements were acquired with
concurrent assessment of sensation. After review of the initial
results of the mixed meal study, there was concern the presence of
dual isotopes in the GS section were causing relatively poor spatial
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resolution for the liquid component and overlap between the
measured counts for the liquid and solid component in some cases.
Due to this a major amendment was granted to complete further
studies within the patient population with no beads in the GS
section. The higher counts acquired with technetium labelled meal
after the amendment reduced the effects of decay and background
counts on measured activity. The beads were kept in the MR
section as there was no issue with dual isotopes within that
modality.
Thus, the healthy volunteers and the initial 8 FD patients in the
mixed meal were studied with liquid and beads labelled with indium
and technetium isotopes respectively. However, the subsequent FD
patients and all GORD patients were studied after the major
amendment (i.e. without beads in GS). The methodology was
identical for the MRI studies in all cases.
As this section of the thesis is a development of a new gastric
emptying study, after the demographic of different groups are
described, the normal values will be presented for HV, initially for
the liquid part and then mixed. Following this, the validation of the
new meal with comparison of results for HV who repeated the
liquid meal twice and HV who completed both liquid and mixed
meal. The results of three observers are compared for both GS and
MRI analysis. This will be followed by FD patients compared to HV
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in the liquid meal and FD and GORD patients and HV in the mixed
meal.
In summary, the main processes of the trial
x Participants recruited, complete questionnaires screening
visit
x All participants complete nutrient drink test as part of
screening visit
Liquid study:
x HV and FD patients studied
x 400ml ingested at MRI study day and GS study day
x Gastric emptying parameters measured
Solid study:
x HV, FD and GORD patients studied
x 400ml ingested with 12 non-nutrient agar beads for all MRI
study days in HV, FD and GORD
x 400ml ingested with 12 beads in all HV and 8 FD patients at
GS
x Further FD and all GORD patients had NO beads in GS
studies due to problems with dual isotope crossover
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4.3.1 Liquid study participants
Healthy volunteers were recruited prospectively in stratified
age/sex blocks. These were separated in to men< 40 years,
women <40 years, men 41-60 years, women 41-60 years, men>
60 years and women > 60 years. The aim was to recruit 10
individuals into each block. 8 men were recruited into the 41-60
block, 9 into men > 60 and 6 women into > 60 block. The
remaining blocks had 10 in each. Therefore 53 HV were recruited
in total. Mean age was 44.6 years (range 18.2  78.2 years). A
total of 59 HV were screened. 1 was taking medications that
precluded them from the study (calcium channel blocker), 3 failed
to come to their second study day, 1 vomited following the nutrient
drink test and 1 had reflux type symptoms.
Each patient was matched to three randomly selected healthy
volunteers from the block age/sex group stratifications.
10 FD patients were screened, 1 vomiting following drinking the
minimum 400ml at nutrient drink test and 1 patient declined to
have the medication washout required for the trial. 8 were included
in total.
4.3.2 Demographics
There were 7 female patients and 1 male with a mean age of 50.2
years (range 23.7-72.1 years). There was no significant difference
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between height and weight between the patients and healthy
volunteers, (p=0.628 and p=0.06 respectively) although weight
had a trend to be lower, with a mean of 57.5 kg for patients and
63.9kg for HV. Patients BMI was significantly lower than their
matched controls (p=0.026).
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Figure 23. BMI in patient and healthy volunteer groups in liquid
study
4.3.3 Mixed meal participants
Only participants who had both MRI and GS results were included
in analysis.
Healthy volunteers were collected prospectively in the same
age/sex blocks again. 24 were collected in total; 3 men <40, 4
women <40, 5 men 41-60, 2 women 41-60, 5 men > 60 and 5
women > 60. Mean age was 47.7 years (range 19.1-69.0). 27
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were screened but 1 could not attend available dates for study
days, 1 withdrew and 1 scored too highly on the ROME III
questionnaire.
26 FD patients were screened, 5 did not complete MRI study day 
1 felt her tattoo heated up and the study day was aborted, 2
vomited during the scans, 1 felt too claustrophobic in the MRI
scanner and 2 did not attend their MRI appointment. 1 patient did
not attend for GS as went back on her medication. Of the 19
remaining, 2 had several scans missing from MRI study day,
therefore their results could not be used. A total of 17 FD patients
had usable results from GS and MRI.
14 GORD patients were screened. 2 declined to stop their
medication and 1 did not attend MRI study day. Therefore 11 were
included in final analysis.
4.3.4 Demographics
12/17 FD patients were female while 9/11 GORD patients were
male. The mean age for FD patient was 40.5 years (range 20-71
years) and 40.7 years (range 23-56 years) for GORD patients.
The mean height for HV, FD and GORD patients were 1.71m,
1.70m and 1.73 respectively. There was no significant difference
between any of the groups.
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Mean weight was HV=73.9kg, FD=66.9kg and 81.2kg. There was
no significant difference between the HV and FD or GORD and HV
(although a trend for lower in FD), but was between FD and GORD
(p=0.002).
Median BMI was HV=24 kg/m2, FD = 22.8 kg/m2 and GORD = 27
kg/m2. FD patients had a significantly lower BMI (p=0.041)
compared to HV and to GORD patients (p=0.0008). There was no
significant difference between the HV and GORD patients.
Figure 24. BMI and participant group in mixed study
4.3.5 Normal values
This study was the development and validation of a liquid and
mixed meal with new gastric emptying parameters measured. As
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such, normal values are first described, along with validation
before the presentation of the patient data.
4.3.5.1 Normal values  liquid study
Table 9. Values for healthy volunteer gastric emptying
parameters in liquid study
Healthy
volunteers
GS liquid
N=53
MRI liquid
N=53 N=53
GCV GCV TCV
GCVO (ml)
Median 353.6 401.7 491.1
IQR 340.6
365.1
379.7
443.4
453.3
550.1
T50 (min)
Median 45.10 70.90 68.15
IQR 37.60
55.75
52.50
85.80
47.90
87.30
GErate@T50 (ml/min)
Median 3.742 2.438 3.328
IQR 3.034
4.487
1.679
2.917
2.315
4.302
The table shows the normal values. Parameters measured are;
GCV  gastric contents volume, TGV  total gastric volume (gastric
contents plus air), GCV0 - gastric contents volume at time 0
(completion of meal), T50  emptying time for half gastric meal,
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GE rate @ T50  gastric empting rate @ emptying time for half
gastric meal.
The data used from gastric emptying measurements for
participants in the trial were modelled, as detailed in the methods
section. This produced the values for GCV0, T50 and GE rate @
T50. An R2 above 0.9 indicated a good fit of the model. The
majority of healthy volunteers had a value above this for the liquid
study. Only 1 HV in GS had an R2 less than 0.9, 1 HV in MRI GCV
and 2 HV in MRI TGV. The two sets of data (all data versus only
that with R2 above 0.9) were statistically compared for each gastric
emptying parameter in both MRI and GS. No significant difference
was found between any of the groups in the liquid study for the
two data sets. Therefore, for further analysis, data is used
regardless of R2 result.
One healthy volunteer didnt have a R2 above 0.9 (0.85) for GS. On
reviewing his gastric emptying curve, initial emptying (represented
by GCV0) was close to the median but GErate@T50 (representative
of later emptying) was slow, below the 25th percentile, although
not the minimum value.
Within the MR data, one healthy volunteer had a low R2 for both
gastric contents volume (labelled fortisip and secretions) and total
gastric volume (labelled fortisip plus gastric secretions and air),
and one further healthy volunteer had a low R2 for total gastric
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volume for MR. The participant with low R2 for both MR
measurements had slow emptying throughout but more
pronounced in the later phase (GEirate@T50) and was interestingly
the oldest healthy volunteer (male, 78 years) in the study. The
participant with low R2 for total gastric volume in MR was slow
emptying throughout, again particularly pronounced in the later
phase. All patients had an R2above 0.9.
The results were compared between GS, MRI GCV and MRI TGV.
x GCVO was significantly lower in GS than MRI GCV and TGV
(p>0.0001in both)
x T50 was significantly lower in GS than MRI GCV and TGV
(p>0.0001 in both)
x GE rate @ T50 was significantly higher in GS than MRI GCV
and non-significantly so in MRI TGV (p>0.001 and p=0.125
respectively)
4.3.5.2 Demographic affect on gastric emptying parameters  healthy
volunteers
The effects of demographic variables were assessed on GCV0
results. Linear regression was performed for height, weight, BMI
and age on GCV0 in both GS and MRI.
198
Table 10. Demographic affects on gastric emptying parameters
GCV0 GS GCV0 MRI GCV GCV0 MR TGV
Height N N N
Weight Y -ve N N
BMI Y -ve N Y +ve
Age N N Y +ve
4.3.5.3 VAS scores  normal values
The normal values from the whole HV cohort were recorded for
fullness at 400 ml during MRI and GS.
Table 11. Normal values for fullness VAS scores at 400ml in test
meal
HV GS MRI
Fullness @ 400 ml
Median 40 30
IQR 18-63 16-45
Normal values  mixed study; liquid component
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Table 12. Values for healthy volunteer gastric emptying
parameters in mixed study
Healthy
volunteers
GS mixed all
N=24
MR mixed N=24
GCV TCV
GCV0 (ml)
Median 368.8 437.1 530.9
IQR 348.4 - 388.0 416.4 - 466.1 483.9 - 569.4
T50 (min)
Median 52.45 68.15 60.50
IQR 37.55 - 72.88 56.03 - 77.08 50.03 - 79.40
GE rate @T50ml/min
Median 3.108 2.985 3.760
IQR 2.068 - 4.073 2.634 - 3.282 3.015 - 4.210
18 of the 24 HV in GS had a R2 < 0.9 while all MRI data had an R2
> 0.9. The GS data was compared for that with R2 > 0.9 and all
data. As with the liquid study, no significant difference was found
between the 2 groups for each of the gastric emptying parameters
dependent on R2 results.
x GCV0 p=0.252,
x T50 p=0.334
x GE rate @ T50 p=0.395
The results were compared between GS, MRI GCV and MRI TGV.
x GCVO was significantly lower in GS than MRI GCV and TGV
(p>0.0001in both)
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x T50 was non-significantly lower in GS than MRI GCV and
TGV (p=0.114 and p=0.584)
x GE rate @ T50 was not significantly different between GS
and MRI GCV or TGV
4.3.5.4 Solid emptying rates
Solid emptying retention rates were recorded for time points 60
minutes (T60) and 120 minutes (T120). MRI records the number of
intact beads seen within the stomach (this can be clearly seen on
MRI image slices). GS records the retention of beads within the
stomach (as a of number of counts), these can be intact or broken
beads. GS is unable to differentiate between intact and broken
beads.
4.3.5.4.1 GS  solid emptying
Table 13. GS solid retention rate
HV T60 (%) T120 (%)
Median 80 65
IQR 74-86.5 42-79.3
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4.3.5.4.2 MR  solid emptying
Table 14. MR solid retention rate
HV T60 (%) T120 (%)
Median 58.3 20.8
IQR 41.7-83.3 2.1-50
4.3.5.5 VAS scores  mixed meal
Fullness at 400ml during the test meal was measured for HV
Table 15. Normal values for VAS scores at 400ml in mixed
meal
HV GS MRI
Fullness @ 400 ml
Median 28 30
IQR 15-56 12-50
4.3.6 Validation of test meals
The liquid and mixed studies have been used to compare HVs to
patient groups. However, should this type of study be used widely
in common clinical practice, validation within the HV population
must be completed. The following section describes this. HVs who
underwent both the liquid and mixed study were compared.
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4.3.6.1 Participants
Of 27 HVs screened, 24 HVs (13 male, 19-69 years; mean age 49
years +/- 19.3 years) successfully completed both MRI and GS
study days for the mixed meal. 9 Subjects (5 male, 21-78 years)
completed the liquid test meal study twice. 11 (of the 24) HVs (9
male, 20-68 years) completed both the liquid test meal study and
the mixed meal study.
All subjects tolerated both the liquid and mixed 400ml test meal.
More than moderate fullness (>70mm VAS) was reported by <20%
HVs during GS and MRI studies. More than mild dyspeptic
symptoms (>30mm VAS for bloating, nausea or pain) were
reported by only one HV on one occasion. There were no significant
differences in sensation of fullness or tolerance of the test meal in
the upright and supine positions.
4.3.6.2 Baseline MRI volumes
For the MRI data the fluid and air present in the fasted stomach
could be measured before the study began. These baseline
volumes of GCV before meal (liquid or mixed) ingestion were small
(median 19 ml (IQR 12-33 ml, maximum 39 ml) and median TGV
46 ml (IQR 24-69ml, maximum 161 ml).
Baseline volume scans were completed on two separate occasions
for 20 subjects that attended for MR studies on more than one
occasion (11 HVs 2 meal types, 9 HVs 2 repeats of same meal).
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Variation was small (<20ml GCV, <60ml TGV) with no evidence of
a sequence effect (P=0.314 and P=0.648) as shown below.
Figure 25. Bland-Altman Plot of baseline (residual) volumes in
HVs measured by MRI prior to ingestion of test meal. The 95%
C.I. are represented by the dotted line in each case (GCV: upper
22 ml, lower -27ml, TGV: upper 61 ml, lower -55ml).
4.3.6.3 Liquid study: Reproducibility
GS and MRI study days for the liquid study were repeated in 9 HVs
as shown in Figure 26. Bland Altman plots compart GS and MRI
GCV in the 9 HV. The HVs repeated both GS study days within a
mean 87 days SD 85 days (95% C.I. Upper 152 days, lower 21
days.). Both MRI study days were carried out between mean 74
days SD 58 days (95% C.I. Upper 118 days, lower 29 days).
The Bland-Altman plots demonstrated for GS GCV0 bias of 9 ml
(95% C.I. upper 34 ml, lower -16ml), T50 bias 8 min (95% C.I.
upper 29 min, lower -14 min) and the GErateT50 bias -0.9 ml/min
(95% C.I. upper 1.1 ml/min, lower 1.1 ml/min ). For MRI (GCV)
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the GCV0 bias was -25 ml (95% C.I. upper 41 ml, lower -91 ml),
T50 13 min (95% C.I. Upper 39 min, lower -13 min) and
GErateT50 bias 0.2 ml/min (95% C.I. upper 2.3 ml/min, lower -1.8
ml/min). Similarly MRI (TGV) followed in the same pattern GCVO 
bias 4.0 (95% upper 47 ml, lower -55 ml), T50 bias 6 min (95%
C.I. Upper 49, lower -37 min) and GErateT50 bias 0.03 (95% C.I.
Upper 3.3 ml/min, lower -3.3 ml/min)
Early and late GE for GS tended to be faster on the second test day
than the first. The average difference in GE between study days for
GS was GCV0 7.5 ml, T50 9 min and GErateT50 was -0.9 ml/min.
In MRI (GCV and TGV) the opposite occurred with early and late
GE tending to be faster on the first test day than the second. The
average difference between study days for MR (GCV) was GCV0 25
ml, T50 9 min and GErateT50 0.2 ml/min. The average difference
for MR (TGV) was GCV0 -4 ml, T50 6 min and GErateT50 0.03
ml/min. The absolute differences are relatively small between
parameters.
In GS only the GErateT50 was shown to vary significantly between
the two study days (GS: GCV0 P=0.070, T50 P=0.077, GErateT50
P=0.036). This effect on the GErateT50 was not seen with MRI
(GCV or TGV). However, MRI (GCV) at GCV0 was shown to differ
significantly between study days (GCV0 P=0.050, T50 P=0.019,
GerateT50 P=0.496. There was no significant sequence effect for
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MRI (TGV) (GCV0 P=0.652, T50 0.460, GErateT50 P=0.956).
However, between the two modalities there was no order effect of
MRI or GS.
Figure 26. Bland-Altman Plots showing GS and MRI GCV results
from 9 HV imaged on two separate occasions after ingestion of
liquid test meal; Panel A: GCV0, Panel B: T50 Panel C: GErateT50.
05,YROXPHVDUHUHSUHVHQWHGE\łZLWKWKH&,UHSUHVHQWHG
by the dotted line. GS volumes are represented by the Ÿ and the
95% C.I. by the dashed line.
206
Figure 27. Bland-Altman Plots showing MRI TGV results from 9
HV imaged on two separate occasions after ingestion of liquid
test meal; Panel A: GCV0, Panel B: T50 Panel C: GErateT50. MRI
YROXPHVDUHUHSUHVHQWHGE\łZLWKWKH&,UHSUHVHQWHGE\
the dotted line.
4.3.6.4 Effect of adding solids to test meal on liquid gastric emptying
GS and MRI study days were repeated for the liquid and mixed
solid/liquid test meal in 11 HVs. The mixed test meal was always
performed after the liquid meal. For GS the study days were
separated by an average of 334 days SD 77 days (95% C.I. Upper
385 days, lower 282 days). The MRI study days were separated by
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an average 358 days SD 76 days (95% C.I. Upper 385 days, lower
282 days).
Bland-Altman plots demonstrate more rapid gastric emptying for
the liquid component of the mixed meal if 12 agar beads without
nutrient value are added to the NTM. GS GCV0 bias was -29 ml
(95% C.I. Upper 46 ml, lower -103 ml), T50 bias -5.0 min (95%
C.I. Upper 38, Lower -48 min) and the GErateT50 bias was -0.1
ml/min (95% C.I. Upper 3.5 ml/min, Lower -3.6 ml/min). There
was a significant difference in GCV0 between the liquid meal and
mixed meal (P=0.032). However, there was no significant
difference between the late phase emptying T50 and GErateT50
(P=0.474 and P=0.903 respectively).
The MRI (GCV) GCV0 bias was -31 ml (95% C.I. Upper 60 ml,
Lower -122 ml), T50 9 min (95% C.I. Upper 49 min, Lower -30
min) and the GErateT50 bias was 0.06 ml/min (95% C.I. Upper 1.9
ml/min, Lower -2.0 ml/min). There was significant difference
between the liquid and mixed meal emptying with MRI GCV for
GCV0 but not T50 or GE rate @ T50 (GCV0: P= 0.050, T50: 0.152,
GErateT50 0.834)
The MRI (TGV) bias was -45 ml (95% C.I. Upper 138.6 ml, Lower -
228.7 ml), T50 8 min (95% C.I. Upper 75 min, Lower -58 min) and
the GErateT50 bias was 0.27 ml/min (95% C.I. Upper 2.5 ml/min,
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Lower -3.0 ml/min). There were no significant difference between
the liquid and mixed meal emptying with MRI TGV (GCV0:
P=0.142, T50: P=0.440, GErateT50: P=0.540).
Figure 28. Bland-Altman Plots showing GS results and GCV for
MRI with 11 HV imaged on two separate occasions after ingestion
of liquid test meal and mixed test meal; Panel A: GCV0, Panel B:
T50 Panel C*(UDWH705,YROXPHVDUHUHSUHVHQWHGE\łZLWK
the 95% C.I. represented by the dotted line. GS volumes are
represented by the Ÿ and the 95% C.I. by the dashed line.
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Figure 29. Bland-Altman Plots showing TGV MRI results from 11
HV imaged on two separate occasions after ingestion of liquid
test meal and mixed test meal; Panel A: GCV0, Panel B: T50 Panel C:
*(UDWH705,YROXPHVDUHUHSUHVHQWHGE\łZLWKWKH&,
represented by the dotted line.
4.3.6.5 Inter-observer agreement
Original image data of 10 HVs were analysed after ingestion of the
liquid meal by three independent observers for both MR and GS
study days. Results from the volume data fitted to the gastric
emptying models were utilised to calculate the inter-observer
agreement for the three key parameters of liquid gastric emptying.
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For GS the raw data (percentage count at GCV0) was also
calculated (Table 16)
The data comparing the number of beads counted by the observers
is shown in Table 17 and it can be seen that the semi-automatic
tracking program increased inter-observer agreement.
Table 16. Intra-class correlation between observers
Intra-class
Correlation
95% Confidence Interval
Lower Bound Upper bound
MR
GCV0 0.830 0.501 0.954
T50 0.990 0.970 0.997
GErate@T50 0.977 0.932 0.994
GS
GCV0 (% Count) 0.764 0.308 0.936
GCV0 (model) 0.687 0.084 0.915
T50 0.960 0.884 0.989
GErate@T50 0.897 0.700 0.972
Table 17. Intraclass correlation for bead counting
Agar bead
count
Intraclass
Correlation
95% Confidence Interval
Lower Bound Upper bound
60 min
Manual
0.727 -0.101 0.935
60 min
Semi-automated
0.982 0.856 0.985
120 min
Manual
0.976 0.904 0.994
120 min
Semi-automated
0.999 0.997 1.000
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4.3.7 Nutrient drink test vs test meal
The nutrient drink test was compared for fullness at 400ml to the
same parameters in GS and MR for the liquid meal.
Figure 30. Nutrient drink test vs liquid meal for fullness at 400ml
Fullness scores were significantly lower for MRI in comparison to
the NDT, and non-significantly lower in GS. The reasons for this
are unclear. GS and MR were randomised as to order, but NDT was
always first, as completed as part of the screening visit to ensure
participants could drink at least 400ml required for the test meal.
This could contribute to the higher scores. Most participants went
on to drink far more at the NDT.
4.3.8 Comparison between health and disease
The above work has demonstrated the normal values and
validation of the gastric emptying study, test meal and its
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measured parameters. The healthy volunteer group have now been
compared to patient groups.
4.3.8.1 Liquid study
4.3.8.1.1 Gastric emptying parameters  FD patients
Table 18. Values for functional dyspeptic patients gastric
emptying parameters in liquid study
FD patients MRI liquid GS liquid
N=8N=8 N=8
GCV TCV GCV
GCV0 (ml)
Median 417.6 506.0 335.0
IQR 393.5-441.1 481.2-576.9 325.2-352.4
T50 (min)
Median 75.45 74.10 48.75
IQR 59.25-96.77 59.08-95.55 40.03-52.28
GErate@T50 (ml/min)
Median 2.012 2.868 2.960
IQR 1.809-2.652 2.173-3.611 2.664-3.050
One patient with a low R2 (0.72) had values for all three
parameters within the interquartile ranges.
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4.3.8.1.2 Gamma scintigraphy
The 8 FD patients were compared to the same healthy volunteers
as in demographics group. The symbol * denotes significance.
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Figure 31. GCV0 in GS between participant groups.
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Figure 32. T50 in GS between participant groups.
* p=0.045
p=0.924
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Figure 33. GE rate @ T50.
As can be seen in the graphs above, GCV0 was significantly lower
in the patient group. T50 was similar. GE rate @ T50 was lower in
the patient group but did not reach significance. This suggests
significantly faster earlier emptying in the patient group with a
trend towards slower later emptying. T50 provided no
discrimination between groups. GE rate maximum was compared
between the 2 groups, median was 4.325 ml/min and 4.578
ml/min in the patient and healthy volunteer group respectively,
with no significant difference (p=0.640).
4.3.8.1.3 MRI
4.3.8.1.3.1 MRI gastric content volume (GCV)
p=0.232
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Figure 34. Gastric contents volume for MRI
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Figure 35. T50 for MRI contents
* p=0.011
p=0.339
216
Figure 36. GE rate @ T50 for MRI contents.
GCV0 was significantly higher in the patient group (p=0.011).
There was no difference between the patient and healthy volunteer
group for T50 (p=0.339). There was no difference between groups
for GErate @ T50 (p=0.062). There was no difference between
groups for GE rate maximum (p=0.0351).
4.3.8.1.3.2 MRI total gastric volume
p=0.062
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Figure 37. Total gastric contents volume for time 0 in MRI total
gastric contents.
Figure 38. T50 in MRI total gastric volume
* p=0.045
p=0.199
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Figure 39. Gastric emptying rate @ T50 in MRI total contents
Total gastric contents volume at time zero was significantly higher
in the patient group (p=0.045). T50, GE rate @ T50 and GE rate
maximum were all similar between groups (p=0.199, p=0.709 and
p=0.557 respectively).
The MRI results for gastric volume and total gastric contents
volume followed the same trends within each group, with GCV0
being significantly higher in patients for both. However, GCV0 was
significantly lower in patients in GS. The predominant difference
between the two modalities is that GS can only measure the
ingested labelled nucleotide, while MRI can measure additional
features such as surrounding soft tissue and other gastric contents,
such as secretions and air. When analysis of the MRI data took
place for gastric contents volume only, the appropriate area of
liquid within the stomach (ingested fortisip plus secretions) is
p=0.709
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drawn around manually. The fortisip is highlighted by the labelling
agent gadolinium. The whole of the liquid stomach contents is then
highlighted for total gastric volume (liquid plus air). The addition of
secretions may account for some of the differences in results
between the 2 modalities. Separating the secretions from the
fortisip to try and establish this is complex. Simple observation
shows secretions can either be a separate layer on top or mixed
within the meal. Therefore simple observation is not sufficient to
differentiate the secretion and meal.
This is supported by 5/8 (63%) patients have GCV0 in MRI
contents above 400ml (400ml was the ingested volume of labelled
fortisip) suggesting secretions are being counted within the MRI
gastric contents volume, while it is not possible to have a volume
greater than 400ml in GS measurements.
However, this does not explain why GCV0 is greater in the patient
population in MR but lower in GS unless the volume of secretions is
greater in the patient population. As noted above, GCV0 is above
the volume of ingested fortisip in 63% of patients. Of the matched
healthy volunteers, 7/24 (29%) had GCV0 above 400ml in MRI
contents. This does support the possibility that patients are
producing more secretions.
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The gastric contents volume of gastric contents and total gastric
contents were compared between patients for MRI and healthy
volunteers.
Figure 40. GCV0 in MRI contents and MRI total contents in
patients
* p=0.004
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Figure 41. GCV0 in MRI contents and MRI total contents for HV
GCV0 is significantly higher in total gastric contents within the
patient population, indicating higher values are recorded with the
second measurement. This is also seen in the HV.
The patient GCV0 went up by 23% from GCV0 contents to GCV0
total, and increased by 22% in the matched healthy volunteers. It
is interesting these are similar to one another. It suggests increase
in total gastric volume is proportional to volume present at time 0.
This is supported by previous MRI work in FD and HV. (178, 184)
The GCV0 in GS and MRI compared for the patient population. This
is significantly greater in MRI.
* p<0.0001
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Figure 42. GCV0 for MRI contents and GS in patient population
The GCV0 was then compared for the same volunteers in GS and
MRI contents who were used in the matched analysis with patients.
GCV0 was significantly greater in MRI contents supporting
secretions being the difference between modalities.
Figure 43. GCV0 for MRI contents and GS in Healthy volunteers
* p=0.0004
* p<0.0001
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Baseline MRI scans were recorded for all subjects as part of the
protocol. This provides a measurement of secretions for all
participants before meal ingestion. The median value of baseline
volume for HV (for the MR contents) was 11.76 ml and 19.35ml for
the patients. There was no significant difference between the two
groups baseline volumes, p=0.278. The difference between the
median values for GCV0 for GS and MR in HV was 35.8ml and
82.6ml for patients. Therefore baseline volumes do not account for
all the differences seen.
4.3.8.2 Mixed meal
4.3.8.2.1 Patient results
The mixed meal results have been split into 2 sections. An initial 8
FD patients who had full original protocol for mixed meal, followed
by the further FD patients and GORD patients with the
amendments described at the start of the results section.
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4.3.8.2.1.1 Pilot FD patient results
Table 19. Values for functional dyspeptics gastric emptying
parameters in mixed study
FD patients GS mixed
N=8
MR mixed N=8
GCV TCV
GCV0 (ml)
Median 366.3 419.0 496.5
IQR 343.5 - 382.7 370.2 - 443.7 464.3 - 674.3
T50 (min)
Median 72.30 77.45 69.65
IQR 42.30 - 88.80 71.80 - 82.15 59.23 - 96.03
GE rate @T50 (ml/min)
Median 2.335 2.286 2.547
IQR 1.767 - 2.955 1.391 - 2.667 1.845 - 3.845
2/8 FD patients had R2<0.9 in GS but none in MRI.
There was no significant difference between group in GS depending
on R2 value (GCV0; p=0.252, T50; p=0.395, GE rate @ T50;
p=0.334).
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4.3.8.2.2 Pilot FD patients versus healthy volunteers
4.3.8.2.2.1 GS
Figure 44. Healthy volunteers compared to patients in GS mixed
meal; GCV0
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Figure 45. Healthy volunteers compared to patients in GS mixed
meal; T50
Figure 46. Healthy volunteers compared to patients in GS mixed
meal; Ge rate @ T50
Comparisons between the FD patient and healthy volunteer group
showed no significant difference between the two groups, GCV0
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was very similar in the two groups, T50 non-significantly higher
and GE rate @ T50 non-significantly lower in the patient group.
4.3.8.2.2.2 MR  gastric contents volume
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Figure 47. Healthy volunteers compared to patients in MR
content; GCV0
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Figure 48. Healthy volunteers compared to patients in MR
contents; T50
Figure 49. Healthy volunteers compared to patients in MR
contents; GE rate @T50
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GCV0 is significantly lower in the patient group, T50 non-
significantly higher and GE rate @ T50 significantly lower in the
patient group.
4.3.8.2.2.3 MR  total gastric volume
Figure 50. Healthy volunteers compared to patients in MR total;
GCV0
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Figure 51. Healthy volunteers compared to patients in MR total;
T50
Figure 52. Healthy volunteers compared to patients in MR total;
GE rate @ T50
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There were no significant differences between the two groups in
MR total but GCV0 trended to lower values in patients, T50 higher
and GE rate @ T50 lower.
4.3.8.3 Comparison between liquid and mixed meal results
Table 20. Comparison of gastric emptying parameters in patients
vs HV in liquid and mixed meal
Patient  liquid meal
(n=8)
Patients  mixed meal
(n=8)
GS
GCVO Ļ* Ļ
T50 Ĺ Ĺ
GE rate @ T50 Ļ Ļ
MR content
GCV0 Ĺ* Ļ*
T50 Ĺ Ĺ
GE rate @ T50 Ļ Ļ*
MR total
GCV0 Ĺ* Ļ
T50 Ĺ Ĺ
GE rate @ T50 Ļ Ļ
*- denotes significance
The results for the patients versus healthy volunteer groups have
been compared between the liquid and mixed meal. The arrows
indicate whether the patients results are higher or lower than the
HV group and * indicates significance.
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GS follows the same trends for both meals. The only parameter
that varies between MR for both contents and total volume is
GCV0. GVCO is higher in the patient group for the liquid meal
(when compared to the HV). This is inconsistent with the liquid
meal. To further examine this result, the two sets of 8 patients
were compared for GCV0 MR content in the mixed and liquid meal.
There was no significant difference between the two patient
groups, p=0.511. However the two sets of 24 HV volunteers were
compared for GCV0 MR contents liquid versus mixed and a
significant difference was found, p>0.001. The mean (±s.d.) of
GCV0 for the HV liquid meal was 390.2 (±27.24) and 442.2
(±37.68) for the HV mixed. Thats a difference between the two
means of 52ml.
Figure 53. HV compared for
GCVO MR content between
liquid and mixed meal
MR
co
nte
nt
liq
uid
MR
co
nte
nt
m
ixe
d
233
Because of the above results, the GCV0 were compared for the HV
in MR total gastric volume. The results were significantly higher in
the mixed meal group, mean 529ml (±62.9ml) compared to 476ml
(±50.0), p=0.002. The effect was still seen when all the HV from
MR content from the liquid study were compared to those in the
mixed study (p=0.008). This excluded a sampling error from the
matched volunteers in the liquid study as a cause for the
differences.
The most obvious possible explanation for this is the presence of
the beads. This would be more prominent in the MR as the beads
in GS are labelled with an alternative isotope so shouldnt be
counted in liquid part of study. There are 12 beads present in the
mixed meal of 11.5mm diameter. The volume of one bead is ~0.8
cm3, a total of 9.6cm3 for all beads. This equates to approximately
9.6ml. This could potentially account for some of the differences
seen between the healthy volunteer groups. However, the simple
volume of the beads present does not account for all. The beads
are less likely to affect the parameters measured in GS as they are
labelled with a separate isotope, so measured differently to the
liquid part of emptying. This also supports the beads are the cause
of the differences seen between the two meals.
Interestingly, its effect is not seen on the emptying parameters
T50 and GE rate @ T50. This could be that the beads presence
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have most effect on early emptying and have been titrated at the
later point of emptying.
The same pattern was not seen in the patients  this could be due
to different meal distribution within the patient population or the
lower number of patients within the study groups.
4.3.8.4 Mixed meal  additional patient groups
As previously described, further FD patients and GORD patients
were studied, under the amendments as described at the start of
the results section.
4.3.8.4.1 Gamma scintigraphy
Figure 54. Comparison of healthy volunteers, FD patients and
GORD patients for GCV0 in mixed meal with no beads in patients
groups
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Figure 55. Comparison of healthy volunteers, FD patients and
GORD patients for T50 in mixed meal with no beads in patients
groups
Figure 56. Comparison of healthy volunteers, FD patients and
GORD patients for GE rate @ T50 in mixed meal with no beads in
patients groups
GCV0 is significantly lower in HV vs FD and HV vs GORD. GCV0 is
lower in FD patients and lower again in GORD patients although
there is no significance difference between the two patient groups.
p=0.765, p=0.764, p=0.343
p=615, p=0.361, p=0.613
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4.3.8.4.2 MR  gastric contents volume
Figure 57. Comparison of healthy volunteers, FD patients and
GORD patients for GCV0 in MR contents
Figure 58. Comparison of healthy volunteers, FD patients and
GORD patients for T50 in MR contents
p=0.840, p=0.779, p=0.706
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Figure 59. Comparison of healthy volunteers, FD patients
and GORD patients for GE rate @ T50 in MR contents
The only significant difference is between the HV and GORD
patients for T50, with T50 significantly higher in the GORD
patients.
4.3.8.4.3 MR  total gastric volume
Figure 60. Comparison of healthy volunteers, FD patients and
GORD patients for GCV0 in MR total gastric contents
p=0.331, p=0.399, p=0.994
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Figure 61. Comparison of healthy volunteers, FD patients and
GORD patients for T50 in MR total gastric contents
Figure 62. Comparison of healthy volunteers, FD patients and
GORD patients for GE rate @ T50 in MR total gastric contents
The only significant difference is between the HV and GORD
patients for GCV0, with GCV0 being significantly higher in the
GORD patient group.
4.3.8.5 Solid emptying rates
Solid emptying retention rates were compared for the patients and
HV who has beads present, at time points 60 minutes (T60) and
p=0.115, p=0.498, p=0.609
p=0.803, p=0.886, p=0.992
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120 minutes (T120). For GS this was 8 patients due to the
previously mentioned amendment and concerns regarding dual
isotope study. The full MR cohort had beads present (including the
GORD patients) as there are no issues with isotope counts. Results
are displayed as % of beads retained. Again, this is intact beads for
MRI and any beads (fragment+whole) in GS.
4.3.8.5.1 GS  solid emptying
Table 21. GS solid retention rate
T60 (%) T120 (%)
HV Median 80 65
IQR 74-86.5 42-79.3
FD Median 69 59
IQR 47.5-85.3 31.5-82.3
There was no significant difference between the groups for T60
(p=0.215) or T120 (p=0.772).
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4.3.8.5.2 MR  solid emptying
Table 22. MR solid emptying retention rate
T60 (%) T120 (%)
HV Median 58.3 20.8
IQR 41.7-83.3 2.1-50
FD Median 83.3 41.7
IQR 58.3-100 12.5-83.3
GORD Median 75 41.7
IQR 50-100 25-75
There was again no significant difference between the groups.
4.3.8.6 Nutrient drink test results
At each screening visit a nutrient drink test was performed with
maximum tolerated volume recorded. This was the same for both
the liquid and mixed study.
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Figure 63. Maximum tolerated volume at nutrient drink test
between healthy volunteers and FD in liquid study.
Figure 64. Maximum tolerated volume at nutrient drink test
between healthy volunteers, FD and GORD patients in mixed
study.
As can be seen, the FD patients drank significantly less than the
healthy volunteer and GORD groups. The GORD patients also drank
significantly less than the HV, suggesting some overlap between
the two conditions.
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4.3.8.7 VAS scores
Fullness at 400ml (i.e. completion of the test meal) was compared
for the patients and HVs. Fullness score in GS was significantly
higher in the FD in comparison to both the HV (p=0.0008) and
GORD (p=0.001). There was no difference between the HV and
GORD patients (p=0.594). The results followed the same trends for
MR (HV:FD p= 0.028, HV:GORD p=0.418) but there was no
significant difference between the GORD and FD (p=0.229)
although the FDs tended to have higher scores.
Table 23. Vales for fullness at 400ml in mixed meal
HV GS MRI
Median 28 30
IQR 15-56 12-50
FD
Median 70 70
IQR 48-100 25-93
GORD
Median 40 40
IQR 30-46 30-50
4.4 Discussion
This research describes the development, validation and
application of a gastric emptying study in a healthy volunteer
population with pilot clinical data in patient groups with functional
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dyspepsia (FD and gastro-oesophageal reflux disease (GORD).
Both a liquid (nutrient drink) and an optional solid (non-nutrient
agar bead) component are tested to provide a modular test of
gastric motor function. Patient symptoms were assessed to test
gastric sensory function as well.
4.4.1 Demographics
Healthy volunteers were collected in age/sex stratified blocks. A
total of 27 men were recruited and 26 women were recruited and
the average age was 44.6 years (min 18.3  max 78.4) in the
liquid study. In the mixed meal there were 13 men and 11 women
with a mean age of 47.7 years (min 20.1 and max 69.2). Within
the patient population, the majority (7/8 in liquid study, 12/17 of
mixed,) of FD patients were female consistent with current
literature (206). Conversely the majority (9/11) GORD patients
were men, consistent with reflux being more common in
men(207). Mean age of the FD patients was 50.2 in the liquid
study and 40.5 years in the mixed. Mean age of the GORD patients
was 40.7 years.
FD patients had a significantly lower BMI than the HV As we
studied a population of FD with post-prandial distress this was
expected (208). Conversely GORD patients tended to have higher
BMI, consistent with literature that GORD is associated with
obesity(207)
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4.4.1.1 Liquid study
The normal values of gastric emptying for both liquid and mixed
meal were established and validated within the healthy volunteer
population. Normal values were provided for both GS (gamma
scintigraphy) (meal volume) and MRI (gastric contents volume
(GCV) and total gastric volume(TGV)).
Gastric contents volume at time 0 (GCV0) was significantly lower in
GCV and TGV in MRI than GS, as was emptying at time taken for
half meal to empty (T50). Gastric emptying rate @ T50 (GE rate @
T50) was significantly higher in GS for MRI GCV and non-
significantly higher in TGV. It should be noted that the residual
volume of secretion observed in the stomach on MRI prior to meal
ingestion was small (median >20ml) and not sufficient to explain
the difference in volume recorded by the two modalities. The
dynamic change in gastric volume over time was different for GS
and MRI studies. Typically, as described by previous authors (209),
gastric emptying of a liquid nutrient meal documented by GS is
linear or exponential and the mathematical model that we applied
to describe this data was designed to fit such data. Conversely
gastric emptying of a liquid nutrient meal documented by MRI
shows a characteristic rise in volume or apparent lag phase (i.e.no
change in volume) after ingestion due to the rapid production of
gastric secretions (178). This is then followed by a linear or
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exponential reduction in volume as the contents leave the
stomach. This pattern of gastric volume change after meal
ingestion required an additional term (kappa, see methods) to be
added to the model of gastric emptying that we used to describe
the data and generate measurements.
It follows that the volume in the stomach immediately after
completing the meal (GCV0) is lower in GS (75th percentile of GS
lower than the 25th percentile of both MRI GCV) because GCV
measured by MRI includes meal and secretion volume (plus some
residual). For the same reason the gastric emptying half time T50
is faster in GS than MRI since only emptying of the meal and not
meal and secretion is documented. The GE rate @ T50 is remains
slightly faster in GS than MR. This again is most likely due to the
ongoing production of secretions.
Fullness at 400ml on VAS score was slightly lower in MRI than GS,
although this was non-significant. It is well known from previous
MRI studies that fullness closely follows changes in GCV in healthy
subjects (210, 211). Obviously although the measured gastric
volume by GS was lower than that for MRI this has no effect on the
actual gastric content volume (meal and secretion) or total gastric
volume. Thus, no difference in fullness would be expected based
only on imaging modality.
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4.4.1.2 Mixed study: liquid component
Overall comparison of measurements obtained by the two
modalities followed the same pattern as for the liquid meal. GCV0
as significantly lower in GS than MRI but other parameters were
non-significantly different.
Comparing the fit results for liquid and solid, the fit for GS in the
mixed meal liquid component for HV is not as good as for the liquid
only, with 18/24 having a r2>0.9 compared to 52/53. This was not,
however, directly related to the presence of the agar beads, but
rather due to dual-labelling of liquid and solid components. In the
liquid study 12MBq of 99mTc DTPA were used. In the mixed meal
0.5 Mbq of In-lll was used to label the liquid component (the beads
were labelled with 5MBq of 99mTc MAA). The relatively low dose of
the liquid in the mixed meal was an attempt to minimise the
radioactive exposure to participants (dual isotope study) but lower
recorded counts are more susceptible to measurement error as
small changes in the absolute counts have a greater effect on the
estimated volume. For further studies it was decided to focus on
liquid emptying for two reason i) because we wanted to keep
exposure to radiation to a minimum in our often young and female
FD patients ii) because, in contrast to liquid emptying, we had no
difference in gastric emptying of solids between groups.
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4.4.1.3 Solid component
Solid emptying retention rate appeared to be lower in MRI than in
GS. This is because MRI measures presence of intact beads in the
stomach and, therefore, the work done by the stomach in breaking
down solid beads over time. In contrast GS measures the rate at
which the solid material leaves the stomach which is a two stage
process.
The agar beads were 11.5 mm in size and it is known that particles
larger than 3mm are unlikely to pass the pylorus and leave the
stomach intact (gastric sieving) (212). Thus MRI measures work
done to break down the beads and GS measures the time is takes
for the beads to break down and leave the stomach. This two-step
process will clearly last longer being an integrated function of the
time taken to break down the beads into tiny fragments and for
these to be emptied into the small bowel.
4.4.1.4 VAS scores
Vas scores are similar for the two modalities. This is not surprising
as the combined volume of the agar beads was only about 10ml
and this is not sufficient to alter gastric stretch or tension.
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4.4.2 Validation of test meals
4.4.2.1 Reproducibility  liquid study
A number of healthy volunteers underwent the liquid meal twice
(n=9) and the mixed liquid and solid meal twice (n=11). GS and
MRI were performed in randomised order on both occasions.
GCV0 and GE rate @ T50 were both faster on the second day for
GS, but these differences were small with an average difference
7.5ml for GS in GCV0 (not significant) and 0.9ml/min for GE rate
@T50 (p=0.036). The opposite was observed for MRI with an
average difference of -25ml for GCV0 (p=0.050) and -0.2ml/min
for GE rate @ T50 (not significant). These findings are within the
documented day-to-day variation and are at the limit of resolution
for individual studies. Further no sequence effect was seen when
the order of study days (GS, MRI) was considered.
Although the effects are small and could be due to random
variation it is interesting that the comparison between the repeated
study days showed opposite effects on day 1 and day 2 in GS and
MRI. It has previously been recognised that stress delays gastric
emptying (213) but increases gastric secretion (214). One could
speculate that an interaction between the imaging modality and
these effects could explain the unexpected findings. You would
anticipate that participants would feel more nervous before their
first imaging day as unsure of the days events, consistent with the
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findings for GS. However, this did not occur for MRI. It may be that
MRI is a more difficult and a less physiologically normal process
for the individuals. It is already well known that MRI is poorly
tolerated in some individuals (215). Consequently, the anticipation
of MRI on the second visit may have been greater leading to the
differences between MRI and GS study days.
4.4.2.2 Liquid  mixed meal differences
Bland Altman between 11 HV showed more rapid early emptying
(GCV0O of the liquid component of the mixed meal (GS -29ml, MRI
GCV -31ml and MRI TGV -45ml). No difference was seen in T50
and GErate @ T50.
The 24 HV who underwent the mixed meal were compared to the
24 matched HV in the liquid study. GCV0 was significantly greater
in mixed meal results for MRI GCV and GS ( t-test/Mann Whitney U
test).
Comparisons are difficult to be drawn between two different
populations who had different statistical tests.
4.4.2.3 Inter-observer variability
Intra-class correlation was 0.83 and above for all three parameters
that describe liquid gastric emptying in MRI. Agreement was lower
in GS with intra-class correlation varying between 0.687  0.960
for the gastric emptying parameters.
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MR has less variability between observers than GS for all three
gastric emptying parameters. Both methods require the individual
analysing results to draw round the ingested labelled fortisip. As
MRI also visualised the surrounded tissue (unlike GS), it is easier
to recognise a distinct outline of the ingested meal. A comparison
of GS and MR that demonstrates the spatial resolution available
from both modalities is included below.
Figure 65. GS image (left) and MRI slice right.
A semi-automated tracking program was used within the MRI
model for the beads. This improved the intra-class correlation
between the observers. Agar bead count at 60 minutes correlation
increased from 0.727 to 0.982 and from 0.976 to 0.999 at 120
minutes with the additional program.
Gadolinium labelled fortisip
in stomach in MRI
Technicium labelled
fortisip in GS
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4.4.2.4 Sensation within modalities
Fullness was non-significantly higher in GS than MRI and was
significantly higher in the NDT than MRI. The NDT was always the
first performed, as part of the screening visit. Stress is known to
delay gastric emptying (213) and the participants were taking part
in the study for the first time during the NDT. It is conceivable that
they may be more nervous/anxious about the first visit. They
frequently went on to drink much more than 400ml. However, it is
surprising that MRI fullness was the lowest. The MRI study day is
potentially considered the more stressful of MRI/GS and the least
physiological as MRI is performed lying down. It may be the
altered position and therefore altered position of fluid within the
stomach affects fullness. Previous studies have shown in health
and FD that fullness is more closely related to antral distention
(103, 216). The gastric contents may lie more proximally when
lying in comparison to upright and could explain some of the
differences seen.
4.4.3 Health versus disease: liquid study
4.4.3.1 GS
GCV0 was significantly lower in the FD population with no
significant difference between T50 and GE rate @ T50 indicating
more rapid early gastric emptying. As this is phase of emptying
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occurs during ingestion of the meal itself (takes place over 10
minutes), this is thought to be representative of receptive
accommodation of the proximal stomach.
As discussed earlier, the primary responsibility of the fundus is to
act as a reservoir when food is delivered into the stomach, allowing
initial mixing of contents with pepsin and hydrochloric acid.
Delivery of the meal into the stomach leads to reflex relaxation
(reduction in tone known as accommodation) which then gradually
recovers. Liquid emptying is driven by a gastro-duodenal pressure
gradient, generated by tonic fundal contraction, with the rate of
emptying regulated by the pylorus (217). Initially, during early
gastric emptying, the process is driven by mechanical factors (i.e.
volume ingested). Later, during the majority of gastric emptying,
fundic tone and emptying rate are also modulated by nutrient
feedback (following nutrient delivery into the duodenum). Thus in
the early phase, non-nutrient and nutrient liquids empty at the
same rate; however, in the later phase non-nutrient empty faster
than nutrient liquids (21).
Previous work in functional dyspepsia has identified impaired
accommodation in at least 40% of patients (37). The lower GCV0
on our patient group within is most likely representative of
impaired receptive accommodation. FD patients have also been
shown to be hypersensitive to antral distension and exhibit reduced
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fundic relaxation in response to antral distension when compared
to healthy volunteers (216). The results of this study are
consistent with the published hypothesis that impaired
accommodation of the proximal stomach leads to relative
distension of the antrum and rapid early emptying of liquids into
the duodenum. This could account for many of the post-prandial
symptoms in the FD population. Also it provides a non-invasive
biomarker of gastric dysfunction that could be amenable to specific
therapy.
The physiology of gastric accommodation is complex. Gastric
accommodation and tone are vagally mediated. Both nitric oxide
(NO) and vasoactive intestinal polypeptide (VIP) inhibit smooth
muscle tone, leading to reduced gastric fundal tone (218, 219). NO
produces these effects by causing the formation of cyclic
JXDQRVLQHĻĻPRQRSKRSVKDWHF*03YLD soluble guanylate
cyclase (220, 221). This has been supported by nitric oxide
inhibitors leading to reduced fundal relaxation post-prandially in
healthy volunteers (221). Also, the cGMP phosphodisesterase
inhibitor, sildenafil, which reduces degradation of cGMP has been
shown to increase fasting intra-gastric volumes and reduce liquid
emptying (194). This supports the findings in this study that the
FD population had faster early liquid emptying due to impaired
accommodation. Sildenafils potential therapeutic activity in gastric
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accommodation and emptying has only been completed in a small
group of healthy volunteers with no FD patient studies to date.
Figure 66. The gastric accommodation reflex  reproduced from Kindt S
and Tack J. Gut. 2006: 55: 1685-1691
Excitory neurones are also involved in accommodation via their
HIIHFWVRQFKROLQHUJLFSDWKZD\VĮ2-adrenorecpetors and 5-HT1A
receptors (which are inhibitory) have been found on these
QHXURQHV6WXGLHVXVLQJFORQLGLQHDĮ2-
adrenorecpetors agonist) and buspirone (a 5-HT1A receptor agonist)
have both been found to improve accommodation to a meal (224).
Buspirone was given to 17 FD patients, in a blinded cross-over
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design with placebo, for a 2 week period. It increased gastric
accommodation and delayed emptying time of liquids (although not
solids). These results support the hypothesis that the lower GCV0
seen in our FD population is due to impaired accommodation which
subsequently causes increased initial liquid emptying.
If initial emptying is faster in FD, this can result in the early
nutrient delivery into the small bowel, which exerts a negative
feedback on further gastric emptying and accommodation. This
mechanism has been described previously and is sometimes
referred to as the duodenal brake (23). Neuro-hormonal and
mechanical factors are important in activating this. The digestive
hormone CCK seems to play a significant role. In studies looking at
this, a non-nutrient water load was given to healthy volunteers 1
hour after a meal and was found to stimulate CCK release and
decrease antral motility (225). The authors hypothesised that this
is due to the remaining fatty chyme in the stomach being flushed
through into the duodenum by the water. This is supported by
other work showing that a selection of lipids infused directly into
the duodenum in healthy volunteers were found to cause CCK
release and increase gastric volume (226). The effect on CCK
release was most pronounced with long-chain triglycerides, as was
the reduction in the sensation of hunger. Medium chain
triglycerides did not cause a release of CCK. In the same study the
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proximal stomach was also distended 30 minutes following the
triglyceride infusions. Although both medium and long chain
triglycerides increased gastric volumes, levels of CCK did not rise
during this period, as it had done in the initial triglyceride infusion.
This suggests that although CCK is plays a role in the duodenal
brake, it is not the only contributing factor.
4.4.3.2 MRI
GCV0 was significantly higher in the FD population in comparison
to the HV. Several factors could be important in this. Stress
(known to often be higher in FD) (168) impairs gastric distension,
reducing accommodation (54) but would be expected to produce
rapid earlier emptying, therefore a lower GCV0. However, it also
increases secretion production (214). MRI can measure
secretion/other gastric contents as well as ingested meal. If
secretion production was greater in FDs, then this would produce
the higher GCV0. Secretion production would have to exceed any
early emptying for this to occur.
There was no difference between T50 and GE rate @ T50. This was
the same in GCV and TGV. MRI showed similar baseline volumes
between HV and FD in MRI.
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4.4.4 Comparison of GS and MRI
One of the most interesting results for the liquid study is that GCV0
was lower in the patient population in GS but greater in MRI. As
discussed in the results section, MRI also measures secretion while
GS cannot. Fasting scans do not show a greater level of secretions.
Thus any difference is most likely due to the secretory response to
the Fortisip ingestion and greater volumes of secretions are
produced (therefore the higher GCV0 values in MRI). 63% of
patients had a GCV0 greater than 400ml (the ingested volume) in
MRI. Due to this difference in measurement abilities between the 2
modalities, it is perhaps not surprising that the differences were
seen. MRI will always be able to potentially measure more than
GS, meaning trying to compare the 2 modalities within one test
may not appropriate unless some attempt is made to correct for
secretion.
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Figure 67. Secretions in MRI (T1 image)  reproduced with
permission from Dr Caroline Hoad, MRI Research Fellow
Some work has been completed in secretion volume production in
MRI. The MRI labelling agent gadolinium reduces the T1 relaxation
time (time taken for protons to return to longitudinal axis). As the
ingested meal is diluted with secretions, the change in T1 can be
measured and is reflective of secretion volume (227, 228). A
recent study has looked at secretion volume production in 14 HV
studied by MRI (179). Meal volume, secretion volume and gastric
contents volume were all measured. Secretion volume was
measured after meal ingestion and was 35ml+/- 30ml. There was
large variability between individuals. When the gastric emptying
was modelled in this group, the secretion rate constant showed
correlation with the meal emptying rate constant. They also found
meal volume decreased in early emptying but gastric contents
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volume (meal and secretions) decreased more slowly or even
remained constant during the same time period. This suggests
gastric secretions affect gastric emptying (particularly in the early
phase) and that for MRI to be used in this manner, secretions must
also be measured.
Our MRI department has been working to quantify these secretions
using the above method. They have recently provided preliminary
data on this, completed by Dr Caroline Hoad, Research Fellow
within the MRI unit. It is included here to support the hypothesis
for different volumes recorded between the two modalities being
due to secretions.
16 HV from the mixed meal have had secretion volume assessed at
time points 15 and 75 minutes. Mean secretion volume at 15
minutes was 64 ml (standard deviation 51ml) and 110 (40) at 75
min. Secretion increased between the two time points in all but
one individual. Increase of secretions was a mean of 52 (29) ml.
The results for GCV as then compared between GS and MRI i) meal
and secretions ii) meal only.
15 min GS 310ml (32)
MRI (meal only) 338ml (50).
MRI (meal and secretion) 402ml (58)
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75 min GS 112ml (61)
MRI (meal only) 92ml (36)
MRI (meal and secretion) 202(50)
This initial work shows that meal volume in MRI is similar to GS
when secretion volume is accounted for.
4.4.5 Mixed meal
Following initial development and analysis there were several
amendments to the mixed meal study during the course of the
study. Due to this and a more heterogeneous method within the
patient population, an initial 8 pilot FD patients were compared to
the HV before extending this to further FD and GORD patients.
4.4.5.1 Pilot 8 FD versus HV
GS showed no significant differences between groups. In MRI GCV,
GCV0 was significantly lower in the patients. A significantly higher
MRI GCV GCV0 was seen in HV between liquid and mixed meal,
while such a difference was not seen between the patients.
4.4.5.2 Additional patient groups
When the study was expanded to additional FD patients and GORD
patients, GS showed significantly lower GCV0 in HV>FD=GORD.
T50 and GE rate @ T50 didnt have any significant results.
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In MRI , T50 was greater in GORD group in MRI GCV and GCV0
MRI TGV was significantly higher in the GORD group versus HV.
Thus the pattern of gastric emptying was different in the three
groups
FD patients were compared to GORD and HV in the mixed meal.
The most interesting parameter was GCV0. GCV0 was significantly
HV>FD=GORD in GS and GORD>HV for GCV0 in MRI total contents
(with the same trends in MRI contents). FD results were non-
significantly higher than HV.
This may support the hypothesis that gastric secretions are the
important variable between health and disease. Considerable work
has been documented in gastric acid suppression in GORD, but less
so on gastric acid secretions volume, although some studies have
suggested this is higher in GORD (229, 230). One study
determined the buffering capacity of a meal in vitro and then used
the same meal to identify the time taken for gastric pH to drop to 2
in GORD patients and HV (231). This study found that meal
stimulated gastric acid secretion and post-prandial gastric acidity
was significantly higher in the GORD group. However, the total
gastric acid secretion over 24 hours was the same in both groups.
This provides an interesting insight, suggesting the speed of
secretions in response to a meal differs between health and GORD.
There are some similarities between GORD and FD (post-prandial
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symptoms, pain) and overlap has been suggested between the two
conditions (2, 232). Increased speed and volume of secretion
production may have an effect in both diseases. The results follow
the same trends in FD and GORD of decreased GCV0 in GS but
higher GCV0 in MRI, supporting this. The mechanism is likely due
to a combination of increased volume and altered composition of
gastric contents.
The altered gastric contents (with more secretions) potentially
result in a more acidic chyme being delivered into the small bowel.
Acid infusion into the duodenum has been studied and has been
shown to affect fundal activity and sensation in a group of healthy
volunteers (233). Acid infusion versus saline infusion was
completed in a randomised, blinded manner with barostat
measurements within the fundus. Fundal compliance increased
with reduced fasting fundal tone with the acid infusion. Meal
induced accommodation was then assessed with the acid versus
saline infusion. Fundal pressures required for discomfort and
relaxation during the meal were lower in the acid infusion group.
Duodenal acid exposure has also been known to delay gastric
emptying (234), which has thought to be a protective mechanism
for the duodenal mucosa. Its role in FD is unclear. One study
showed that duodenal acid induced nausea in FD patients and not
healthy volunteers (235) but other studies have shown that
263
duodenal acid can also induce nausea in healthy individuals along
with other dyspeptic symptoms (236, 237). Duodenal acid
exposure has also been shown to be increased in FD patients and
that its clearance reduced (238). This may explain the subset of FD
patients that report symptomatic benefit to PPIs, despite not
having GORD. The mechanism by which duodenal acid induces
symptoms still remains unclear though. It may be that an
increased volume of secretion partly promotes this effect.
Another area where meal composition is important in FD is with
lipids. Lipid infusion into FD patients results in increased dyspeptic
symptoms of nausea and bloating in comparison to healthy
controls (239) and lipid infusion can differentiate between FD
patients and healthy controls (56). Glucose does not produce the
same differentiation between patients and volunteers or symptom
production (240). This may be partly due to CCK. It is consistent
with the FD population describing symptoms following fatty foods
and often stimulates gastro-oesophageal reflux symptoms as well
(241). It may be the fortisip meal used in this study stimulated
symptoms and even secretion production.
4.4.6 Nutrient drink test
Maximum tolerated volume was significantly lower in FD compared
to HV for both liquid and mixed meal. GORD patients drank
significantly less than HV but more than FD patients. This is
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interesting and supports the theory that there are significant
overlap between GORD (particularly non-erosive reflux disease)
and FD (232). Symptom profile can be similar (e.g. post-prandial
period affected). The population of GORD patients recruited are
those who were referred for pH studies. These are commonly only
completed if there is a lack of full response to PPI, if anti-reflux
surgery is being considered or if the diagnosis is unclear. Therefore
there is potential for significant crossover between the two patient
populations.
4.4.7 VAS scores
FD patients reported significantly greater fullness at 400ml for both
GS and MRI in comparison to HV. They also reported more fullness
than the GORD patients in GS. Similar trends were followed in MRI
but not significant. Asking participants to drink to 400ml is a more
practical than asking them to drink to maximum tolerated volume.
4.4.8 Limitations
No study is without problems. Some limitations have been
discussed earlier in the text. Given that FD and GORD are likely to
be heterogeneous conditions the patient numbers are relatively
small for both studies. One of the difficulties of recruiting was the
need for both FD and GORD patients being required to come off
any medications that may affect the gastric parameters or
sensation. Obviously, many patients are reluctant to do. This is
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especially important as gastric function does vary in individuals on
a daily basis and increasing overall numbers would minimise this
effect.
Differences were seen between MRI and GS, with GS GCV0 being
consistently lower in GS than MRI in both the liquid and mixed
meal. This has been discussed and due to the addition of gastric
secretions.
The measurement of gastric secretions would seem to be pertinent
to the results. This technique is being developed by the MRI
section of the study team. Quantifying the amount and speed of
gastric secretions in health and disease will hopefully elicit more
differences between these groups. Preliminary work has been
completed within the HV but this needs to be extended to the
patient groups.
4.5 Conclusion
The study has sought to develop and validate a new test meal that
assesses gastric function alongside sensory function in a non-
invasive manner. A large group of age/sex stratified healthy
volunteers have been assessed to establish normal values and
validation work completed within this population. Once complete,
FD and GORD patient groups were included. Results for these
groups have confirmed pathophysiology, such as impaired
accommodation but also highlighted less described differences,
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such as increased gastric secretion in FD. The balance between
these two factors may explain some of the variation in gastric
emptying study results currently seen in FD patients. These results
are important as can be used to make a positive diagnosis in FD,
rather than the current diagnosis of exclusion often used. They can
be completed with relatively accessible technology (GS) and MRI if
further input is needed. Sensory function has also been recorded
and shown that hypersensitivity is an important feature in FD in a
practical manner at 400ml ingestion. Using studies like this to
separate conditions dependent on underlying pathophysiology can
only help guide effective treatment.
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5 Overall conclusion
This thesis has detailed how new, emerging modalities can add to
our understanding of gastro-oesophageal disease, potentially guide
therapy and utilise current tests in a more clinically useful way.
High resolution oesophageal manometry is a minimally invasive
test with few side effects that can be used to correctly identify the
causes of and classify patients with rumination syndrome and
recurrent belching. This can have direct clinical impact on care, by
directing treatment to the stimulus for rumination while applying
generic biofeedback therapy to the learned behaviour. In a case
where reflux triggered this behaviour it identified an individual who
benefited from fundoplication. This requires careful thought and
consideration as in the wrong patient it will simply lead to the
development of new behaviour.
EndoFLIP® technology was a promising prospect in the diagnosis if
GORD. However, its measurement of the gastro-oesophageal
junction and associated parameters (distensibility and CSA) have
been shown to be highly variable within patients and healthy
volunteers, limiting its use as a diagnostic aid. Obesity seems to be
a particular confounding factor, one which is common in the
presence of GORD. However, it could be that situations in which
patients are their own control, it may prove more beneficial.
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Gastric emptying studies have long been completed in functional
dyspepsia with relatively limited clinical impact. This work has
shown that the modalities GS and MRI produce different results for
the gastric emptying parameters GCV0, T50 and GE rate at T50.
GCV0, representative of early emptying is greater in MRI than GS
due to the presence of gastric secretions. GS has advantages of
accessibility, cost and ease of interpretation. Advantages of MRI is
that additional components of gastric secretions, gastric size, air
quantification within the stomach can all be measured, while GS
can only measure in the ingested, labelled meal. Lower GCV0 in GS
in liquid studies suggests that early gastric emptying is quicker in a
FD population. But contrast with MRI indicates that this is offset by
greater secretion production in these patients. When the study was
extended to additional patient groups, the GORD population seems
to follow trends seen in the FD population.
Ongoing work is needed to further subdivide the different results
seen in the liquid and solid sections of the gastric emptying study.
Pilot secretion work within a limited number of the healthy
volunteers has been completed and needs to be further extended
out to the patient population. MRI provided a wealth of information
that provides the potential of relating symptoms to underlying
pathophysiology
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Although it remains a significant challenge, trying to find the right
treatment for the right patient should be the aim for all doctors
working with patients with so-called functional gastrointestinal
diseases, in the same way as in other areas of medicine. Only by
exploring and testing new devices and discovering the differences
between health and disease can we hope to improve the care we
deliver to our patients.
270
6 References
1. Talley NJ. Functional gastrointestinal disorders as a public health
problem. Neurogastroent Motil. 2008 May;20:121-9. PubMed PMID:
ISI:000255868900014. English.
2. Choung RS, Locke GR, 3rd, Schleck CD, Zinsmeister AR, Talley NJ.
Overlap of dyspepsia and gastroesophageal reflux in the general population: one
disease or distinct entities? Neurogastroenterol Motil. 2011 Dec 12. PubMed
PMID: 22150874. Eng.
3. Small PK, Loudon MA, Waldron B, Smith D, Campbell FC. Importance of
reflux symptoms in functional dyspepsia. Gut. 1995 Feb;36(2):189-92. PubMed
PMID: 7883215. eng.
4. Tack J, Caenepeel P, Arts J, Lee KJ, Sifrim D, Janssens J. Prevalence of
acid reflux in functional dyspepsia and its association with symptom profile. Gut.
2005 Oct;54(10):1370-6. PubMed PMID: 15972301. eng.
5. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-
oesophageal reflux disease: a systematic review. Gut. 2005 May;54(5):710-7.
PubMed PMID: 15831922. eng.
6. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal
definition and classification of gastroesophageal reflux disease: a global
evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz
43. PubMed PMID: 16928254. eng.
7. Becher A, El-Serag H. Systematic review: the association between
symptomatic response to proton pump inhibitors and health-related quality of
life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther.
2011 Sep;34(6):618-27. PubMed PMID: 21770991. eng.
8. Bodger K TN. Guidelines for oesophageal manometry and pH monitoring.
BSG Guidelines. 2006 2006.
9. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu PJ, Malagelada JR, et al.
Functional gastroduodenal disorders. Gastroenterology. 2006 Apr;130(5):1466-
79. PubMed PMID: ISI:000237520400008. English.
10. Aro P, Talley NJ, Agreus L, Johansson SE, Bolling-Sternevald E,
Storskrubb T, et al. Functional dyspepsia impairs quality of life in the adult
population. Aliment Pharm Ther. 2011 Jun 1;33(11):1215-24. PubMed PMID:
ISI:000290174300005. English.
11. Schuurkes JA, Meulemans AL. Nitric oxide and gastric relaxation. Dig Dis
Sci. 1994 Dec;39(12 Suppl):79S-81S. PubMed PMID: 7995223. eng.
12. Patrick A, Epstein O. Review article: gastroparesis. Aliment Pharmacol
Ther. 2008 May;27(9):724-40. PubMed PMID: 18248660. eng.
13. Sanger GJ, Lee K. Hormones of the gut-brain axis as targets for the
treatment of upper gastrointestinal disorders. Nat Rev Drug Discov. 2008
Mar;7(3):241-54. PubMed PMID: 18309313. eng.
14. Troncon LE, Thompson DG, Ahluwalia NK, Barlow J, Heggie L. Relations
between upper abdominal symptoms and gastric distension abnormalities in
dysmotility like functional dyspepsia and after vagotomy. Gut. 1995
Jul;37(1):17-22. PubMed PMID: 7672673. eng.
15. Van Citters GW, Lin HC. Ileal brake: neuropeptidergic control of intestinal
transit. Curr Gastroenterol Rep. 2006 Oct;8(5):367-73. PubMed PMID:
16968603. eng.
16. Hinder RA, Kelly KA. Human gastric pacesetter potential. Site of origin,
spread, and response to gastric transection and proximal gastric vagotomy. Am
J Surg. 1977 Jan;133(1):29-33. PubMed PMID: 835775. eng.
17. Hirst GD, Edwards FR. Role of interstitial cells of Cajal in the control of
gastric motility. J Pharmacol Sci. 2004 Sep;96(1):1-10. PubMed PMID:
15351789. eng.
271
18. Waldron B, Cullen PT, Kumar R, Smith D, Jankowski J, Hopwood D, et al.
Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial
study. Gut. 1991 Mar;32(3):246-51. PubMed PMID: 2013418. eng.
19. Tougas G, Anvari M, Dent J, Somers S, Richards D, Stevenson GW.
Relation of pyloric motility to pyloric opening and closure in healthy subjects.
Gut. 1992 Apr;33(4):466-71. PubMed PMID: 1582588. Pubmed Central PMCID:
1374060.
20. Sanger GJ, Hellstrom PM, Naslund E. The hungry stomach: physiology,
disease, and drug development opportunities. Front Pharmacol. 2010;1:145.
PubMed PMID: 21927604. eng.
21. Collins PJ, Houghton LA, Read NW, Horowitz M, Chatterton BE, Heddle R,
et al. Role of the proximal and distal stomach in mixed solid and liquid meal
emptying. Gut. 1991 Jun;32(6):615-9. PubMed PMID: 2060870. eng.
22. Collins PJ, Horowitz M, Maddox A, Myers JC, Chatterton BE. Effects of
increasing solid component size of a mixed solid/liquid meal on solid and liquid
gastric emptying. Am J Physiol. 1996 Oct;271(4 Pt 1):G549-54. PubMed PMID:
8897871. eng.
23. Kusano M, Zai H, Shimoyama Y, Hosaka H, Kuribayashi S, Kawamura O,
et al. Rapid gastric emptying, rather than delayed gastric emptying, might
provoke functional dyspepsia. J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:75-
8. PubMed PMID: 21443715. eng.
24. Shimoyama Y, Kusano M, Kawamura O, Zai H, Kuribayashi S, Higuchi T,
et al. High-viscosity liquid meal accelerates gastric emptying.
Neurogastroenterol Motil. 2007 Nov;19(11):879-86. PubMed PMID: 17973639.
eng.
25. Raybould HE, Glatzle J, Robin C, Meyer JH, Phan T, Wong H, et al.
Expression of 5-HT3 receptors by extrinsic duodenal afferents contribute to
intestinal inhibition of gastric emptying. Am J Physiol Gastrointest Liver Physiol.
2003 Mar;284(3):G367-72. PubMed PMID: 12409280. eng.
26. McLaughlin J, Grazia Luca M, Jones MN, D'Amato M, Dockray GJ,
Thompson DG. Fatty acid chain length determines cholecystokinin secretion and
effect on human gastric motility. Gastroenterology. 1999 Jan;116(1):46-53.
PubMed PMID: 9869601. eng.
27. Seimon RV, Feltrin KL, Meyer JH, Brennan IM, Wishart JM, Horowitz M, et
al. Effects of varying combinations of intraduodenal lipid and carbohydrate on
antropyloroduodenal motility, hormone release, and appetite in healthy males.
Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R912-20. PubMed
PMID: 19211720. eng.
28. Raybould HE, Lloyd KC. Integration of postprandial function in the
proximal gastrointestinal tract. Role of CCK and sensory pathways. Ann N Y Acad
Sci. 1994 Mar 23;713:143-56. PubMed PMID: 8185155. eng.
29. Johnson AG. Gastroduodenal motility and synchronization. Postgrad Med
J. 1973 Jul;49 Suppl 4:suppl 4:29-34. PubMed PMID: 4804464. eng.
30. Schulze K. Imaging and modelling of digestion in the stomach and the
duodenum. Neurogastroenterol Motil. 2006 Mar;18(3):172-83. PubMed PMID:
16487408.
31. Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms
associated with impaired gastric emptying of solids and liquids in functional
dyspepsia. Am J Gastroenterol. 2003 Apr;98(4):783-8. PubMed PMID:
12738456. eng.
32. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of
functional dyspepsia. Gastroenterology. 2004 Oct;127(4):1239-55. PubMed
PMID: 15481001. eng.
33. Quartero AO, de Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW.
Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis.
Dig Dis Sci. 1998 Sep;43(9):2028-33. PubMed PMID: 9753269.
272
34. Talley NJ, Verlinden M, Jones M. Can symptoms discriminate among
those with delayed or normal gastric emptying in dysmotility-like dyspepsia? Am
J Gastroenterol. 2001 May;96(5):1422-8. PubMed PMID: 11374677. eng.
35. Zai H, Kusano M. Investigation of gastric emptying disorders in patients
with functional dyspepsia reveals impaired inhibitory gastric emptying regulation
in the early postcibal period. Digestion. 2009;79 Suppl 1:13-8. PubMed PMID:
19153485. eng.
36. Troncon LE, Bennett RJ, Ahluwalia NK, Thompson DG. Abnormal
intragastric distribution of food during gastric emptying in functional dyspepsia
patients. Gut. 1994 Mar;35(3):327-32. PubMed PMID: 8150341. eng.
37. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms
associated with hypersensitivity to gastric distention in functional dyspepsia.
Gastroenterology. 2001 Sep;121(3):526-35. PubMed PMID: 11522735. eng.
38. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired
gastric accommodation to a meal in functional dyspepsia. Gastroenterology.
1998 Dec;115(6):1346-52. PubMed PMID: 9834261. eng.
39. Piessevaux H, Tack J, Walrand S, Pauwels S, Geubel A. Intragastric
distribution of a standardized meal in health and functional dyspepsia:
correlation with specific symptoms. Neurogastroenterol Motil. 2003
Oct;15(5):447-55. PubMed PMID: 14507346. eng.
40. Simren M, Vos R, Janssens J, Tack J. Unsuppressed postprandial phasic
contractility in the proximal stomach in functional dyspepsia: relevance to
symptoms. Am J Gastroenterol. 2003 Oct;98(10):2169-75. PubMed PMID:
14572563. eng.
41. Mundt MW, Hausken T, Samsom M. Effect of intragastric barostat bag on
proximal and distal gastric accommodation in response to liquid meal. Am J
Physiol Gastrointest Liver Physiol. 2002 Sep;283(3):G681-6. PubMed PMID:
12181183. eng.
42. Sarnelli G, Vos R, Cuomo R, Janssens J, Tack J. Reproducibility of gastric
barostat studies in healthy controls and in dyspeptic patients. Am J
Gastroenterol. 2001 Apr;96(4):1047-53. PubMed PMID: 11316145. eng.
43. Kindt S, Dubois D, Van Oudenhove L, Caenepeel P, Arts J, Bisschops R, et
al. Relationship between symptom pattern, assessed by the PAGI-SYM
questionnaire, and gastric sensorimotor dysfunction in functional dyspepsia.
Neurogastroenterol Motil. 2009 Nov;21(11):1183-e105. PubMed PMID:
19663903. eng.
44. Fock KM. Functional dyspepsia, H. pylori and post infectious FD. J
Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:39-41. PubMed PMID: 21443707.
eng.
45. Danesh J, Lawrence M, Murphy M, Roberts S, Collins R. Systematic
review of the epidemiological evidence on Helicobacter pylori infection and
nonulcer or uninvestigated dyspepsia. Arch Intern Med. 2000 Apr
24;160(8):1192-8. PubMed PMID: 10789614. eng.
46. McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form
Health Survey (SF-36): II. Psychometric and clinical tests of validity in
measuring physical and mental health constructs. Med Care. 1993
Mar;31(3):247-63. PubMed PMID: 8450681. eng.
47. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical
symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med.
2003 Jul-Aug;65(4):528-33. PubMed PMID: 12883101.
48. Kindt S, Van Oudenhove L, Mispelon L, Caenepeel P, Arts J, Tack J.
Longitudinal and cross-sectional factors associated with long-term clinical course
in functional dyspepsia: a 5-year follow-up study. Am J Gastroenterol. 2011
Feb;106(2):340-8. PubMed PMID: 20978482. eng.
49. Drossman DA, Leserman J, Nachman G, Li ZM, Gluck H, Toomey TC, et
al. Sexual and physical abuse in women with functional or organic
273
gastrointestinal disorders. Ann Intern Med. 1990 Dec 1;113(11):828-33.
PubMed PMID: 2240898. eng.
50. Geeraerts B, Van Oudenhove L, Fischler B, Vandenberghe J, Caenepeel P,
Janssens J, et al. Influence of abuse history on gastric sensorimotor function in
functional dyspepsia. Neurogastroenterol Motil. 2009 Jan;21(1):33-41. PubMed
PMID: 18694440.
51. Tanaka T, Manabe N, Hata J, Kusunoki H, Ishii M, Sato M, et al.
Characterization of autonomic dysfunction in patients with irritable bowel
syndrome using fingertip blood flow. Neurogastroenterol Motil. 2008
May;20(5):498-504. PubMed PMID: 18248583. eng.
52. Bohmelt AH, Nater UM, Franke S, Hellhammer DH, Ehlert U. Basal and
stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional
gastrointestinal disorders and healthy controls. Psychosom Med. 2005 Mar-
Apr;67(2):288-94. PubMed PMID: 15784796. eng.
53. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, et al.
Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome:
plasma cytokines as a potential biomarker? Gastroenterology. 2006
Feb;130(2):304-11. PubMed PMID: 16472586. eng.
54. Geeraerts B, Vandenberghe J, Van Oudenhove L, Gregory LJ, Aziz Q,
Dupont P, et al. Influence of experimentally induced anxiety on gastric
sensorimotor function in humans. Gastroenterology. 2005 Nov;129(5):1437-44.
PubMed PMID: 16285945.
55. Schwartz MP, Samsom M, Smout AJ. Chemospecific alterations in
duodenal perception and motor response in functional dyspepsia. Am J
Gastroenterol. 2001 Sep;96(9):2596-602. PubMed PMID: 11569681. eng.
56. Bjornsson E, Sjoberg J, Ringstrom G, Norstrom M, Simren M,
Abrahamsson H. Effects of duodenal lipids on gastric sensitivity and relaxation in
patients with ulcer-like and dysmotility-like dyspepsia. Digestion.
2003;67(4):209-17. PubMed PMID: 12966228. eng.
57. Yazaki E, Shawdon A, Beasley I, Evans DF. The effect of different types of
exercise on gastro-oesophageal reflux. Australian journal of science and
medicine in sport. 1996 Dec;28(4):93-6. PubMed PMID: 9040897.
58. Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower
oesophageal sphincter incompetence in patients with symptomatic
gastrooesophageal reflux. Gut. 1988 Aug;29(8):1020-8. PubMed PMID:
3410327. Pubmed Central PMCID: 1433911.
59. Schoeman MN, Tippett MD, Akkermans LM, Dent J, Holloway RH.
Mechanisms of gastroesophageal reflux in ambulant healthy human subjects.
Gastroenterology. 1995 Jan;108(1):83-91. PubMed PMID: 7806066.
60. Jozkow P, Wasko-Czopnik D, Dunajska K, Medras M, Paradowski L. The
relationship between gastroesophageal reflux disease and the level of physical
activity. Swiss medical weekly. 2007 Aug 25;137(33-34):465-70. PubMed PMID:
17990130.
61. Cammack J, Read NW, Cann PA, Greenwood B, Holgate AM. Effect of
prolonged exercise on the passage of a solid meal through the stomach and
small intestine. Gut. 1982 Nov;23(11):957-61. PubMed PMID: 7129205.
Pubmed Central PMCID: 1419808.
62. van Nieuwenhoven MA, Brouns F, Brummer RJ. The effect of physical
exercise on parameters of gastrointestinal function. Neurogastroenterol Motil.
1999 Dec;11(6):431-9. PubMed PMID: 10583850.
63. Costill DL, Saltin B. Factors limiting gastric emptying during rest and
exercise. Journal of applied physiology. 1974 Nov;37(5):679-83. PubMed PMID:
4436193.
64. Fordtran JS, Saltin B. Gastric emptying and intestinal absorption during
prolonged severe exercise. Journal of applied physiology. 1967 Sep;23(3):331-
5. PubMed PMID: 6047953.
274
65. Brown BP, Ketelaar MA, Schulze-Delrieu K, Abu-Yousef MM, Brown CK.
Strenuous exercise decreases motility and cross-sectional area of human gastric
antrum. A study using ultrasound. Dig Dis Sci. 1994 May;39(5):940-5. PubMed
PMID: 8174435.
66. Bi L, Triadafilopoulos G. Exercise and gastrointestinal function and
disease: an evidence-based review of risks and benefits. Clin Gastroenterol
Hepatol. 2003 Sep;1(5):345-55. PubMed PMID: 15017652.
67. Franke A, Nakchbandi IA, Schneider A, Harder H, Singer MV. The effect of
ethanol and alcoholic beverages on gastric emptying of solid meals in humans.
Alcohol and alcoholism. 2005 May-Jun;40(3):187-93. PubMed PMID: 15699055.
68. Inamori M, Iida H, Endo H, Hosono K, Akiyama T, Yoneda K, et al. Aperitif
effects on gastric emptying: a crossover study using continuous real-time 13C
breath test (BreathID System). Dig Dis Sci. 2009 Apr;54(4):816-8. PubMed
PMID: 18688714.
69. Kaufman SE, Kaye MD. Effect of ethanol upon gastric emptying. Gut.
1979 Aug;20(8):688-92. PubMed PMID: 39879. Pubmed Central PMCID:
1412536.
70. Moore JG, Christian PE, Datz FL, Coleman RE. Effect of wine on gastric
emptying in humans. Gastroenterology. 1981 Dec;81(6):1072-5. PubMed PMID:
7286585.
71. Heinrich H, Goetze O, Menne D, Iten PX, Fruehauf H, Vavricka SR, et al.
Effect on gastric function and symptoms of drinking wine, black tea, or schnapps
with a Swiss cheese fondue: randomised controlled crossover trial. BMJ.
2010;341:c6731. PubMed PMID: 21156747. Pubmed Central PMCID: 3272707.
72. Feinle-Bisset C, Azpiroz F. Dietary and lifestyle factors in functional
dyspepsia. Nat Rev Gastroenterol Hepatol. 2013 Mar;10(3):150-7. PubMed
PMID: 23296252.
73. Watson AJ. Guuidelines for the diagnosis and management of Barratt's
columnar-lined oesophagus. British Society of Gastroenterology Guidelines.
2005;1.
74. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P.
Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J
Med. 2011 Oct 13;365(15):1375-83. PubMed PMID: 21995385. eng.
75. Korn O, Stein HJ, Richter TH, Liebermann-Meffert D. Gastroesophageal
sphincter: a model. Dis Esophagus. 1997 Apr;10(2):105-9. PubMed PMID:
9179479. eng.
76. Curcic J, Roy S, Schwizer A, Kaufman E, Forras-Kaufman Z, Menne D, et
al. Abnormal structure and function of the esophagogastric junction and
proximal stomach in gastroesophageal reflux disease. Am J Gastroenterol. 2014
May;109(5):658-67. PubMed PMID: 24589669.
77. Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of
transient lower esophageal sphincter relaxation. Am J Physiol. 1995 Jan;268(1
Pt 1):G128-33. PubMed PMID: 7840195. eng.
78. Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient
lower esophageal sphincter relaxation. Gastroenterology. 1995 Aug;109(2):601-
10. PubMed PMID: 7615211. eng.
79. Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Gastro-oesophageal
reflux of liquids and gas during transient lower oesophageal sphincter
relaxations. Neurogastroenterol Motil. 2006 Oct;18(10):888-93. PubMed PMID:
16961691. eng.
80. Trudgill NJ, Riley SA. Transient lower esophageal sphincter relaxations
are no more frequent in patients with gastroesophageal reflux disease than in
asymptomatic volunteers. Am J Gastroenterol. 2001 Sep;96(9):2569-74.
PubMed PMID: 11569677.
275
81. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric
acid and pepsin secretion in clinical esophagitis. Gastroenterology. 1991
Nov;101(5):1149-58. PubMed PMID: 1936784.
82. Daum C, Sweis R, Kaufman E, Fuellemann A, Anggiansah A, Fried M, et
al. Failure to respond to physiologic challenge characterizes esophageal motility
in erosive gastro-esophageal reflux disease. Neurogastroenterol Motil. 2011
Jun;23(6):517-e200. PubMed PMID: 21272162. eng.
83. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal
reflux in patients with hiatus hernia is caused by mechanisms other than
transient LES relaxations. Gastroenterology. 2000 Dec;119(6):1439-46. PubMed
PMID: 11113064. eng.
84. Pandolfino JE, Shi G, Trueworthy B, Kahrilas PJ. Esophagogastric junction
opening during relaxation distinguishes nonhernia reflux patients, hernia
patients, and normal subjects. Gastroenterology. 2003 Oct;125(4):1018-24.
PubMed PMID: 14517784. eng.
85. Mittal RK, Lange RC, McCallum RW. Identification and mechanism of
delayed esophageal acid clearance in subjects with hiatus hernia.
Gastroenterology. 1987 Jan;92(1):130-5. PubMed PMID: 3781181. eng.
86. Kahrilas PJ, McColl K, Fox M, O'Rourke L, Sifrim D, Smout AJ, et al. The
acid pocket: a target for treatment in reflux disease? Am J Gastroenterol. 2013
Jul;108(7):1058-64. PubMed PMID: 23629599.
87. Bardhan KD, Strugala V, Dettmar PW. Reflux revisited: advancing the
role of pepsin. Int J Otolaryngol. 2012;2012:646901. PubMed PMID: 22242022.
eng.
88. Shay S, Tutuian R, Sifrim D, Vela M, Wise J, Balaji N, et al. Twenty-four
hour ambulatory simultaneous impedance and pH monitoring: a multicenter
report of normal values from 60 healthy volunteers. Am J Gastroenterol. 2004
Jun;99(6):1037-43. PubMed PMID: 15180722.
89. Chander B, Hanley-Williams N, Deng Y, Sheth A. 24 Versus 48-hour
Bravo pH Monitoring. J Clin Gastroenterol. 2011 Sep 28. PubMed PMID:
21959323. Eng.
90. Sweis R, Fox M, Anggiansah A, Wong T. Prolonged, wireless pH-studies
have a high diagnostic yield in patients with reflux symptoms and negative 24-h
catheter-based pH-studies. Neurogastroenterol Motil. 2011 May;23(5):419-26.
PubMed PMID: 21235685. eng.
91. Fox MR, Bredenoord AJ. Oesophageal high-resolution manometry:
moving from research into clinical practice. Gut. 2008 Mar;57(3):405-23.
PubMed PMID: 17895358. eng.
92. Gregersen H, Liao D. New perspectives of studying gastrointestinal
muscle function. World J Gastroenterol. 2006 May 14;12(18):2864-9. PubMed
PMID: 16718810. Epub 2006/05/24. eng.
93. Pandolfino JE, Shi G, Curry J, Joehl RJ, Brasseur JG, Kahrilas PJ.
Esophagogastric junction distensibility: a factor contributing to sphincter
incompetence. Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G1052-
8. PubMed PMID: 12016131. eng.
94. Kwiatek MA, Pandolfino JE, Hirano I, Kahrilas PJ. Esophagogastric
junction distensibility assessed with an endoscopic functional luminal imaging
probe (EndoFLIP). Gastrointest Endosc. 2010 Aug;72(2):272-8. PubMed PMID:
20541755. Pubmed Central PMCID: 3019759. Epub 2010/06/15. eng.
95. Piessevaux H, Tack J, Wilmer A, Coulie B, Geubel A, Janssens J.
Perception of changes in wall tension of the proximal stomach in humans. Gut.
2001 Aug;49(2):203-8. PubMed PMID: 11454795. eng.
96. Notivol R, Coffin B, Azpiroz F, Mearin F, Serra J, Malagelada JR. Gastric
tone determines the sensitivity of the stomach to distention. Gastroenterology.
1995 Feb;108(2):330-6. PubMed PMID: 7835573. eng.
276
97. Ang D. Measurement of gastric accommodation: a reappraisal of
conventional and emerging modalities. Neurogastroenterol Motil. 2011
Apr;23(4):287-91. PubMed PMID: 21624107. eng.
98. Breen M, Camilleri M, Burton D, Zinsmeister AR. Performance
characteristics of the measurement of gastric volume using single photon
emission computed tomography. Neurogastroenterol Motil. 2011 Apr;23(4):308-
15. PubMed PMID: 21210894. eng.
99. Brown MSRC. MRI: Basic Principles and Applications. 4th ed. Hoboken,
New Jersey: Wiley-Blackwell; 2010.
100. Fruehauf H, Menne D, Kwiatek MA, Forras-Kaufman Z, Kaufman E,
Goetze O, et al. Inter-observer reproducibility and analysis of gastric volume
measurements and gastric emptying assessed with magnetic resonance imaging.
Neurogastroenterol Motil. 2011 Sep;23(9):854-61. PubMed PMID: 21740482.
Epub 2011/07/12. eng.
101. Choi MG, Camilleri M, Burton DD, Zinsmeister AR, Forstrom LA, Nair KS.
Reproducibility and simplification of 13C-octanoic acid breath test for gastric
emptying of solids. Am J Gastroenterol. 1998 Jan;93(1):92-8. PubMed PMID:
9448183. Epub 1998/02/03. eng.
102. Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, et al.
Measurement of gastric emptying rate of solids by means of a carbon-labeled
octanoic acid breath test. Gastroenterology. 1993 Jun;104(6):1640-7. PubMed
PMID: 8500721. Epub 1993/06/01. eng.
103. Mundt MW, Samsom M. Fundal dysaccommodation in functional
dyspepsia: head-to-head comparison between the barostat and three-
dimensional ultrasonographic technique. Gut. 2006 Dec;55(12):1725-30.
PubMed PMID: 16439420. eng.
104. Jones KL, O'Donovan D, Horowitz M, Russo A, Lei Y, Hausken T. Effects of
posture on gastric emptying, transpyloric flow, and hunger after a glucose drink
in healthy humans. Dig Dis Sci. 2006 Aug;51(8):1331-8. PubMed PMID:
16838120. eng.
105. Boeckxstaens GE, Hirsch DP, van den Elzen BD, Heisterkamp SH, Tytgat
GN. Impaired drinking capacity in patients with functional dyspepsia:
relationship with proximal stomach function. Gastroenterology. 2001
Nov;121(5):1054-63. PubMed PMID: 11677196. eng.
106. Tack J, Caenepeel P, Piessevaux H, Cuomo R, Janssens J. Assessment of
meal induced gastric accommodation by a satiety drinking test in health and in
severe functional dyspepsia. Gut. 2003 Sep;52(9):1271-7. PubMed PMID:
12912857. eng.
107. Drossman DA. The functional gastrointestinal disorders and the Rome III
process. Gastroenterology. 2006 Apr;130(5):1377-90. PubMed PMID:
16678553.
108. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller
RC. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91.
PubMed PMID: 16678561.
109. Bredenoord AJ, Weusten BL, Sifrim D, Timmer R, Smout AJ. Aerophagia,
gastric, and supragastric belching: a study using intraluminal electrical
impedance monitoring. Gut. 2004 Nov;53(11):1561-5. PubMed PMID:
15479671. eng.
110. Rommel N, Tack J, Arts J, Caenepeel P, Bisschops R, Sifrim D.
Rumination or belching-regurgitation? Differential diagnosis using oesophageal
impedance-manometry. Neurogastroenterol Motil. 2010 Apr;22(4):e97-104.
PubMed PMID: 19930540. eng.
111. Bredenoord AJ. Excessive belching and aerophagia: two different
disorders. Dis Esophagus. 2010 May;23(4):347-52. PubMed PMID: 20095992.
277
112. O'Brien MD, Bruce BK, Camilleri M. The rumination syndrome: clinical
features rather than manometric diagnosis. Gastroenterology. 1995
Apr;108(4):1024-9. PubMed PMID: 7698568. eng.
113. Tack J, Blondeau K, Boecxstaens V, Rommel N. Review article: the
pathophysiology, differential diagnosis and management of rumination
syndrome. Aliment Pharmacol Ther. 2011 Apr;33(7):782-8. PubMed PMID:
21303399. eng.
114. Lee H, Rhee PL, Park EH, Kim JH, Son HJ, Kim JJ, et al. Clinical outcome
of rumination syndrome in adults without psychiatric illness: a prospective
study. J Gastroenterol Hepatol. 2007 Nov;22(11):1741-7. PubMed PMID:
17914944. eng.
115. Fox M, Young A, Anggiansah R, Anggiansah A, Sanderson J. A 22 year old
man with persistent regurgitation and vomiting: case outcome. Bmj. 2006 Jul
15;333(7559):133; discussion 4-7. PubMed PMID: 16840471. eng.
116. Chial HJ, Camilleri M, Williams DE, Litzinger K, Perrault J. Rumination
syndrome in children and adolescents: diagnosis, treatment, and prognosis.
Pediatrics. 2003 Jan;111(1):158-62. PubMed PMID: 12509570. eng.
117. Fox M, Sweis R. Future directions in esophageal motility and function -
new technology and methodology. Neurogastroenterol Motil. 2012 Mar;24 Suppl
1:48-56. PubMed PMID: 22248108. eng.
118. Tutuian R, Castell DO. Rumination documented by using combined
multichannel intraluminal impedance and manometry. Clin Gastroenterol
Hepatol. 2004 Apr;2(4):340-3. PubMed PMID: 15067630. eng.
119. Roman S, Zerbib F, Belhocine K, des Varannes SB, Mion F. High
resolution manometry to detect transient lower oesophageal sphincter
relaxations: diagnostic accuracy compared with perfused-sleeve manometry,
and the definition of new detection criteria. Aliment Pharmacol Ther. 2011
Aug;34(3):384-93. PubMed PMID: 21651594. eng.
120. Chitkara DK, Bredenoord AJ, Rucker MJ, Talley NJ. Aerophagia in adults:
a comparison with functional dyspepsia. Aliment Pharmacol Ther. 2005 Nov
1;22(9):855-8. PubMed PMID: 16225495. eng.
121. Chitkara DK, Bredenoord AJ, Talley NJ, Whitehead WE. Aerophagia and
rumination: recognition and therapy. Curr Treat Options Gastroenterol. 2006
Jul;9(4):305-13. PubMed PMID: 16836949. eng.
122. Sweis R, Anggiansah A, Wong T, Kaufman E, Obrecht S, Fox M.
Normative values and inter-observer agreement for liquid and solid bolus
swallows in upright and supine positions as assessed by esophageal high-
resolution manometry. Neurogastroenterol Motil. 2011 Jun;23(6):509-e198.
PubMed PMID: 21342362. eng.
123. Holloway RH, Lyrenas E, Ireland A, Dent J. Effect of intraduodenal fat on
lower oesophageal sphincter function and gastro-oesophageal reflux. Gut. 1997
Apr;40(4):449-53. PubMed PMID: 9176069. Pubmed Central PMCID: 1027116.
124. Bredenoord AJ, Fox M, Kahrilas PJ, Pandolfino JE, Schwizer W, Smout AJ,
et al. Chicago classification criteria of esophageal motility disorders defined in
high resolution esophageal pressure topography. Neurogastroenterol Motil. 2012
Mar;24 Suppl 1:57-65. PubMed PMID: 22248109. Pubmed Central PMCID:
3544361.
125. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux
monitoring: review and consensus report on detection and definitions of acid,
non-acid, and gas reflux. Gut. 2004 Jul;53(7):1024-31. PubMed PMID:
15194656. Pubmed Central PMCID: 1774114.
126. Conklin JL. Evaluation of Esophageal Motor Function With High-resolution
Manometry. J Neurogastroenterol Motil. 2013 Jul;19(3):281-94. PubMed PMID:
23875094. Pubmed Central PMCID: 3714405.
278
127. Shelly MP, Nightingale P. ABC of intensive care: respiratory support. BMJ.
1999 Jun 19;318(7199):1674-7. PubMed PMID: 10373174. Pubmed Central
PMCID: 1116024.
128. Chitkara DK, Van Tilburg M, Whitehead WE, Talley NJ. Teaching
diaphragmatic breathing for rumination syndrome. Am J Gastroenterol. 2006
Nov;101(11):2449-52. PubMed PMID: 17090274. eng.
129. Shay SS, Johnson LF, Wong RK, Curtis DJ, Rosenthal R, Lamott JR, et al.
Rumination, heartburn, and daytime gastroesophageal reflux. A case study with
mechanisms defined and successfully treated with biofeedback therapy. J Clin
Gastroenterol. 1986 Apr;8(2):115-26. PubMed PMID: 3462241. eng.
130. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of
amitriptyline on symptoms, sleep, and visceral perception in patients with
functional dyspepsia. Am J Gastroenterol. 1998 Feb;93(2):160-5. PubMed PMID:
9468233. eng.
131. Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the
predominant symptom with clinical characteristics and pathophysiological
mechanisms in functional dyspepsia. Gastroenterology. 2006 Feb;130(2):296-
303. PubMed PMID: 16472585.
132. Cremonini F, Delgado-Aros S, Talley NJ. Functional dyspepsia: drugs for
new (and old) therapeutic targets. Best Pract Res Clin Gastroenterol. 2004
Aug;18(4):717-33. PubMed PMID: 15324710.
133. Bredenoord AJ, Weusten BL, Timmer R, Akkermans LM, Smout AJ.
Relationships between air swallowing, intragastric air, belching and gastro-
oesophageal reflux. Neurogastroenterol Motil. 2005 Jun;17(3):341-7. PubMed
PMID: 15916621.
134. Hemmink GJ, Bredenoord AJ, Weusten BL, Timmer R, Smout AJ.
Supragastric belching in patients with reflux symptoms. Am J Gastroenterol.
2009 Aug;104(8):1992-7. PubMed PMID: 19455107.
135. Blondeau K, Boecxstaens V, Rommel N, Farre R, Depeyper S, Holvoet L,
et al. Baclofen Improves Symptoms and Reduces Postprandial Flow Events in
Patients With Rumination and Supragastric Belching. Clin Gastroenterol Hepatol.
2011 Nov 9. PubMed PMID: 22079512. Eng.
136. Oelschlager BK, Chan MM, Eubanks TR, Pope CE, 2nd, Pellegrini CA.
Effective treatment of rumination with Nissen fundoplication. J Gastrointest
Surg. 2002 Jul-Aug;6(4):638-44. PubMed PMID: 12127134. eng.
137. Hemmink GJ, Ten Cate L, Bredenoord AJ, Timmer R, Weusten BL, Smout
AJ. Speech therapy in patients with excessive supragastric belching--a pilot
study. Neurogastroenterol Motil. 2010 Jan;22(1):24-8, e2-3. PubMed PMID:
19650772.
138. el-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or
pulmonary disease with esophagitis in United States military veterans.
Gastroenterology. 1997 Sep;113(3):755-60. PubMed PMID: 9287965. eng.
139. Nice. Dyspepsia: managing dyspepsia in adults in primary care. National
Institute for Health and Clinical Excellence. 2004.
140. Fox M, Forgacs I. Gastro-oesophageal reflux disease. BMJ. 2006 Jan
14;332(7533):88-93. PubMed PMID: 16410582. Pubmed Central PMCID:
1326932.
141. Chander B, Hanley-Williams N, Deng Y, Sheth A. 24 Versus 48-hour
bravo pH monitoring. J Clin Gastroenterol. 2012 Mar;46(3):197-200. PubMed
PMID: 21959323.
142. Zentilin P, Savarino V, Mastracci L, Spaggiari P, Dulbecco P, Ceppa P, et
al. Reassessment of the diagnostic value of histology in patients with GERD,
using multiple biopsy sites and an appropriate control group. Am J
Gastroenterol. 2005 Oct;100(10):2299-306. PubMed PMID: 16181384. eng.
279
143. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux
disease. Clin Gastroenterol Hepatol. 2007 Jan;5(1):4-16. PubMed PMID:
17157563.
144. Sweis RC, F. Fox, M. Anggiansah, A. Lee, A. Valdes, A. Wong, T.
Diagnosis of GORD by histology of mucosal biopsies from distal oesophagus;
agreement with prolonged pH monitoring. gut. 2013;62(Supplement 1):A116.
145. Sweis R, Fox M, Anggiansah R, Anggiansah A, Basavaraju K, Canavan R,
et al. Patient acceptance and clinical impact of Bravo monitoring in patients with
previous failed catheter-based studies. Aliment Pharmacol Ther. 2009 Mar
15;29(6):669-76. PubMed PMID: 19183144.
146. Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ.
Ambulatory esophageal pH monitoring using a wireless system. Am J
Gastroenterol. 2003 Apr;98(4):740-9. PubMed PMID: 12738450. eng.
147. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of
gastro-oesophageal reflux perception in patients with persistent symptoms
despite proton pump inhibitors. Gut. 2008 Feb;57(2):156-60. PubMed PMID:
17951358.
148. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton
pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J
Gastroenterol. 2011 Aug;106(8):1419-25; quiz 26. PubMed PMID: 21537361.
149. Kahrilas PJ, Jonsson A, Denison H, Wernersson B, Hughes N, Howden
CW. Regurgitation is less responsive to acid suppression than heartburn in
patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012
Jun;10(6):612-9. PubMed PMID: 22343515.
150. Singh S, Stein HJ, DeMeester TR, Hinder RA. Nonobstructive dysphagia in
gastroesophageal reflux disease: a study with combined ambulatory pH and
motility monitoring. Am J Gastroenterol. 1992 May;87(5):562-7. PubMed PMID:
1595641.
151. Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in
ambulatory gastro-oesophageal reflux monitoring. Gut. 2005 Dec;54(12):1810-
7. PubMed PMID: 16284291. Pubmed Central PMCID: 1774780.
152. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-
Sternevald E, et al. High prevalence of gastroesophageal reflux symptoms and
esophagitis with or without symptoms in the general adult Swedish population: a
Kalixanda study report. Scand J Gastroenterol. 2005 Mar;40(3):275-85. PubMed
PMID: 15932168.
153. Lee J, Anggiansah A, Anggiansah R, Young A, Wong T, Fox M. Effects of
age on the gastroesophageal junction, esophageal motility, and reflux disease.
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1392-8. PubMed PMID: 17936081.
eng.
154. Curcic J, Fox M, Kaufman E, Forras-Kaufman Z, Hebbard GS, Roy S, et al.
Gastroesophageal junction: structure and function as assessed by using MR
imaging. Radiology. 2010 Oct;257(1):115-24. PubMed PMID: 20713610.
155. Anggiansah R, Sweis R, Anggiansah A, Wong T, Cooper D, Fox M. The
effects of obesity on oesophageal function, acid exposure and the symptoms of
gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013 Jan. PubMed
PMID: 23305085. ENG.
156. Wilson A, Longhi J, Goldman C, McNatt S. Intra-abdominal pressure and
the morbidly obese patients: the effect of body mass index. J Trauma. 2010
Jul;69(1):78-83. PubMed PMID: 20622581. Epub 2010/07/14. eng.
157. Nathanson LK, Brunott N, Cavallucci D. Adult esophagogastric junction
distensibility during general anesthesia assessed with an endoscopic functional
luminal imaging probe (EndoFLIP(R)). Surg Endosc. 2012 Apr;26(4):1051-5.
PubMed PMID: 22038169. Epub 2011/11/01. eng.
280
158. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk
for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005
Aug 2;143(3):199-211. PubMed PMID: 16061918.
159. Ilczyszyn A, Botha A. Adding a Fundoplication during Hellers Myotomy for
Achalasia Does Not Reduce the Distensibilty of the Oesophagogastric Junction.
UEGW 2011; October 2011; Stockholm, Sweden: Endoscopy; 2011. p. A238.
160. Perretta S, Dallemagne B, McMahon B, D'Agostino J, Marescaux J. Video.
Improving functional esophageal surgery with a "smart" bougie: Endoflip. Surg
Endosc. 2011 Sep;25(9):3109. PubMed PMID: 21437739.
161. Ilczyszyn A, Botha AJ. Feasibility of esophagogastric junction distensibility
measurement during Nissen fundoplication. Dis Esophagus. 2013 Aug 30.
PubMed PMID: 24033477.
162. Simpson A, Wilsom MSJ, Ellefson A, Colley S, Attwood SE. The clinical
utility of the Endoscopic Functional Luminal Imaging Probe in Eosinophilic
oesophagitis: A case series. Digestive Diseases Federation 2012; Liverpool,
United Kingdom: Gut; 2012. p. A252-A3.
163. Vandenberghe J, Vos R, Persoons P, Demyttenaere K, Janssens J, Tack J.
Dyspeptic patients with visceral hypersensitivity: sensitisation of pain specific or
multimodal pathways? Gut. 2005 Jul;54(7):914-9. PubMed PMID: 15951533.
Pubmed Central PMCID: 1774593.
164. Jones MP, Coppens E, Vos R, Holvoet L, Luyten P, Tack J, et al. A
multidimensional model of psychobiological interactions in functional dyspepsia:
a structural equation modelling approach. Gut. 2012 Sep 8. PubMed PMID:
22917658.
165. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new
measure for evaluating the severity of somatic symptoms. Psychosom Med.
2002 Mar-Apr;64(2):258-66. PubMed PMID: 11914441.
166. Mahadeva S, Wee HL, Goh KL, Thumboo J. The EQ-5D (Euroqol) is a valid
generic instrument for measuring quality of life in patients with dyspepsia. BMC
Gastroenterol. 2009;9:20. PubMed PMID: 19284606. Pubmed Central PMCID:
2662871.
167. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
psychiatrica Scandinavica. 1983 Jun;67(6):361-70. PubMed PMID: 6880820.
168. Aro P, Talley NJ, Ronkainen J, Storskrubb T, Vieth M, Johansson SE, et al.
Anxiety is associated with uninvestigated and functional dyspepsia (Rome III
criteria) in a Swedish population-based study. Gastroenterology. 2009
Jul;137(1):94-100. PubMed PMID: 19328797.
169. Kindt S, Coulie B, Wajs E, Janssens J, Tack J. Reproducibility and
symptomatic predictors of a slow nutrient drinking test in health and in
functional dyspepsia. Neurogastroenterol Motil. 2008 Apr;20(4):320-9. PubMed
PMID: 18371010.
170. Gregersen H, Kassab G. Biomechanics of the gastrointestinal tract.
Neurogastroenterol Motil. 1996 Dec;8(4):277-97. PubMed PMID: 8959733.
171. Karamanolis G, Caenepeel P, Arts J, Tack J. Determinants of symptom
pattern in idiopathic severely delayed gastric emptying: gastric emptying rate or
proximal stomach dysfunction? Gut. 2007 Jan;56(1):29-36. PubMed PMID:
16840507. Pubmed Central PMCID: 1856678. Epub 2006/07/15. eng.
172. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M.
Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001
Jul;24(7):1264-9. PubMed PMID: 11423513. Epub 2001/06/26. eng.
173. Pasricha PJ, Colvin R, Yates K, Hasler WL, Abell TL, Unalp-Arida A, et al.
Characteristics of patients with chronic unexplained nausea and vomiting and
normal gastric emptying. Clin Gastroenterol Hepatol. 2011 Jul;9(7):567-76 e1-
4. PubMed PMID: 21397732. Pubmed Central PMCID: 3123425. Epub
2011/03/15. eng.
281
174. Frier APaM. Nuclear Medicine in Pharmaceutical Research. London: Taylor
and Francis; 1999. 201
p.
175. Digenis GA, Sandefer EP, Page RC, Doll WJ. Gamma scintigraphy: an
evolving technology in pharmaceutical formulation development-Part 1.
Pharmaceutical Science & Technology Today. 1998 6/1/;1(3):100-8.
176. Tougas G, Eaker EY, Abell TL, Abrahamsson H, Boivin M, Chen J, et al.
Assessment of gastric emptying using a low fat meal: establishment of
international control values. Am J Gastroenterol. 2000 Jun;95(6):1456-62.
PubMed PMID: 10894578. eng.
177. Rao SS, Camilleri M, Hasler WL, Maurer AH, Parkman HP, Saad R, et al.
Evaluation of gastrointestinal transit in clinical practice: position paper of the
American and European Neurogastroenterology and Motility Societies.
Neurogastroenterol Motil. 2011 Jan;23(1):8-23. PubMed PMID: 21138500.
178. Kwiatek MA, Menne D, Steingoetter A, Goetze O, Forras-Kaufman Z,
Kaufman E, et al. Effect of meal volume and calorie load on postprandial gastric
function and emptying: studies under physiological conditions by combined
fiber-optic pressure measurement and MRI. Am J Physiol Gastrointest Liver
Physiol. 2009 Nov;297(5):G894-901. PubMed PMID: 19779010.
179. Sauter M, Curcic J, Menne D, Goetze O, Fried M, Schwizer W, et al.
Measuring the interaction of meal and gastric secretion: a combined quantitative
magnetic resonance imaging and pharmacokinetic modeling approach.
Neurogastroenterol Motil. 2012 Jul;24(7):632-8, e272-3. PubMed PMID:
22452723.
180. Kwiatek MA, Fox MR, Steingoetter A, Menne D, Pal A, Fruehauf H, et al.
Effects of clonidine and sumatriptan on postprandial gastric volume response,
antral contraction waves and emptying: an MRI study. Neurogastroenterol Motil.
2009 Sep;21(9):928-e71. PubMed PMID: 19413683.
181. Feinle C, Kunz P, Boesiger P, Fried M, Schwizer W. Scintigraphic
validation of a magnetic resonance imaging method to study gastric emptying of
a solid meal in humans. Gut. 1999 Jan;44(1):106-11. PubMed PMID: 9862835.
Pubmed Central PMCID: 1760059. Epub 1998/12/24. eng.
182. Camilleri M, Malagelada JR. Abnormal intestinal motility in diabetics with
the gastroparesis syndrome. Eur J Clin Invest. 1984 Dec;14(6):420-7. PubMed
PMID: 6441717. Epub 1984/12/01. eng.
183. Oh JH, Pasricha PJ. Recent advances in the pathophysiology and
treatment of gastroparesis. J Neurogastroenterol Motil. 2013 Jan;19(1):18-24.
PubMed PMID: 23350043. Pubmed Central PMCID: 3548121.
184. Fruehauf H, Goetze O, Steingoetter A, Kwiatek M, Boesiger P, Thumshirn
M, et al. Intersubject and intrasubject variability of gastric volumes in response
to isocaloric liquid meals in functional dyspepsia and health. Neurogastroenterol
Motil. 2007 Jul;19(7):553-61. PubMed PMID: 17593136. Epub 2007/06/27. eng.
185. Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M.
Gastric emptying in diabetes: clinical significance and treatment. Diabet Med.
2002 Mar;19(3):177-94. PubMed PMID: 11918620. Epub 2002/03/29. eng.
186. Lacy BE, Talley NJ, Locke GR, 3rd, Bouras EP, DiBaise JK, El-Serag HB, et
al. Review article: current treatment options and management of functional
dyspepsia. Aliment Pharmacol Ther. 2012 Jul;36(1):3-15. PubMed PMID:
22591037.
187. Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Liu XG, et al. Effects
of proton-pump inhibitors on functional dyspepsia: a meta-analysis of
randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2007
Feb;5(2):178-85; quiz 40. PubMed PMID: 17174612.
188. Hiyama T, Yoshihara M, Matsuo K, Kusunoki H, Kamada T, Ito M, et al.
Meta-analysis of the effects of prokinetic agents in patients with functional
282
dyspepsia. J Gastroenterol Hepatol. 2007 Mar;22(3):304-10. PubMed PMID:
17295758.
189. Otaka M, Jin M, Odashima M, Matsuhashi T, Wada I, Horikawa Y, et al.
New strategy of therapy for functional dyspepsia using famotidine, mosapride
and amitriptyline. Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:42-6. PubMed
PMID: 15943846.
190. van Kerkhoven LA, Laheij RJ, Aparicio N, De Boer WA, Van den Hazel S,
Tan AC, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a
randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol.
2008 Jul;6(7):746-52; quiz 18. PubMed PMID: 18424191.
191. Tack J, Broekaert D, Coulie B, Fischler B, Janssens J. Influence of the
selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor
function in humans. Aliment Pharmacol Ther. 2003 Feb 15;17(4):603-8. PubMed
PMID: 12622770.
192. Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M,
et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal
motility and gastric emptying in healthy men. Am J Gastroenterol. 2007
Jun;102(6):1276-83. PubMed PMID: 17378904.
193. von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5,
a phytopharmacon for patients with functional dyspepsia: results of a
multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007
Jun;102(6):1268-75. PubMed PMID: 17531013.
194. Sarnelli G, Sifrim D, Janssens J, Tack J. Influence of sildenafil on gastric
sensorimotor function in humans. Am J Physiol Gastrointest Liver Physiol. 2004
Nov;287(5):G988-92. PubMed PMID: 15475488.
195. Delgado-Aros S, Camilleri M, Cremonini F, Ferber I, Stephens D, Burton
DD. Contributions of gastric volumes and gastric emptying to meal size and
postmeal symptoms in functional dyspepsia. Gastroenterology. 2004
Dec;127(6):1685-94. PubMed PMID: 15578506.
196. Couturier O, Bodet-Milin C, Querellou S, Carlier T, Turzo A, Bizais Y.
Gastric scintigraphy with a liquid-solid radiolabelled meal: performances of solid
and liquid parameters. Nuclear medicine communications. 2004
Nov;25(11):1143-50. PubMed PMID: 15577595.
197. Hornbuckle K, Barnett JL. The diagnosis and work-up of the patient with
gastroparesis. J Clin Gastroenterol. 2000 Mar;30(2):117-24. PubMed PMID:
10730917.
198. Siegel JA, Krevsky B, Maurer AH, Charkes ND, Fisher RS, Malmud LS.
Scintigraphic evaluation of gastric emptying: are radiolabeled solids necessary?
Clinical nuclear medicine. 1989 Jan;14(1):40-6. PubMed PMID: 2714039.
199. Fisher RS, Malmud LS, Bandini P, Rock E. Gastric emptying of a
physiologic mixed solid-liquid meal. Clinical nuclear medicine. 1982
May;7(5):215-21. PubMed PMID: 7083695.
200. Ziessman HA, Chander A, Clarke JO, Ramos A, Wahl RL. The added
diagnostic value of liquid gastric emptying compared with solid emptying alone. J
Nucl Med. 2009 May;50(5):726-31. PubMed PMID: 19372480.
201. Christian PE, Datz FL, Sorenson JA, Taylor A. Technical factors in gastric
emptying studies. J Nucl Med. 1983 Mar;24(3):264-8. PubMed PMID: 6338172.
202. Ziessman HA, Fahey FH, Collen MJ. Biphasic solid and liquid gastric
emptying in normal controls and diabetics using continuous acquisition in LAO
view. Dig Dis Sci. 1992 May;37(5):744-50. PubMed PMID: 1563318. Epub
1992/05/01. eng.
203. Harris E.K. BJC. Statistical Bases of Reference Values in Laboratory
Medicine. New York: CRC Press; 1995.
204. Marciani L, Gowland PA, Fillery-Travis A, Manoj P, Wright J, Smith A, et
al. Assessment of antral grinding of a model solid meal with echo-planar
283
imaging. Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G844-9.
PubMed PMID: 11292591.
205. Rahim MK, Durr ES, Mateen A, Najam U, Yousaf M. Studies of gastric
emptying time in patients with non-ulcer dyspepsia. Nuclear medicine
communications. 2007 Nov;28(11):852-8. PubMed PMID: 17901768.
206. Talley NJ. Functional gastrointestinal disorders as a public health
problem. Neurogastroenterol Motil. 2008 May;20 Suppl 1:121-9. PubMed PMID:
18402649. eng.
207. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux
disease: the present, the past and the future. Gut. 2014 Jul;63(7):1185-93.
PubMed PMID: 24607936.
208. Jones MP, Talley NJ, Eslick GD, Dubois D, Tack J. Community subgroups
in dyspepsia and their association with weight loss. Am J Gastroenterol. 2008
Aug;103(8):2051-60. PubMed PMID: 18796099.
209. Maurer AH. Advancing gastric emptying studies: standardization and new
parameters to assess gastric motility and function. Seminars in nuclear
medicine. 2012 Mar;42(2):101-12. PubMed PMID: 22293165.
210. Mundt MW, Hausken T, Smout AJ, Samsom M. Relationships between
gastric accommodation and gastrointestinal sensations in healthy volunteers. A
study using the barostat technique and two- and three-dimensional
ultrasonography. Dig Dis Sci. 2005 Sep;50(9):1654-60. PubMed PMID:
16133965.
211. Marciani L, Gowland PA, Spiller RC, Manoj P, Moore RJ, Young P, et al.
Effect of meal viscosity and nutrients on satiety, intragastric dilution, and
emptying assessed by MRI. Am J Physiol Gastrointest Liver Physiol. 2001
Jun;280(6):G1227-33. PubMed PMID: 11352816.
212. Meyer JH. Gastric emptying of ordinary food: effect of antrum on particle
size. Am J Physiol. 1980 Sep;239(3):G133-5. PubMed PMID: 7001918.
213. Zheng J, Dobner A, Babygirija R, Ludwig K, Takahashi T. Effects of
repeated restraint stress on gastric motility in rats. Am J Physiol Regul Integr
Comp Physiol. 2009 May;296(5):R1358-65. PubMed PMID: 19261914.
214. Pare WP, Isom KE. Gastric secretion as a function of acute and chronic
stress in the gastric fistula rat. Journal of comparative and physiological
psychology. 1975 Jan;88(1):431-5. PubMed PMID: 1168212.
215. Brennan SC, Redd WH, Jacobsen PB, Schorr O, Heelan RT, Sze GK, et al.
Anxiety and panic during magnetic resonance scans. Lancet. 1988 Aug
27;2(8609):512. PubMed PMID: 2900435.
216. Caldarella MP, Azpiroz F, Malagelada JR. Antro-fundic dysfunctions in
functional dyspepsia. Gastroenterology. 2003 May;124(5):1220-9. PubMed
PMID: 12730863.
217. Indireshkumar K, Brasseur JG, Faas H, Hebbard GS, Kunz P, Dent J, et al.
Relative contributions of "pressure pump" and "peristaltic pump" to gastric
emptying. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G604-16.
PubMed PMID: 10762615.
218. Grundy D, Gharib-Naseri MK, Hutson D. Role of nitric oxide and
vasoactive intestinal polypeptide in vagally mediated relaxation of the gastric
corpus in the anaesthetized ferret. J Auton Nerv Syst. 1993 Jun;43(3):241-6.
PubMed PMID: 8366253.
219. Desai KM, Sessa WC, Vane JR. Involvement of nitric oxide in the reflex
relaxation of the stomach to accommodate food or fluid. Nature. 1991 Jun
6;351(6326):477-9. PubMed PMID: 1675430.
220. Kindt S, Tack J. Impaired gastric accommodation and its role in
dyspepsia. Gut. 2006 Dec;55(12):1685-91. PubMed PMID: 16854999. Pubmed
Central PMCID: 1856470.
221. Kuiken SD, Vergeer M, Heisterkamp SH, Tytgat GN, Boeckxstaens GE.
Role of nitric oxide in gastric motor and sensory functions in healthy subjects.
284
Gut. 2002 Aug;51(2):212-8. PubMed PMID: 12117882. Pubmed Central PMCID:
1773317.
222. Tack JF, Janssens J, Vantrappen G, Wood JD. Actions of 5-
hydroxytryptamine on myenteric neurons in guinea pig gastric antrum. Am J
Physiol. 1992 Dec;263(6 Pt 1):G838-46. PubMed PMID: 1476191.
223. Thumshirn M, Camilleri M, Choi MG, Zinsmeister AR. Modulation of gastric
sensory and motor functions by nitrergic and alpha2-adrenergic agents in
humans. Gastroenterology. 1999 Mar;116(3):573-85. PubMed PMID: 10029616.
Epub 1999/02/25. eng.
224. Tack J, Janssen P, Masaoka T, Farre R, Van Oudenhove L. Efficacy of
buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin
Gastroenterol Hepatol. 2012 Nov;10(11):1239-45. PubMed PMID: 22813445.
225. Kusano M, Minashi K, Maeda M, Shimoyama Y, Kuribayashi S, Higuchi T,
et al. Postprandial water intake inhibits gastric antral motility with increase of
cholecystokinin in humans. Scand J Gastroenterol. 2005 Oct;40(10):1176-81.
PubMed PMID: 16265774.
226. Feinle C, Rades T, Otto B, Fried M. Fat digestion modulates
gastrointestinal sensations induced by gastric distention and duodenal lipid in
humans. Gastroenterology. 2001 Apr;120(5):1100-7. PubMed PMID: 11266374.
227. Treier R, Steingoetter A, Goetze O, Fox M, Fried M, Schwizer W, et al.
Fast and optimized T1 mapping technique for the noninvasive quantification of
gastric secretion. J Magn Reson Imaging. 2008 Jul;28(1):96-102. PubMed PMID:
18581398.
228. Goetze O, Treier R, Fox M, Steingoetter A, Fried M, Boesiger P, et al. The
effect of gastric secretion on gastric physiology and emptying in the fasted and
fed state assessed by magnetic resonance imaging. Neurogastroenterol Motil.
2009 Jul;21(7):725-e42. PubMed PMID: 19344341.
229. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in
refractory gastroesophageal reflux disease. Gastroenterology. 1990
Mar;98(3):654-61. PubMed PMID: 2298369.
230. Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis,
signs of reflux, and gastric acid secretion in patients with symptoms of gastro-
oesophageal reflux disease. Scand J Gastroenterol. 1986 Sep;21(7):837-47.
PubMed PMID: 3775250.
231. Gardner JD, Sloan S, Miner PB, Robinson M. Meal-stimulated gastric acid
secretion and integrated gastric acidity in gastro-oesophageal reflux disease.
Aliment Pharmacol Ther. 2003 Apr 1;17(7):945-53. PubMed PMID: 12656697.
232. Quigley EM, Lacy BE. Overlap of functional dyspepsia and GERD--
diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol. 2013
Mar;10(3):175-86. PubMed PMID: 23296247.
233. Lee KJ, Vos R, Janssens J, Tack J. Influence of duodenal acidification on
the sensorimotor function of the proximal stomach in humans. Am J Physiol
Gastrointest Liver Physiol. 2004 Feb;286(2):G278-84. PubMed PMID: 12760903.
234. Hunt JN, Knox MT. The slowing of gastric emptying by four strong acids
and three weak acids. J Physiol. 1972 Apr;222(1):187-208. PubMed PMID:
5037069. Pubmed Central PMCID: 1331422.
235. Samsom M, Verhagen MA, vanBerge Henegouwen GP, Smout AJ.
Abnormal clearance of exogenous acid and increased acid sensitivity of the
proximal duodenum in dyspeptic patients. Gastroenterology. 1999
Mar;116(3):515-20. PubMed PMID: 10029608.
236. di Stefano M, Vos R, Vanuytsel T, Janssens J, Tack J. Prolonged duodenal
acid perfusion and dyspeptic symptom occurrence in healthy volunteers.
Neurogastroenterol Motil. 2009 Jul;21(7):712-e40. PubMed PMID: 19236580.
237. Lee KJ, Kim JH, Cho SW. Dyspeptic symptoms associated with
hypersensitivity to gastric distension induced by duodenal acidification. J
Gastroenterol Hepatol. 2006 Mar;21(3):515-20. PubMed PMID: 16638092.
285
238. Lee KJ, Demarchi B, Demedts I, Sifrim D, Raeymaekers P, Tack J. A pilot
study on duodenal acid exposure and its relationship to symptoms in functional
dyspepsia with prominent nausea. Am J Gastroenterol. 2004 Sep;99(9):1765-
73. PubMed PMID: 15330916.
239. Barbera R, Feinle C, Read NW. Abnormal sensitivity to duodenal lipid
infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol. 1995
Nov;7(11):1051-7. PubMed PMID: 8680904.
240. Barbera R, Feinle C, Read NW. Nutrient-specific modulation of gastric
mechanosensitivity in patients with functional dyspepsia. Dig Dis Sci. 1995
Aug;40(8):1636-41. PubMed PMID: 7648962.
241. El-Serag HB, Satia JA, Rabeneck L. Dietary intake and the risk of gastro-
oesophageal reflux disease: a cross sectional study in volunteers. Gut. 2005
Jan;54(1):11-7. PubMed PMID: 15591498. Pubmed Central PMCID: 1774352.
